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Abstract 
While the tuberculosis (TB) burden in England is low compared to some parts of the word, 
annual incidence rates have not declined in over two decades, and remain among the 
highest in developed countries.  
In the first part of my thesis, I examined trends in TB notifications rates in England with 
emphasis on the UK-born population, which because of its relatively lower incidence, has 
received less attention than foreign-born groups. This analysis showed that for nearly two 
decades, rates have remained mostly stagnant in White UK-born populations, except in 
the elderly in which rates continue to decline, whereas TB rates have been declining in 
foreign-born subjects and UK-born ethnic minority groups in the past decade. Given the 
strong link between poverty and TB, I also investigated the association between socio-
economic deprivation and the risk of TB in England. An ecological analysis suggested that 
the association between small-area level deprivation and TB rates in a recent 5-year period 
was much stronger in the UK-born population than in the foreign-born population. To 
investigate the role of deprivation in the UK-born White population further, I used data 
from a case-control study of UK-born White young adults in which information was 
collected on individual-level socio-economic determinants of health. The analysis showed 
a four times higher risk of TB in subjects with an education level below O-levels compared 
to those with a degree, as well as an association between increased TB risk and area-level 
deprivation, tobacco smoking, drug use, and homelessness.  
In the second part of the thesis, I focused on BCG vaccination, a longstanding part of the 
TB prevention toolkit, and which has been somewhat overlooked compared to case finding 
and treatment. I reported a survey of the implementation at the local level of the 2005 
change to England’s BCG policy replacing the universal vaccination of schoolchildren by 
targeted vaccination of higher-risk infants.  Heterogeneity in the healthcare service 
pathways for BCG vaccination was noted, as well as challenges to the identification of, and 
service delivery to, the targeted groups. I also conducted an ecological study estimating 
the vaccine uptake in a 3-year period (2006-2008) following the policy change and its 
association to some area-level factors, with results suggesting that about one third of 
eligible infants may have missed vaccination. Finally, I conducted a historical cohort study 
measuring the long-term duration of BCG-derived protection against tuberculosis using 
data from Norway, a low-incidence setting comparable to England. I found that BCG 
effectiveness lasts for at least 20 years, longer than previously estimated.  
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Overall, my thesis highlights the existence of stagnant TB rates in UK-born White young 
adults, and particular social determinants such as tobacco smoking, drug use and 
homelessness, that are amenable to specific interventions to reduce the risk of TB in a 
currently neglected population group. It also presents evidence to improve BCG policies 
targeted at high-risk groups in low-incidence settings and vaccination uptake. The new 
information on the duration of BCG protection can also help inform any review of the cost-
effectiveness of BCG vaccination in the general population. 
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1. Introduction 
Tuberculosis remains a major cause of morbidity and mortality in many parts of the 
world. It is estimated that about 1.7 to 2 billion people across the world are infected by 
Mycobacterium tuberculosis (Mtb) (1, 2); approximately 10% are expected to progress 
to clinical disease, of which nearly half develop lung disease and become potentially 
infectious, sustaining the transmission cycle (3). Since the 1980s, TB has been 
resurging as a public health problem in several high-income countries (HIC) with low 
TB incidence, including in England where the disease was once considered to be on a 
steady elimination course (4). Nowadays in England, the highest TB incidences are 
reported in large metropolitan areas, with the heaviest burden on those subjects born 
abroad in high TB incidence countries, as well as in older people (5). A great proportion 
of disease in these two groups appears to be caused by the reactivation of latent Mtb 
infection (LTBI) most likely acquired in their country of origin in the case of foreign-
born subjects, or in the past when the risk of infection was slightly higher for older 
native individuals (6).  
By contrast, the TB incidence and risk of infection in the general native population 
(those born in the UK) are relatively low, and the TB-associated morbidity appears to 
mostly concentrate in the more vulnerable and socio-economically deprived segments 
of the population, in which there is evidence of sustained transmission (5). These 
deprived populations include groups at high risk of TB, like people with current or past 
history of homelessness and prison stay, in which high prevalence of Mtb infection 
have consistently been reported (7). Socio-economic deprivation and the resulting 
social stratification have also been associated with unequal distribution of health-
related behaviours and other determinants of health, including some presumed or 
known TB risk factors (e.g. tobacco smoking, alcohol abuse, and use of controlled 
drugs), as well as limited access to, and/or contact with, the health system (8). In 
addition to the direct disease burden on the affected population subgroups, the 
continued local TB transmission - albeit concentrated in these groups - also represents 
a risk for the wider community, and outbreaks have been reported (9, 10). The risk is 
further compounded by the spread of multi-drug resistant TB (MDR-TB), which by 
defeating the arsenal of available antibiotics, paradoxically renders casual encounters 
with a prehistoric pathogen like Mtb potentially lethal even in the richest countries 
(11).  
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The localised pockets of TB transmission in the native population have proven 
challenging to control, compromising the progress towards eliminating TB as a public 
health problem. Projections based on recent modelling work have suggested that in 
spite of the current range of control tools and measures, the current average rates of 
decline in TB rates in most countries, including in the majority of low TB incidence 
countries (i.e. those with annual TB notifications <10 per 100,000 people) would most 
likely be insufficient to meet the targets sets by the World Health Organization’s 
(WHO) global TB strategy beyond 2015 to reach pre-elimination levels (defined as 
annual notifications <1 per 100,000) by 2035 and elimination levels (defined as annual 
notifications < 1 per million) by 2050 (12). In light of these projections, among other 
recommendations to strengthen and boost TB control efforts, the latest global TB 
strategy recommends increasing efforts and actions to reduce the effect of the 
underlying social determinants of tuberculosis (12-14). This includes mapping and 
targeting TB high-risk groups, as well as gaining a better understanding of the social 
determinants underlying the risk of TB and appropriately addressing these. 
Tuberculosis has been known as a disease of poverty for almost as long as population-
wide records exist, with the disease burden greater in the least affluent segments of 
the population (15). However, our understanding of some of the causal pathways 
through which poverty affects the risk of tuberculosis remains limited. Furthermore, 
these pathways are likely to be setting and context specific, and probably change as 
societies evolve. While reducing social injustice and related health inequalities must 
remain the long-term goal, a better understanding of some of the pathways through 
which poverty affects the risk of tuberculosis may help inform and/or improve more 
targeted interventions directed at relevant pathways and within the grasp of public 
health.  
The WHO global TB strategy (13, 14) and several mathematical models (16) also concur 
that amongst other tools, effective vaccination against tuberculosis has a major role to 
play in order to achieve TB elimination. The Bacillus Calmette-Guerin vaccine (BCG) 
remains the sole TB vaccine licensed for use in humans to date, with good efficacy 
against severe childhood tuberculosis reported consistently throughout the world (17, 
18), and variable, but up to 80% protection against pulmonary TB reported in several 
countries (19), including in the United Kingdom. Since its introduction in the 1920s, 
BCG has grown to become one of the most used vaccines in the world; more than 4 
billion doses have been administered in humans and universal vaccination is currently 
recommended in over 157 countries (20, 21). The limitations of BCG have been 
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recognised, including the variations in the vaccine efficacy between settings and 
populations (19), and major efforts are underway to develop new and more effective 
TB vaccines. At least twelve vaccine candidates are currently at various stages of 
development, although only one is undergoing human testing (22, 23). However, 
vaccine development efforts have so far been hampered by the complexities and 
limitations of the current understanding of human’s immune response to Mtb 
infection and TB disease, as well as the mechanism of BCG-derived immune protection 
against tuberculosis (22). Therefore, additional insights gained into BCG-derived 
protection against tuberculosis, including the duration of protection, can potentially 
be useful to vaccine development efforts. Furthermore, the implications of prior BCG 
vaccination and any potential interaction with newly developed TB vaccines will most 
likely have to be considered, in light of the widespread use of BCG vaccination 
throughout the world. This includes for example the duration and changes in levels of 
BCG effectiveness against tuberculosis, which may be relevant to the timing and effect 
of TB booster vaccines (24), a major family of current TB vaccine candidates designed 
to improve immunity elicited by BCG.  
Until new and more effective TB vaccines become available, the WHO global TB 
strategy recommends continuing BCG vaccination (13, 14). While universal vaccination 
of all neonates soon after birth is still advised in high TB incidence areas, many low TB 
incidence countries have changed or are in the process of revising their BCG 
vaccination policies to discontinue or move from universal to more targeted 
approaches, based on changes in the epidemiology of TB and BCG vaccination’s cost-
benefit and cost-effectiveness (21). Updated information on BCG, including on the 
duration of protection, could also assist in the revision of the cost-effectiveness of 
various BCG vaccination strategies that currently assume waning in the vaccine’s 
efficacy 10-years after vaccination. 
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2. Objectives and Overview of Thesis 
The stated long-term aim of the WHO strategy against TB is to eliminate the disease as a 
public health problem, which is often defined as reducing the annual incidence below one 
case per million. Achieving this vision would require countries where TB incidence is 
currently low to make swift progress towards pre-elimination by 2035, i.e. annual 
incidence of less than 1 per 100,000 persons. The overall aim of this research project was 
to explore aspects of the epidemiology and control of tuberculosis in England, a high-
income country with low TB incidence in Western Europe where technical measures to 
reach pre-elimination stage might be more feasibly implemented. Although the greatest 
proportion of TB cases in England are now reported in people born abroad, the emphasis 
in this project was on tuberculosis in the UK-born population, in which it can be 
reasonably argued that most of the disease is associated with local infection, and to some 
extent re-activation in later life, and where the effect of measures to prevent TB at the 
local level should be demonstrated for progress towards elimination. My expectation is 
that the findings may inform control strategies, as well as some research priorities 
targeting this specific population group.  
My thesis is two-pronged, as follows:  
In the first part,  
(1) I revisited trends in TB notification rates in England over the past three decades, from 
1983 to 2014, while noting the similarities and differences in trajectories between the UK-
born and foreign-born populations.  
(2) I then explored the association at the ecological level between small-area level of 
deprivation and population composition, and tuberculosis notification rates over a recent 
5-year period (2008-2012), again contrasting the UK-born and foreign-born populations.  
(3) Finally, I used a nationwide TB case-control study to further investigate how socio-
economic status and some related social determinants of health inequality are associated 
with the risk of tuberculosis at the individual level in UK-born adults from White ethnic 
background. I used a formal causal framework to explore possible behavioural and lifestyle 
determinants of health through which poverty may contribute to perpetuating TB in the 
study population.  
The second part of this project concentrated on BCG vaccination, one of the longstanding 
TB prevention tools that has been less well examined than case finding and treating 
recently.  
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(4) First, I reported a 2010-2011 survey of the implementation at local-level of a major 
change in BCG vaccination policy recommendations in England in 2005, when universal 
vaccination of schoolchildren was discontinued, and replaced by targeted vaccination of 
high-risk infants.  
(5) I also estimated the BCG uptake in a 3-year period (2006-2008) after the policy change, 
and I explored the association of local vaccine uptake to some area-level factors. 
(6) Lastly, I used linked-registers data from Norway, a low-incidence European setting 
comparable to England in its level of development, to measure the long-term duration of, 
and changes to BCG levels of effectiveness against TB with time since vaccination.  
The last chapter summarises the key results and the relationship between these findings, 
a brief discussion of some of the shared strengths and frailty of the work presented, as well 
as some reflections on the findings’ relevance to policy and potential future research.  
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3. Background 
3.1 Overview of the Natural History of Tuberculosis  
Tuberculosis (TB) is one of humanity’s oldest scourges, with evidence of skeletal 
tuberculosis found in prehistoric human remains dated as old as 5000BC (25, 26). The 
disease is caused by species of mycobacteria, a ubiquitous family of rod-shaped bacteria 
(bacilli) that are readily found in the environment, including in water, soil, various 
animals, and even some plants (27). The main aetiological agent of TB in humans is 
Mycobacterium tuberculosis (Mtb), although disease caused by other closely related 
mycobacterial species has been reported, notably from M. africanum, and M. bovis (28).  
Tuberculosis causative agents’ main route of transmission is airborne (29). In respiratory 
TB patients who have sufficient mycobacteria in their respiratory tract, coughing, 
sneezing, shouting or even singing can aerosolise the infectious sputum, producing 
droplet nuclei; these are tiny airborne particles of 1-5 microns in diameter that can remain 
suspended in the air for up to several hours. Inhaling droplet nuclei containing Mtb can 
lead to infection in susceptible individuals exposed to this air. The effectiveness of 
transmission is affected by a number of factors, including the infectiousness of the source 
TB patient, the susceptibility of the individuals exposed, the proximity, duration and 
frequency of exposure, as well as the infectious dose / concentration of Mtb particles in 
the air. The infectiousness is greater in patients in whom Mtb can be found in the sputum 
under microscopy (Smear Positive patients [Sm+]), as well as those expelling more bacilli 
in the air for other reasons (e.g. lung cavitation, chronic and frequent cough) (30, 31). 
Individual susceptibility to infection when exposed can be increased by various factors, 
including a compromised immune system. Various environmental factors may affect the 
concentration of Mtb infected air particles, including for example poor ventilation or 
enclosed spaces, high humidity and dampness (32); whereas closer, prolonged and/or 
frequent exposure increases the likelihood of transmission (3). In practical terms, this 
means that the risk of transmission is higher among household contacts of patients with 
respiratory tuberculosis, especially those with Sm+ TB (30, 31). It has been estimated that 
about 30% to 50% household contacts and one in six casual contacts of patients with smear 
positive active respiratory tuberculosis get infected (30, 33).  
Upon effective transmission, most subjects develop a chronic latent infection with Mtb 
(Latent TB infection or LTBI); although it is now thought that some individuals are able 
to successfully clear the pathogen (34, 35). Only a minority, about 5-15% infected subjects 
will progress to TB disease in their lifetime (3, 36). The risk of progression to disease is 
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highest 1-2 years after infection, with an estimated risk of disease in the 1st year of 1.5%; 
the cumulative risk of disease in the first 5 years after infection is between 5-10%, 
compared to ~5% for the rest of the lifetime. This is likely the result of a selection process 
through which those with the least natural immunity to Mtb develop the disease shortly 
after infection, whereas others may ‘resist’ the infection until a later time (3). For this latter 
group, the development of disease is usually considered to be caused by the ‘re-activation’ 
of their latent infection. This is common in the elderly, consistent with old age-related 
immuno-senescence. However, frequent and prolonged exposure, as well as higher 
infectious doses may increase the likelihood of progression to disease (3). Similarly, 
increased susceptibility in the host increase the risk of progression to disease, with for 
example about 30% lifetime risk of disease in people with untreated diabetes (37) and up 
to 10% risk per year in those with untreated HIV infection (38). There is also evidence that 
re-infection may occur (39, 40), which is an important risk factor for disease, considering 
that progression to disease is 10 times more likely following recent infection than if an 
older infection (3).  
  
3.2 Summary of Tuberculosis Epidemiology with emphasis on 
low burden countries 
Tuberculosis remains a disease of great burden across the world, both in terms of mortality 
and morbidity. It was the global leading cause of death by any single infectious disease in 
2014, responsible for about 1.5 million deaths, of which 1.1 million were HIV negative 
subjects, and 140000 were children (1). The World Health Organisation (WHO) also 
estimated that there was 9 to 10 million incident cases worldwide in the same year, for a 
global incidence of about 133 per 100000, and including nearly half-a-million cases of 
Multi-Drug Resistant TB (MDR-TB) (1). The burden of disease is unequally distributed 
between countries along gradients of economic output, with over 80% of TB cases 
occurring in 22 high-TB burden low-income developing countries that account for only 
60% of the world population. The worst affected area is sub-Saharan Africa, a region with 
the poorest countries in the world, and where the average incidence was estimated at 281 
cases per 100,000 in 2014, more than twice the global incidence (1).  
While TB is truly a disease of poverty and low-income countries, it still poses significant 
concerns to public health in most developed countries. The annual number of cases in 
many high-income countries is not negligible, considering that TB is a prehistoric disease 
for which relatively affordable advanced diagnostic tools and effective treatment regimens 
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have been available for 70-80 years. It is notable that nearly 50000 new TB cases were 
notified in the seven most advanced economies in the world in 2014 (G7 i.e., France, 
Germany, Italy, United Kingdom, Japan, Canada and the United States of America) (1, 41). 
It was also estimated that approximately 340000 new TB cases occurred in Europe in 2014, 
including over 40000 in subjects born and living in the European Union or European 
Economic Area (EU/EEA) (41). The threat that TB represents in Europe is further 
compounded by the fact that approximately one quarter of all MDR-TB cases in the world 
occurred in this region which only account for about 10% of the world population  (1).  
 
Table 3.1: Annual TB notifications and rates in G7 countries in 2014 
(Source Global TB report 2015 (1)) 
Country name Population 
Number of 
new TB cases 
Rate per 
100000 
Canada 36000000 1568 4.4 
France 64000000 4845 7.4 
Germany 81000000 4488 5.6 
Italy* 60000000 3153 5.3 
Japan 127000000 19615 15 
United 
Kingdom 
64000000 7077 11 
United States 319000000 8949 2.8 
*Note: Italy did not report to WHO and ECDC in 2014 so numbers were extrapolated from 2013 
 
One major change in the global epidemiology of TB was the advent and global spread of 
HIV in the 1980s, which provided TB with the opportunity to thrive in immunologically 
weaker hosts; TB in turn became one of the principal causes of death in HIV-infected 
subjects (42, 43). Although HIV-TB co-infection is less common in HIC than in low and 
middle-income countries (LMIC), it remains a challenge, not least because it mainly 
affects vulnerable subgroups like migrants, homeless people and injecting drug users (44). 
Also, the impact of HIV on TB epidemiology in high-burden settings has worldwide 
repercussions, because of increased population mobility and migration fluxes. Another 
development is the emergence of multi- and extensively- drug-resistant TB (respectively 
MDR-TB [i.e. Mtb strains resistant to both isoniazid and rifampicin, the core components 
of the first line anti-tuberculosis treatment], and XDR-TB [i.e. MDR-TB also resistant to 
fluoroquinolone drugs and at least one of the three injectable second line drugs]), whose 
genetic selection was probably helped by suboptimal treatments and patients’ poor 
adherence to therapy. Outbreaks of MDR-TB were reported from the late 1980s in the USA, 
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with MDR strains subsequently found almost everywhere in the world where drug 
resistance testing is available (45). These resistant strains not only represent a major global 
threat to the arsenal of antibiotics available to combat this old disease, further 
compounded by the substantial lag in discovery and development of novel effective 
therapies (11, 46), but they are also more virulent and severe, more difficult and costlier to 
treat (11); the gruelling treatment regimen often requires patients to take nearly 20 pills 
per day for 24 months (over 14000 tablets in total) and has more adverse side effects than 
standard therapy, and a lower cure rate and higher case-fatality rate than drug sensitive 
TB (11).  
The trends in TB incidence in many developed countries changed from around the mid-
1980s, with a slowing in the pace of decline in annual notification rates, or even a reversal 
with increasing rates (4, 47). While the change was partly attributed to the degradation of 
TB control services in some settings (48), another major contributing factor was the 
increasing number of TB cases reported in people who have migrated from developing 
countries with higher TB incidence towards developed countries where TB incidence was 
lower (4). Nowadays, the burden of TB in most developed countries is greater in people 
with ties to high-TB incidence parts of the world. In the past 5 years in the UK, two-third 
of TB cases have been reported among people born abroad, with a TB notification rate 
estimated at 83/100,000 in this group (5). Large metropolitan areas are more affected; 40% 
of TB cases in the UK occurred in London in 2011, with the TB annual rate nearly three-
times higher than the national average (49). A similar pattern is reported in most Western 
European countries (41, 50). It is thought that most TB in the foreign-born population in 
developed countries is caused by Mtb infection prior to arrival in the country of residence, 
although there is also evidence that re-infection may also contribute to the lifelong risk of 
disease (51). TB rates in the native-born population of these developed countries are not 
negligible, and while a proportion occurs in the elderly population in which the 
reactivation of older LTBI is common, other age groups are also affected. Over the past 10 
years in the UK, nearly 60% of UK-born TB cases were reported in subjects aged 15-64 
years old; this age-group also accounted for three-quarters of MDR-TB among the UK-
born (5). Strain-typing studies from low-incidence developed countries additionally 
suggest that substantial proportions of TB in locally-born adults in such settings are 
caused by recent infection (52, 53). Transmission chains have been shown to be 
concentrated in high-risk population groups including homeless, drug users and prisoners 
(53), and probably sustained by these groups relative social marginalization, deprivation, 
overcrowding and often limited access/contact with the health system. Overall, the re-
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emergence of TB presents a complex and challenging epidemiologic picture in high-
income countries. 
 
3.3. Tuberculosis control strategies in low burden countries  
The main objective of tuberculosis control is to interrupt Mtb transmission cycle, which 
can be achieved through a number of interventions, including the reduction of the source 
of infection in the community through case finding  and effective treatment, with priority 
given to infectious individuals (those with respiratory TB), depleting the reservoir of those 
latently infected using screening and preventive chemotherapy, and prevention of new 
infections through BCG vaccination and infection control measures (54-56).  
In most developed countries, especially in the Western hemisphere, tuberculosis rates 
declined steadily during the 20th century, at an estimated annual rate of 4% in the post-
industrial period, due to a combination of improvement in hygiene and in living standards, 
with some contribution from the sanatorium movement (26, 57-60), then accelerating to 
over 10% per year when medical interventions were added to control measures from 
around the mid-20th century (54, 61). The latter included antibiotic therapy, mass BCG 
vaccination, nationwide mass tuberculin skin testing (TST) and chest X-ray screenings in 
several countries in the 1960s-70s (55). Preventive treatment of latent TB was not widely 
used for various reasons, including the fact that relative to the general population, it was 
a burdensome treatment (antibiotics for up to 9-12 months, with non-negligible risk of 
toxicity in otherwise healthy subjects) with a relatively low impact (very large number of 
individuals need to be treated to avert a single TB case), and there were challenges to the 
diagnosis of LTBI (low specificity of TST and interaction with BCG) (56). Nonetheless, the 
other interventions contributed to bringing down TB incidence in many developed 
countries to such low levels that by the late 1970s, TB control in these countries mainly 
centred around passive case finding and treatment though routine care, and BCG 
vaccination.  
Unfortunately, as noted in the previous section, a global resurgence in TB was observed 
from around the mid-1980s, which also affected trends in low-incidence countries (4). The 
upswing in TB incidence in Western countries was initially thought to be mostly due to 
the emergence and spread of HIV; but the contribution of disinvestment in TB control 
programmes and degradation of services was also noted, as well as the role of socio-
economic factors like the rise in homelessness (48). The change in trends was unfortunate 
because TB incidence had declined to such low levels in some countries that the prospect 
22 
 
of elimination (defined by WHO as TB incidence <1 per million population) was not 
unreasonable (62). It is considered that TB elimination is possible with the interventions 
currently available, because Mtb is a relatively inefficient pathogen with a slow replication 
rate and low transmissibility; there are effective diagnostic tools to identify infectious 
individuals, and these subjects can rapidly be rendered non-infectious with existing 
treatments, therefore interrupting transmission.  
In several high-income settings, the resurgence of TB in the context of low incidence has 
been accompanied by changes to the epidemiological paradigm that have challenged the 
established control strategies and services. Some of the emerging challenges have included 
adapting the TB control strategy to a context in which a substantial proportion of reported 
cases are in foreign-born subjects and results from transmission that occurred out of the 
country, and the concentration of disease in the native population to specific groups with 
high levels of socio-economic deprivation and often social marginalisation, with limited 
interaction with the health system (often identified as ‘hard-to-reach’ or ‘under-served’ 
population groups) (4). These epidemiological changes have contributed to creating 
localised pockets of transmission that have proven difficult to eliminate. For example, 
protracted TB outbreaks limited to specific groups (e.g. UK-born young adults from White 
ethnic background, drug dealers and drug users, sex workers, prisoners etc.) have been 
reported in England (9, 10, 63), and a recent examination of universal strain typing data in 
London has suggested that clustering was more frequent in the UK-born population (53).  
Most affected developed countries have gradually re-invested in their TB control 
programmes and services, and revised their TB control strategies in response to the 
resurgence of TB, including increasingly moving from mostly passive to active case 
finding, through interventions like screening of migrants at higher risk of TB, outreach 
screening activities to high risk populations, and active screening of TB cases’ contacts. 
For example, in England, the recently adopted Collaborative TB Strategy 2015-2020 has 
called for substantial investment in the nationwide expansion of an outreach TB screening 
service targeted at under-served population (including homeless shelters), based on an 
existing model that has been implemented in London since 2005, as well as funding to 
establish new services for testing and treating LTBI in people recently arriving from high 
TB incidence countries; the infrastructure and coordination of TB control services was also 
revised (64, 65). In addition, the development of new medical technologies has 
contributed to improved TB control, including for instance the development of a more 
specific diagnostic test for LTBI, the Interferon Gamma Release Assay (IGRA) (66, 67), and 
shorter chemoprophylaxis regimens (3 to 6 months) (68-70). The IGRA is a blood assay 
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that measures the cell-mediated immune response to selected antigens specific to Mtb, 
including the early secreted antigenic target 6 (ESAT-6) and the culture filtrate protein 10 
(CFP-10), two proteins not produced by all strains of the BCG M. bovis as well as most non-
tuberculosis mycobacteria; this makes the assay more specific than the TST which uses a 
non-specific Pure Protein Derivative (PPD) that contain over 200 mycobacterial antigens 
that causes cross-reactions with mycobacteria other than Mtb  (67, 71). The availability of 
a more specific diagnostic test for LTBI and shorter treatment regimens have permitted 
some countries to expand the prevention of new cases through targeted screening and 
treatment of high risk individuals (including TB cases contacts) (72-74). While these 
improvements to TB control efforts are commendable, recent modelling work has 
suggested that in spite of the contribution of all current medical technologies, the current 
pace of decline in TB incidence even in low incidence countries in which steady decline is 
observed is still not enough to reach the 2015 End-TB global strategy target of TB 
elimination (12). A review of trends in 33 countries and territories with notified TB 
incidence <100 notified cases per million estimated that the average annual decline in the 
27 countries in which steady decline was reported between 2000 and 2012 was about 3% 
per year, and that only 4 countries were likely to meet the pre-elimination target (<10 
notified cases per million) by 2035 (12). The review also noted that the current decline rates 
were far below the 18% or 11% average annual decline required to reach TB elimination (<1 
notified case per million) by 2035 or 2050 respectively (12). The WHO 2015 End-TB global 
strategy recognises that additional actions will be required to make substantial progress 
towards the goal of TB elimination, including for example addressing health inequalities 
in the society and the underlying social determinants of TB, and the development of 
innovative tools like a more effective preventive vaccine (12-14). Poverty reduction can be 
a longer term, complex endeavour requiring political will to be achieved. However, some 
poverty-related social determinants of health inequalities (SDH) may be modified more 
easily, and could represent useful targets for intervention in the short to medium term 
(e.g. good nutrition, better accommodation with adequate ventilation and UV lights etc.). 
The design of such targeted interventions can be informed by a better understanding of 
the pathways through which socio-economic deprivation affects the risk of tuberculosis.  
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Figure 3.1: Observed versus required annual rate of change in tuberculosis (TB) incidence 
to reach TB elimination (less than one case per million) by 2035 in 33 low-incidence 
countries (reproduced from Lonnroth et al 2015 (12), Creative Common Licence). 
 
 
3.4. BCG vaccination against tuberculosis 
The Bacillus Calmette-Guerin (BCG) is an attenuated vaccine developed by the 
eponymous French scientists between 1908 and 1920 through over 230 successive in vitro 
subcultures of a strain of Mycobacterium bovis every 3 weeks (75, 76).  The vaccine was 
first administered to humans orally in 1921, and has since being given mainly via the 
subcutaneous or intradermal route. The use of BCG vaccination as part of TB control 
programmes rapidly expanded after its introduction, especially in response to TB 
resurgence in Europe following the Second World War; it has been estimated that between 
1948 and 1974, more than 1.5 billion infants and children were vaccinated with BCG, 
including through large vaccination campaigns by UNICEF, WHO and the Scandinavian 
Red Cross (76, 77). Nowadays, BCG remains one of the most widely used vaccines in the 
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world; it is part of the routine immunisation programme in more than 165/194 (85%) 
independent countries and territories, including at least 157 where universal vaccination 
of neonates is recommended (21), and the WHO estimates that the vaccine is given to 
about 100 million children every year (20). The BCG vaccine currently used is derived from 
various cultures of the initial BCG strain by various laboratories under different 
conditions, therefore with some genetic diversity between various strains; this has led 
some authors to argue that BCG should not be considered as a single vaccine, but as a 
family of closely related vaccines (75).  
 
Efficacy of BCG vaccination against tuberculosis 
The efficacy of BCG against tuberculosis has been controversial since the initial 
evaluations of the vaccine, with direct effect on national policies and recommendations. 
Most published studies around the world have reported good protection of BCG 
vaccinated infants and children against tuberculous meningitis and miliary, two severe 
forms of the disease commonly reported in young children. The results from these studies 
have been synthesised and discussed in at least four systematic reviews and meta-analyses 
(17-19, 78), with pooled average vaccine effectiveness (VE) against miliary and meningitis 
estimated at about 75% in case-control studies and over 80% in randomised control trials 
(RCT) (17, 19). The most recent systematic review of the six BCG trials in which these 
outcomes have been reported has estimated that on average the vaccine is associated with 
85% (95%CI 69% to 92%) reduction in the risk of meningeal and/or miliary tuberculosis 
compared to placebo, with greater efficacy (90% to 92%) measured in the trials in which 
participants were less likely to have been sensitised to tuberculin prior to vaccination 
(neonatal vaccination or stringent tuberculin skin testing prior to vaccination) (19). 
However, the estimates of BCG’s protection against pulmonary tuberculosis have been 
much more variable between study settings, ranging from no evidence of efficacy, for 
example in India’s Tuberculosis Prevention Trial (TBPT) (VE = -5%, 95%CI -25% to 12%) 
(79), to strong protective effect, including in the British MRC trial (VE = 78%, 95%CI 69% 
to 84%) (80). Overall, eighteen RCTs of BCG efficacy against tuberculosis have been 
published, of which ten did not report any significant protection in the vaccinated group, 
whereas eight trials found significant protection ranging from 28% to 90% (19, 81). The 
possible reasons for this heterogeneity in efficacy have been widely debated, and are 
extensively reviewed by Fine (75, 82). It has been speculated based on the available 
evidence that one of the most important factors is prior infection with Mtb or sensitisation 
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by environmental mycobacteria (both detectable by positive reaction to the tuberculin 
skin test (TST)), which might interfere with BCG. Among other evidence, one argument 
advanced in support of this hypothesis is the geographical gradient in BCG efficacy noted 
in several reviews (17, 19, 75), with greater vaccine efficacy observed in studies at latitudes 
further away from the equator, which is consistent with greater exposure to the ubiquitous 
environmental mycobacteria in the warm and wet climates nearer the equator (27). 
Furthermore, Mangtani et al in their meta-regression analyses of BCG trials found that the 
pooled BCG efficacy was greater in trials in which participants were vaccinated in the 
neonatal period, or after stringent TST, thus less likely to have been sensitised to 
tuberculin prior to vaccination (19). Overall, the meta-analysis of all 18 BCG trials 
estimated BCG average efficacy against pulmonary tuberculosis of respectively 73% 
(95%CI 68% to 77%) at latitudes of ≥40o, 33% (95%CI 9%;50%) at latitudes of 20-40o, and 
13% (95%CI 1% to 23%) at latitudes of 0-20o. The pooled BCG efficacy against pulmonary 
tuberculosis was estimated at 60% (95%CI 44% to 72%) when administered to neonates, 
and 75% (95%CI 69% to 79%) when given to children negative after stringent TST (19, 81). 
In summary, in spite of the variability in the observed levels of protection, the available 
evidence strongly suggests that BCG provides moderate protection against pulmonary 
tuberculosis when administered to uninfected and unsensitised (TST-negative) subjects. 
The current understanding of BCG’s mechanism of action remains limited, and it is 
plausible that the vaccine-derived immune memory wanes with time, leading to a gradual 
decline in BCG efficacy. This is important because while neonatal vaccination as 
recommended by most countries can help prevent severe TB in childhood, the wider 
impact of BCG on transmission depends on preventing pulmonary TB (the infectious form 
of disease), which is more common in later life. Data on BCG duration of protection also 
has implications for cost-effectiveness modelling of vaccination strategies (24). 
Unfortunately, there is little empirical data on the long-term efficacy of BCG against 
tuberculosis and factors that may affect it (24).  
Only a few BCG studies followed-up participants beyond 15-20 years after vaccination, and 
the small number of events beyond 15 years of observation has limited the power of studies 
with longer follow-up. In a previous systematic review of the literature, Sterne et al 
reviewed data from ten RCTs with information on BCG efficacy in tuberculin-negative 
subjects in successive periods of time since vaccination (83). Seven trials reported efficacy 
beyond 10 years of follow-up, but only two trials provided data up to 20-years post-
vaccination. The efficacy of BCG in seven of the ten trials reviewed appear to wane with 
time since vaccination at annual rates varying from 5% to 14%, although this decline was 
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only significant in the British MRC trial, with BCG VE dropping from about 84% 0-5 years 
after vaccination to 69%, then 59% respectively 5-10 and 10-15 years later (84), 
corresponding to an average annual decline of 8% (95%CI 3% to 13%) (83). The systematic 
review of studies on the duration of BCG efficacy was updated in 2013, with the addition 
of 22 non-experimental studies (including nine case-control and five cohort studies) to the 
ten trials in the previous review (81). The conclusions of this latter review were similar to 
the previous, with good evidence of BCG protection against tuberculosis for up to 10-15 
years after vaccination, with effectiveness estimates of between 20% and 50% protection 
after 15 years (81). Only one study with a 60-year follow-up of participants of the US 
American Indians and Alaska Natives BCG trial reported an average VE over 50-years of 
55% (95%CI 31% to 77%), with estimated VE = 48% 40 to 49 years after vaccination (85). 
Overall, the current evidence suggests that BCG-derived protection against tuberculosis 
may decline in time after vaccination, but also that the vaccine efficacy may last beyond 
15 years, which would be longer than previously assumed. Given the variation in VE 
observed across settings, it is also possible that the rate at which the VE decline vary 
between settings.  
 
Population impact of BCG vaccination against tuberculosis 
The overall population impact of BCG vaccination on the TB epidemic has not been 
formally evaluated. There is good evidence of the direct impact of BCG on severe TB in 
children, consistent with the vaccine-derived protection that it affords against miliary and 
meningitis TB (78). For example, the analyses of routine surveillance data from Sweden 
revealed a seven-fold increase in the cumulative incidence of TB in children <5 years old 
in the 5 years following the discontinuation of universal infant BCG in 1975, compared to 
the cumulative incidence in the 5-years prior to discontinuation (86), although the overall 
increase in case number cases was assessed too small to warrant the reintroduction of 
universal vaccination in that country at the time. Similarly, in West Germany, a 2-year 
interruption of infant BCG in the birth cohort 1975-77 was associated with a ten-fold 
increase in the cumulative TB rates, with a re-introduction of routine vaccination due to 
the high TB rates (60 per 100000) in children under 5 years (87). More broadly, Trunz et 
al have estimated through modelling that the 100 million BCG doses administered to 
children throughout the world in 2002 may have prevented between 24000 to 36000 TB 
meningitis and 7300 to 26000 miliary cases in their first 5 years of life, making BCG a very 
cost-effective health intervention with a cost of only about 206USD (95%CI 150USD to 
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272USD) per Disability Adjusted Life Year (DALY) gained (78). By comparison, note that 
England’s National Health Service (NHS) general threshold for public health interventions 
to be considered cost-effective is between 20000GBP (~25000USD) and 30000GBP 
(37500USD) per quality-adjusted life years. 
On the other hand, there is little consensus on the magnitude BCG’s contribution to 
interrupting TB transmission and the broader reduction of TB burden. The variations in 
measured levels of efficacy in different parts of the world, and the fact that the burden of 
TB remains very high in many developing countries in spite of high BCG coverage have 
often been used to support the argument that the vaccine has contributed little to TB 
control (75). Besides, the formal evaluation of the population impact of vaccination has 
been complicated by the fact that even in European countries where high levels of vaccine 
efficacy have consistently been reported, large scale vaccination was introduced at a time 
when several other TB control interventions were concurrently implemented (e.g. 
introduction of antibiotic therapy and chemoprophylaxis, mass TB screening with chest 
X-ray and TST), all of these in the context of rapid recovery in living standards following 
WWII (26, 88). However, there is some evidence in the literature in support of BCG’s role 
in TB Control efforts. For instance, Bjarveit & Waaler (89) compared trends in TB 
notifications in the 1950-60s between three Scandinavian countries in which routine mass 
BCG vaccination was implemented (Norway Sweden and Denmark) to two US states 
where no mass BCG was employed (Upstate New-York and Ohio), but with otherwise 
comparable TB control programmes and surveillance systems. Although TB had declined 
in all five settings over the study period, the average annual rates of decline in TB and 
pulmonary TB (PTB) incidence in the birth cohorts that had received BCG 5-10 years 
earlier were 2-3 times faster than the same birth cohorts in the US states with no routine 
BCG, whereas the pace of decline were similar in all five settings in the older birth cohorts 
which did not benefit from BCG, therefore supporting the hypothesis that BCG may have 
been responsible for some acceleration in the pace of TB decline (89). Similar findings 
were reported by Styblo & Meijer when comparing TB rates in Norway and Denmark to 
The Netherlands where BCG was not used routinely, although it was more difficult to 
disentangle the indirect effect of BCG from that of other interventions  (90).  Using model-
based data, Brewer et al (91) suggested that in the USA, the annual BCG vaccination of 10% 
TST negative non-HIV infected children <15 years and 1% TST negative adults ≥15 years 
could help prevent about 17% TB cases over 10 years, assuming a vaccine effectiveness of 
50% (between 16% cases if VE = 34% and 22% cases if VE = 70%). The importance and 
potential contribution of TB prevention through vaccination to the global fight against TB 
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have also been explored in numerous mathematical models in recent years, including 
various vaccination strategies, as well as the potential impact of new vaccines that could 
interrupt various stages of TB natural history (e.g. prevention of infection or pre-exposure 
vaccination, prevention of progression to disease in infected individual or post-exposure 
vaccination) (16). Most models concur that TB vaccines with better and more consistent 
efficacy than BCG would greatly contribute to reducing the global burden of TB (16), and 
there are ongoing efforts to develop more effective TB vaccines (22, 23).  
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Abstract 
Background: Tuberculosis (TB) notification rates in England and Wales (EW) have 
ceased to decline from the 1980s, due to increased incidence in foreign-born residents and 
plateauing of rates in the UK-born population. Long-term trends in the UK-born 
population and their potential determinants have received relatively less scrutiny than the 
foreign-born population because of the greater burden of disease in the latter group.  
Objectives: To investigate trends in TB notifications rates in England and Wales between 
1983 and 2014 in relation to place of birth, age-group and ethnicity, and assess the interplay 
between these factors and the long-term trends in the UK-born population.  
Methods: Annual notification rates were calculated using numerator data from the 5-
yearly National Tuberculosis Surveys of 1983, 1988, 1993 and 1998 (with information on 
age, sex, place of birth, ethnicity, and clinical data of notified TB cases) and routine 
notifications from the Enhanced Tuberculosis Surveillance system (ETS) from 1999 to 
2014. Adjustment for changes in age-and-sex population composition with time was done 
by direct standardisation using the 2013 population estimates as the standard population.  
Results: The overall TB rates declined at an average annualised rate of 6.5% between 1983 
and 1988 (from 13.2 per 100000 to 9.4 per 100000), with similar trends in the UK-born and 
foreign-born populations. However, the rates ceased to decline from 1988, and had 
increased to 11.1 per 100000 by 1998, and 15 per 100000 by 2005, plateauing thereafter until 
2012. The reversal of trends from 1988 to 2005 appeared to be driven by increased foreign-
born rates and plateauing of rates in the UK-born population. However, since 2006, rates 
have been declining in foreign-born residents, at an average annual pace of 7% (from 121 
per 100000 in 2005 to 63 per 100000 in 2014), whereas TB rates in UK-born have continued 
to be stagnant. The analysis by age-groups shows that in the UK-born population, rates 
have continued to decline in the elderly (≥75 years old) age groups since 1983, whereas 
rates in younger adults have gradually increased, and those in children and older adults 
have plateaued. A stratification by ethnicity also suggested that between 2000 and 2014, 
TB rates have been declining in UK-born ethnic minority groups, whereas they have been 
stagnant in the White ethnic groups.  
Conclusions: The failure of TB rates to decline in the UK-born population of England and 
Wales for over a quarter of a century, especially in young adults and in the White ethnic 
group, suggest the persistence of local pockets of ongoing transmission that challenge TB 
elimination efforts, and underscore the fact that current TB control efforts have not had 
the success expected in these groups, in spite of the availability of effective treatments and 
accessible services.  
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Introduction 
The tuberculosis (TB) notification rate in England and Wales (EW) in 2014 was estimated 
at 12 per 100,000 subjects (1), the same level reported over 30 years ago in 1983 (2). It is well 
documented that from the mid-1980s, trends in TB rates in several developed Western 
countries deviated from the rapid and steady decline observed since the early 20th century, 
to either stagnate or increase (3, 4). The failure of annual TB rates to decline was first noted 
in the United States (US) in 1985 (4), with similar observations following from several other 
developed low TB-incidence countries shortly after, including England (3). The resurgence 
of TB in several developed countries was due to a combination of TB rates ceasing to 
decline in native populations, and to a greater extent, a steep rise in the number of TB 
cases among foreign-born migrants from high TB incidence parts of the world (3). The 
latter was a direct consequence of increased global population mobility, and reflected 
migration patterns from low-income developing countries where the TB burden is greater, 
towards high-income developed countries with low-TB incidence. In most developed 
Western countries, more than 50% of all TB cases are now reported among foreign-born 
subjects (5, 6). Since the resurgence of TB, the epidemiology of tuberculosis in foreign-
born migrants in developed countries has received much attention, including in the UK 
(7-9), and trends in these groups are closely monitored by surveillance systems. 
Understandably, more resources have been allocated to fighting TB in these groups, and 
the TB control strategy and measures have been intensified and adapted to the changing 
face of TB epidemiology in these developed low-incidence countries.  
However, while comparable countries (e.g. USA, Germany, the Netherlands) have been 
able to bring their TB rates under control and return to a sustained decline in annual 
incidence over the past 10-20 years (5, 6), TB notifications in EW have steadily increased 
since the mid-1980s, from under 10 per 100,000 subjects in the mid-1980s to a peak of 15.6 
per 100,000 subjects in 2011 (10). The number of TB cases has dropped slightly since 2012 
(1), but the decline appears to be mostly among foreign-born cases, with very little change 
to TB rates in the UK-born population (1). It is also unclear to which extent the recent 
decline among foreign-born populations in EW is attributable to specific TB control 
measures or other factors, for example migration patterns or global TB trends, and 
whether this decline will be sustained in the medium to long term.  
The stagnant TB incidence among UK-born population in EW have received relatively less 
scrutiny than trends in the foreign-born population. The initial analyses of increased 
notifications from the mid-1980s suggested a possible contribution from the increase in 
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life expectancy and shift in the population age distribution towards older age groups, in 
whom immune-senescence increases the risk of disease due to reactivation of Latent TB 
Infection (LTBI) (11, 12). Other investigations have also noted increasing rates among UK-
born subjects from ethnic minorities, who are at greater risk of Mycobacterium 
tuberculosis (Mtb) exposure and infection. However, the 2015 TB surveillance report in 
England notes a decrease in the number of UK-born cases aged ≥65 years old over the past 
10 years, notably those from the White ethnic group, which contrast with the lack of 
decline in other age groups (1). In contrast to foreign-born TB cases, for whom a substantial 
proportion of cases is thought to result from Mtb infection prior to entry into the UK, thus 
affected by the global TB epidemiology, it is likely that a non-negligible amount of TB in 
the UK native population is caused by recent local transmission. The corollary would be 
that national policies can be tailored to interrupt such transmission, and in doing so, 
progress further towards TB elimination within the country. A better understanding of the 
dynamics and factors that affect TB trends in the UK born population can help inform 
those policies.  
In this study, I investigated trends in the epidemiology of tuberculosis in England and 
Wales between 1983 and 2014 in relation to age-groups, place of birth and ethnicity. My 
main objectives were to gain further insight into the interplay between place of birth and 
ethnicity, and to assess if those three factors affect the trends in the UK-born population.  
 
Methods 
Tuberculosis Notifications (Numerators) Data Sources 
1983-1998: Before the establishment of a central TB surveillance system in EW in 1999, the 
statutory TB notifications reported at the central level through the Notification of 
Infectious Diseases system (NOIDS) did not record information on patient characteristics 
such as the ethnicity, country of birth, time since entry in the UK, and clinical details (date 
of diagnosis, site of disease, previous treatment, bacteriology and histology results, drug 
sensitivity), making it difficult to examine the effect of such parameters on TB trends. 
These variables were examined periodically through special national surveys organised 
starting in 1965, then done in 1978-79, and approximately every 4-5 years thereafter until 
1998 (13). For this study, I used data from the 1983, 1988, 1993 and 1998 national TB surveys, 
respectively conducted by the British Medical Research Council (MRC – 1983 and 1988 
surveys), and the Public Health Laboratory Service (PHLS)/British Thoracic Society 
(BTS)/Department of Health Collaborative Group (1993 and 1998 surveys). The detailed 
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methods for these surveys are published (2, 14-16). Briefly, in the survey year, a copy of all 
TB notification forms received from all 403 local authorities in England and Wales were 
sent to the survey team, which in turn obtained from the notifying clinicians further 
information for each notified case using a clinical form. The detailed demographic and 
clinical information required for the analyses was extracted from the clinical form, with 
additional information on drug-sensibility obtained from the regional centres for 
tuberculosis bacteriology and the Mycobacterium Reference Unit of the PHLS. The 
notifications copies were also checked by the survey team against the weekly returns 
routinely made by local authorities to the Office of Population Censuses and Surveys 
(OPCS), to ensure that all notifications were captured. 
In line with previous national TB surveys, the 1983, 1988 and 1993 surveys collected data 
for the first 6 months of the year from 02nd January to 02nd July, and the number of TB 
cases reported over the survey period was then multiplied by an appropriate scaling 
coefficient that account for the survey period as well as seasonal differences in the 
notifications, to obtain estimates for the whole year. I obtained each survey’s scaling factor 
from the official reports (2, 14, 15) (respectively 1.953 for 1983, 1.9348 for 1988, and 1.886 for 
1993) and applied the same methodology to calculate numerators for these three survey 
years.  
1999-2014: For this time-period, I used TB notifications to the central continuous TB 
surveillance system (also known as the Enhanced Tuberculosis Surveillance system or 
ETS). This system was piloted in EW in 1998 alongside the last national TB survey (16), and 
was formally introduced in 1999. The notification of all TB cases by clinicians to the 
surveillance system is compulsory, with each case report including detailed demographic 
and clinical information. Details on the surveillance system is available from the annual 
surveillance reports (1). Anonymised TB notification data were kindly provided by Public 
Health England (PHE).  
 
Population Estimates (Denominators) Data Sources 
For each notification year, I obtained population estimates by age, sex, ethnicity and place 
of birth from the Office for National Statistics (ONS) Labour Force Surveys (LFS). The LFS 
is a continuous large national survey of household living at private addresses, whose chief 
purpose is to provide information on the residential labour market (17). The survey data 
are primarily used by the UK government for planning and monitoring various social and 
economic policies, but they also routinely used for various health statistics and they have 
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been used to monitor TB notification rates since the 1970s (17). The LFS were done between 
March and May every two years from 1973 to 1983, then annually from 1984 to 1991 
(including quarterly data collection throughout the year and a boost survey between 
March and May), and they have been quarterly since 1992, with various enhancements 
(18). For the analysis period 1993 onwards, I used LFS data from the ‘Spring’ quarter, which 
correspond to the “March to May” period used in previous LFS surveys. Briefly, the survey 
includes the selection and interview of around 150,000 individuals from about 60,000 
households every quarter, using a complex sampling design (17, 18); the reported response 
rates vary between waves from 55 to 80%, and the ONS carry out various adjustment and 
weighting after data collection to account for non-response, as well as reweighting using 
exact population census estimates (17, 18). The details on the surveys’ methodology and 
changes in time are described in details in the LFS documentation (18).  
LFS data are subject to sampling variability given the survey design and sample size. 
However, an advantage of the survey data over ONS mid-year population estimates is that 
whereas the latter are aggregated by age-and-sex, the LFS also provide detailed concurrent 
information by place of birth, ethnicity and time since entry in the UK for those subjects 
born abroad, useful denominators to examine various trends in TB rates. Using this 
population denominator also allows the comparison of our estimates to those in the 
literature, and existing surveillance reports on TB by ethnicity and place of birth, given 
that routine statistics and previous national TB surveys used LFS data as denominators. 
 
Statistical analysis 
Overall and subgroup specific crude annual TB notification rates were obtained by 
dividing the number of TB cases by the corresponding denominator, and the data were 
plotted in graphs. I also calculated age and sex standardised rates to investigate any effect 
of change in the population structure on trends, using direct standardisation by 5-year 
age-sex groups with the 2013 LFS population estimates as the standard population. Average 
trends in TB rates between time periods t0 and ta were examined by calculating the 
annualised percent change (APC) using the formula APC(%) = 100*([TB rate at ta / TB 
rate at t0](1/[ta-t0]) - 1). The APC were based on standardised rates, thus accounting for 
changes in the population age structure. All rates are based on full population data, 
including the very large population denominators (hundred thousand to millions person 
per year), which combined with relatively low TB rates, lead to extremely small standard 
errors and very narrow 95% confidence intervals. 
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I examined trends by place of birth, contrasting the UK born to the non-UK born 
population (called here foreign born), then by broad ethnic group. Self-defined ethnicity 
in the national TB surveys and the ETS are based on the standard categories used by the 
ONS for censuses and LFS. The information on ethnicity was merged into four groups, 
respectively White, Indian Subcontinent (including Indians, Pakistani and Bangladeshi), 
Black (including Black Africans, Black British, Black Caribbean, and Black Other1), and 
Mixed/Others (including Mixed White/Other and Other Ethnicity). I also examined the 
distribution of type of disease by comparing cases with pulmonary involvement 
(Pulmonary TB or PTB) to those with no pulmonary involvement (Extra-pulmonary TB or 
EPTB).  
The information on whether some subjects were born in the UK and the ethnicity was 
missing for a small proportion of notifications since the introduction of the continuous 
surveillance system. Besides the analysis of the subset with complete data, the association 
between missingness and other notifications’ characteristics was first investigated by 
logistic regression. Variables associated with missingness were then used as predictors in 
multiple imputation by chained equations (MICE) models to impute ten datasets. As a 
sensitivity analysis for place of birth and ethnicity subgroups, rates were computed for 
each imputed dataset and then averaged across all ten datasets.  
All analyses were performed in Stata 14® and graphs were produced using Microsoft 
Excel®. 
 
Results 
The estimated numbers of TB notifications for the 5-yearly survey years 1983, 1988, 1993, 
and 1998 were respectively 6449, 4659, 5102 and 5653. There were 117655 TB cases notified 
to the Enhanced Tuberculosis Surveillance system (ETS) from its inception in 1999 till 
2014, increasing gradually from 5692 cases in 1999 to a peak of about 8300 notifications in 
2011 - 2012, then dropping to 6635 cases in 2014 (figure 1). Over the study period, the 
population of EW increased from about 49 million in 1983 to over 57 million in 2014; this 
included more than a doubling in the estimated population of foreign-born subjects from 
about 3.5 million in 1983 to over 7.5 million in 2014. 
The information on whether patients were born in the UK or abroad was available for 96% 
(21089/21863) of notifications in survey years, and 92% (108512/117655) cases in the ETS 
                                                          
1 Number of TB cases and population for Black British, Black Caribbean (formerly named West Indians) 
and Other Blacks were very small, therefore grouped with the larger Black African group. 
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(supplementary table 4.1). The proportion with missing data on place of birth in the ETS 
steadily declined over time from 13% in 1999 to only 2% in 2014. The information on the 
self-reported ethnicity was missing in about 4% cases notified between 1999 and 2014, and 
less than 1% in the surveys data. Missing data on place of birth was strongly associated 
with the year of case report, age, type of TB, ethnic group and sex; and missing data on 
ethnicity was strongly associated with the year of case report, age, type of TB, and whether 
UK-born or not. The detailed results are presented in supplementary tables 4.2 and 4.3. 
All analyses reported below were repeated using the imputed datasets as a sensitivity 
analysis, and the results were identical, including all trends. Therefore, only the complete 
case analyses are reported here.  
 
Overall Tuberculosis Notification Rates in UK-born and Foreign-born 
populations 
The detailed trends in TB notifications and TB rates overall and by place of birth are 
presented in figure 4.1. Between 1983 and 1988, overall TB notification rates (per 100000 
population (/105) in EW declined from 13.2 to 9.4, equivalent to an average annualised 
percent change (APC) of -6.5% per annum (pa). The TB rates were nearly 10 times higher 
in foreign-born than in UK-born subjects, but the decline was observed in both UK-born 
(APC ≈ -7% pa) and foreign-born subjects (APC ≈ -6% pa). The overall rates ceased to 
decline from 1988, with a slight increase to 11.1/105 by the 1998 survey, an average APC of 
about +2% pa During that period, there was an average increase of about +3% pa among 
foreign-born subjects (from 60/105 in 1988 to 80/105 in 1998). TB rates in the UK-born 
population went from about -7% pa decline in the 1983-1988 period to become stagnant at 
about 5/105 from around 1988 onwards. The steady increase in the overall TB rate 
continued after the introduction of the ETS in 1999, until 2005 when rates peaked at about 
15/105 and remained unchanged until 2012. The overall TB rates seem to be declining since 
2013, with a lower notification rate of 12/105 reported in 2014 (see figure 4.1).  
Between 1999 and 2005, TB rates in foreign-born population rose by an average 6% per 
annum (average APC1999-2005 ≈ +6% pa), while TB rates in UK-born subjects remained 
stagnant. During that period, the proportion of foreign-born cases who had developed TB 
within 5 years of entry to the UK also increased, from 45% in 1999 to 60% in 2005. The 
foreign-born population TB rates started to decline consistently from 2006, with an 
average annual percent decline of 7% pa between 2005 and 2014 (including ~14% decline 
between 2013 and 2014 from 72/105 to 63/105). The proportion of foreign-born TB cases who 
were recent migrants also reduced over that period, dropping back to 40% by 2014. The 
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notifications in the UK-born population did not significantly decline over this 2006-2014 
period. The direct standardisation by age and sex did not change any of the observed 
trends (see figure 1). All subsequent results presented are based on age-and-sex 
standardised analyses. 
 
Type of disease  
When looking at the trends in the numbers and distribution of type of TB (figure 4.2), the 
rapid increase in TB rates among foreign-born until 2005 was due to a near 10% average 
annual increase in the number of both pulmonary (PTB) and extra-pulmonary (EPTB) 
cases, going from about 1500 cases each in 1999 to respectively 2700 and 2600 cases by 
2005. The number of foreign-born PTB cases ceased to rise between 2005 and 2012, and 
the yearly increase in EPTB cases slowed from 10% over the same period to about 3% per 
year. From 2013 and 2014, the numbers of foreign-born cases for both type of disease appear 
to be declining in recent years (about 10% and 17% decline between 2013 and 2014 
respectively for PTB and EPTB). In the UK-born population, the numbers and distribution 
of type of TB seem to have been relatively stagnant since 1988 onwards. 
 
Trends in Tuberculosis Notification Rates by Age Groups 
The examination of notification rates by age groups (figure 4.3) show that overall, the 
steady decline in TB rates observed in the elderly population aged ≥75 years in the 1980s 
has continued at a relatively similar pace until 2014 (figure 4.3a). Meanwhile, rates in 
young adults aged 15-34 years rapidly increased from 1988, progressively overtaking TB 
rates in all other age groups to move from being the age group with the 2nd lowest rates in 
1988 (after children aged 0-14 years) in 1988 to become the one with the highest TB rates 
by 2001.  
Focusing on the foreign-born population (figure 4.3b), the increase in TB rates from 1988 
was observed in nearly all age groups, although the rates in the elderly population ceased 
to increase from 1993. By 2005, TB rates in all age groups except the elderly were 
approximately double those observed in 1988, with for example a steep increase among 
young adults aged 15-34 years from TB rate of about 83/105 in 1998 to peak at 166/105 in 
2005, and among children aged 0-14 years from 15/105 in 1988 to 39/105 in 2005. Since 2005, 
TB rates appear to be declining steadily in all age-groups in foreign-born populations, with 
the fastest decline observed in the group with the highest rate, young adults aged 15-34 
years (APC ≈ -9% pa between 2005 and 2014).   
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In the UK-born population (figure 4.3c), the decrease in TB rates observed in the early 
1980s appears to have continued at relatively similar pace in the older age-group (≥75 years 
old). A similar decline in TB rates was observed among subjects aged 55-74 years, until 
around 2005 when rates ceased to decline. In contrast to the older age-groups, the TB rates 
in young adults (15-34 years) gradually increased to move from the age-group with the 2nd 
lowest rates after children aged 0-14 years in 1988 to being the group with the 2nd highest 
rates after the elderly by 2005, and they have relatively been stable since then. The 
notification rates in the other age groups (0-14 and 35-54 years) ceased to decline around 
1988 and they have remained relatively stagnant until recently. 
 
Ethnicity and Tuberculosis Notification Rates 
The trends in TB rates by ethnicity are presented in figure 4.4. It appears the rapid increase 
in TB rates since the 1980s was mostly driven by a steep increase in TB rates among the 
foreign-born Black ethnic group (figure 4.4b), as well as the failure of TB rates to decline 
among foreign-born from the Indian sub-continent (ISC; Indian, Pakistani and 
Bangladeshi). Among foreign-born subjects with Black ethnicity, TB rates increased from 
48/105 in the 1988 survey to 169/105 in the 1998 survey, and from 190/105 in 1999 to peak at 
356/105 in 2005, overtaking the ISC as the group with the highest TB rates in EW among 
foreign-born subjects by 2001; this corresponded to 18 years of over 10% pa year-on-year 
increase in rates. Since 2005, TB rates in Black foreign-born subjects have been falling at a 
steep and steady pace of about 12% per year, dropping below rates in the ISC ethnic group 
in 2009. The TB rates in the foreign-born ISC ethnic group have also been declining since 
2009, by an annual average of 8% pa, although they remain higher than in all other ethnic 
groups in 2014. 
On average, TB rates in the UK-born ISC and Black minority ethnic groups have been 
declining between 2000 and 2014, with the trends since 2008 mirroring those in the same 
ethnic groups in the foreign-born population (figure 4.4c). On the other hand, although 
TB rates in the White majority ethnic group and Mixed and other ethnic groups are much 
lower than among ethnic minorities, they have mainly stagnated over the past 15 years. 
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Discussion 
Summary of main findings 
This long-term retrospective analysis reveals a relatively complex dynamic in the TB 
epidemiology between various population subgroups that underpins trends in TB 
notification rates in EW over the more than 30-year study period. In agreement with 
existing literature, I found that a major contributor to the failure of TB rates to decline 
from the mid-1980s was the rapid rise in TB rates in the foreign-born population. However, 
our analysis further highlighted the fact that this steep increase in rates was 
disproportionately in the Black ethnic group and among young adults since 1993, while 
rates in foreign-born population from the Indian subcontinent (ISC) remain relatively 
stable. I also found that after peaking in 2005, TB rates in the foreign-born population 
groups appear to have been declining at a steady pace in the past 10 years, with the steepest 
drop observed in young adults and the Black ethnic group.  
On the other hand, TB rates in the UK-born population ceased to decline in the mid-1980s 
and have since been stagnating. I found that TB rates in the elderly have been declining 
consistently over the analysis period, whereas TB rates in other age groups, including 
young adults have increased then plateaued. In general in the UK-born population, TB 
rates appear to have been declining consistently in the ethnic minority groups since 2008, 
whereas they have remained relatively stable in the White ethnic group. 
 
Tuberculosis in the foreign-born population 
The rapid increase in number of cases and TB rates in the foreign-born population in the 
mid-1980s, especially the Black ethnic group, is not surprising and reflected migration 
patterns at that time. During that period, the UK experienced large new immigration 
currents from sub-Saharan Africa (SSA), a part of the world in which TB incidence rates 
are among the highest in the world. This population movement was a combination of 
migration from low-income countries in SSA towards higher income countries like the UK, 
in search of better life opportunities in the context of the global economic recession of the 
1980s, and refugees and asylum seekers fleeing hardships from their home countries (19, 
20). This is further evidenced by the fact that the steepest increase in TB rates was observed 
among working-age adults, which represent the largest demographic group of migrants 
(20). The number of asylum applicants to the UK also increased steeply over that period, 
for example from about 5000 in 1987 to over 73000 by 1991 (21). The more stable rates in 
foreign-born subjects from the Indian subcontinent (ISC) are likely explained by older and 
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relatively stabilised migration patterns, dating from the 1950-60s, which were restricted 
by the 1970s following the passage of the UK Immigration Act 1971.  
It is likely that the emergence and spread of HIV in the 1980s and the associated resurgence 
of TB in sub-Saharan Africa (22) have also contributed to increasing TB rates in foreign-
born young adults in EW, especially in those from Black African ethnic background. The 
linkage of data from the 1993 and 1998 national TB surveys to HIV surveillance databases 
showed that in 1993, 8.5% TB cases in Black Africans aged ≥15 years were HIV positive, 
increasing to 10% in 1998 (23). Furthermore, an audit of surveillance data from 1999 to 
2003 suggested that about 20% of TB cases reported in non-UK born Black Africans aged 
≥15 years were co-infected with HIV (24). However, the impact of HIV on overall TB trends 
in foreign-born subjects was slightly mitigated by the fact that HIV/TB coinfection rates 
were much lower in the other foreign-born ethnic groups. For example, the HIV/TB co-
infection rates in foreign-born TB cases aged ≥15 years from Indian, Pakistani or 
Bangladeshi ethnic background remained stable at 0.4% in 1993, 1998, and between 1999 
and 2003 (at a time when they constituted between 40% and 50% of foreign-born TB cases 
aged ≥15 years, compared to 11% to 25% for Black Africans) (23, 24), with an overall rate of 
HIV/TB co-infection among all foreign-born TB cases aged ≥15 years between 1999 and 
2003 of 7.2% (24).    
The reasons behind the decline in TB rates among foreign-born subjects observed since 
2006 are less clear. The close monitoring of TB epidemiology in foreign-born populations 
in most low-incidence countries since the disease resurgence from the mid-1980s to early 
1990s may have played a role in disease control. In several countries, including in the UK, 
the TB prevention and control strategies have been adapted to account for changes to TB 
epidemiology, and substantial investment were made in control efforts targeting TB in 
foreign-born subjects. Such efforts included for example the introduction or scaling up of 
various combinations of pre-entry, upon-entry and post-entry screenings for active 
pulmonary tuberculosis and treatment, and treatment of LTBI (25). However, there is little 
evidence of the effect of these specific measures on the TB trends in England. Interventions 
like chest X-ray screening of travellers for tuberculosis at ports of entry have been shown 
to have a very low yield and not to be cost-effective (26, 27). The implementation of global 
system for the systematic pre-entry screening of prospective travellers from 101 high TB 
burden countries towards the UK only completed recently between 2012 and in 2014 (28, 
29). Before that, the pre-entry system was piloted between October 2005 and September 
2012 in only 15 countries (Bangladesh, Burkina Faso, Cambodia, Cote D’Ivoire, Eritrea, 
Ghana, Kenya, Laos, Niger, Pakistan, Somalia, Sudan, Tanzania, Thailand and Togo), with 
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the analysis showing an annual screening yield during the pilot period ranging from about 
10 cases in 2006 to a maximum of just over 100 cases in 2009 (29). Overall, while the now 
expanded pre-screening programme may have an impact on future TB epidemiology in 
foreign-born subjects, it is unlikely to explain the decline in rates in the foreign-born 
populations, observed since 2006. Overall, while investments in TB control have gradually 
improved, and public health control efforts have been scaled up, there is no obvious public 
health interventions to which the steady decline in TB notifications observed in the 
foreign-born population since 2006 can be attributed.  
Meanwhile, prior publications have highlighted the strong correlation between 
immigration policies and migration patterns, and tuberculosis rates in low-incidence high-
income countries (30). Our analysis also noted the positive correlation between the trends 
in TB rates in foreign-born subjects and the proportion of foreign-born cases who were 
recent migrants. It is interesting that the 2005 peak in TB incidence among foreign-born 
observed in EW and subsequent decline in rates coincided with a similar pattern in the 
number of asylum applications to the UK three years earlier and changes to migration 
laws. In 2002, the UK passed the National, Immigration and Asylum Act 2002, a major 
policy change aimed at discouraging asylum seekers and some migrants from coming to 
the UK, including a range of measures such as curtailing support and rights for asylum 
seekers. The changes to the immigration laws that lead to a drastic reduction in the 
number of asylum applications in the UK, from a peak of 103081 applications in 2002 to 
60047 in 2003, and 22644 by 2010 (31). Although asylum seekers may only constitute a 
small proportion of net migration to the UK, this population group tend to include more 
vulnerable and relatively poorer subjects, compared to other migrants from the same 
country of origin, thus likely to have higher risk of disease. Several authors have reported 
the high prevalence of TB and LTBI among asylum seekers (32, 33), and given that the risk 
of active disease is highest in the 2-5 years following infection, it would not be surprising 
if recent trends in TB rates among foreign-born subjects were significantly influenced by 
the number and country of origin of refugees and asylum seekers. The trends in number 
and provenance of asylum seekers to the UK may have contributed to the decline in TB 
rates observed in the foreign-born population since 2006, especially in the Black African 
groups in which the number of asylum application dropped almost exponentially from 
over 36000 in 2002 to approximately 8500 by 2010 (31), while TB rates fell from about 
350/105 in 2005 to 125/105 by 2013. There was no major change in TB public health policy or 
public health interventions around 2004-2005 or earlier, to which the sudden and 
complete reversal in TB trends in foreign-born population may be solely attributed. As the 
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number of asylum applications to the UK has been increasing since 2011, health policy 
makers may need to be aware of its potential influences on future TB trends, which would 
be important for planning. Finally, TB trends in the foreign-born population are likely also 
influenced by the trends in their respective country of origin. Substantial gains have been 
registered in the past 10 years in the global fight against TB, with significant reduction in 
incidence and disease burden in many countries (34, 35). It is therefore possible that part 
of the recent decline in TB rates in the foreign-born population of EW may be ripples from 
the shift in the global epidemiology of TB, although this would difficultly by itself explain 
the near 10% average annual decline in foreign-born TB rates registered in recent years.  
 
Tuberculosis in the UK-born population 
In contrast to the foreign-born population in which TB rates have been dropping in recent 
years, TB rates in the UK-born population of EW appear largely unchanged in over two 
decades. It is not surprising that in the UK-born population, the rates are higher in British 
Asians and Black ethnic minority groups compared to the White ethnic majority. These 
groups have a higher risk of TB due to their links to high-TB incidence regions the world, 
including through relatives and community contacts, as well as possible travels to these 
areas (36, 37). Note that the TB trends in the UK-born ethnic minority groups in recent 
years have largely mirrored those in their respective foreign-born counterparts, including 
a similar steady decline in rates observed since 2005. One hypothesis is that the greater 
proportion of TB among UK-born subjects from ethnic minority groups results from 
transmission within the UK rather than during travels abroad in the high-TB incidence 
regions to which they have links. It also highlights the importance that TB control efforts 
in the foreign-born population may play in reducing transmission locally. But note that 
the White ethnic group still account for more than 60% of UK-born TB cases, and the rates 
in this group have mostly been stagnant. 
The trends by age groups in the UK-born population also suggest that the status quo is 
not a mere consequence of an aging population and a shift in the age distribution of 
disease towards the elderly. Overall in the UK-born population, TB notification rates in 
the older population groups have continued to decline at fairly steady pace over the past 
three decades, whereas the incidence in younger adults have increased in the mid-1980s, 
then stabilised. Disease in the adult population is more likely to be a consequence of recent 
infection rather than reactivation of an older infection, especially given the very low risk 
of infection in the UK (e.g. average annual risk of infection estimated to <4 per 1000 in 
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1971-73 and rapidly declining) (38). This suggest that ongoing Mtb transmission within the 
UK may substantially contribute to the failure of TB rates to decline in the UK-born 
population.  
It has been noted that in countries with low TB incidence, including the UK, the disease 
tends to be concentrated in specific groups with higher risk, and often limited access or 
contacts with the health system (5). Tuberculosis has long been known as a disease of 
poverty, with high prevalence reported in groups like the socio-economically deprived, 
homeless people and ex-prisoners. There have been consistent reports of rising levels of 
poverty in EW over the past three decades, which may have contributed to sustaining low 
levels of TB transmission in some segments of the population. For example, the Economic 
and Social Research Council (ESRC)-funded Poverty and Social Exclusion in the UK 
surveys (PSE) have estimated that in 2012, household overcrowding was back to levels 
found in 1983, with nearly 10% household affected, and also that number of people living 
in inadequate housing conditions had increased from 9.5 million in 1999 to nearly 13 
million (39). A rise in the number of homeless subjects and rough sleepers has also been 
noted across the country (40). However, poverty does not directly cause TB, and it would 
be helpful to better understand the pathways through which poverty and deprivation 
increase the risk of TB in the adult UK-born population. The insight that such an analysis 
will provide can help inform the TB control efforts directed at this specific population 
group.  
 
Strengths and Limitations  
My interpretation of TB trends in EW is dependent on the results being accurate, 
unbiased, and not substantially affected by artefacts. The population denominators used 
to calculate the rates were derived from the Labour Force Survey (LFS) data. These surveys 
are designed to be representative of the resident population, and the datasets offer readily 
available estimates for different population subgroups that are otherwise not routinely 
available, for example estimated numbers by place of birth, ethnicity and age groups; this 
is the reason the data is commonly used for various official health statistics and for policy 
planning (17). A limitation of the LFS data is that some smaller segments of the population 
may be underrepresented (e.g. older subjects from non UK-born minority ethnic groups) 
(18), which in turn may lead to unstable and/or inaccurate estimates. While this limitation 
may affect the accuracy of TB notification rates estimates in smaller population groups, it 
is unlikely to have had great effect on the trends over the more than 30-year study period, 
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especially given that the same denominator source was used throughout. Another 
challenge with the denominator was accounting for changes in the population structure 
over the long study period, as well as the doubling of the foreign-born population. I 
explored this through direct standardisation or age and sex, and there was very little effect 
on the TB rates trends.  
The TB notifications on the other hand depend on the completeness of reporting. The data 
I used to examine trends from 1983 to 1998 were collected as part of an extensive national 
survey that included an audit of routine notifications (2, 14-16), and therefore unlikely to 
be affected by under-notification. An audit of the ETS using capture-recapture methods in 
the four years 1999-2002 following its implementation suggested about 15% under-
notification overall, but improving in time (41). A triangulation exercise that compared TB 
reports from routine notifications, the national surveys (and the surveillance system from 
1999) as well as laboratory data between 1988 and 2000, also found that trends in 
notifications over that period were not greatly affected by completeness (42).  
While I acknowledge that the results presented here are purely descriptive, no obvious 
events in the study timelines could be found that may have caused an artefact that affected 
or explained the observed trends. A pan-London surveillance system – the London TB 
Register - was introduced in 2002 to improve TB surveillance across the capital city, given 
that London accounts for over one-third TB cases in EW (43). However, it did not have 
any visible effect in the trend, as there was no sudden change in the number of TB cases 
reported following the implementation of the register. Another significant change to TB 
control was the introduction of a mobile screening unit in London in April 2005, for active 
case finding in hard-to-reach groups like the homeless (44, 45). But this outreach service 
only report about 100 cases per year (44), so it cannot explain the peak in TB notification 
rates in 2005, nor the subsequent steady decline observed in foreign-born and UK-born 
ethnic minorities since 2006. Overall, in spite of the data limitations, the estimates 
presented here are likely to be a robust reflection of the underlying trends in TB rates in 
England and Wales over the study period. 
I also note that TB surveillance data published since the present analyses were conducted 
have shown a steady year-on-year decline in TB rates in the UK-born population in recent 
years, including across all ethnic groups (46). Although the relative distribution of cases 
by ethnic group has remained stable, the number of UK-born TB cases has dropped by 
22.7% between 2012 and 2015, including a 21.5% decline in White UK-born subjects (46). 
This correspond to an average 8% annual decline in the overall number of UK-born TB 
cases over this 4-year period. However, the reason for the recent decline after decades of 
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stagnation are not clear. It has been speculated that this might be linked to a combination 
of a reduction in the number of foreign-born cases (via the pre-entry screening programme 
and also lower number of migrants from high TB burden countries), and better TB control 
measures in the UK (including improvement in TB control and early impact of the new 
programme of testing and treating latently infected (LTBI) subjects) (46). Investigations 
are required to understand factors that underlines these recent trends and whether they 
are likely to be sustained; but these are beyond the scope of this thesis.  
 
Conclusions and recommendations  
In summary, my analyses of trends in TB notification rates in various population 
subgroups in EW reveals a relatively complex epidemiology. It appears that TB rates have 
been declining at steady pace in the foreign-born populations as well as the UK-born 
ethnic minorities in recent 8-10 years. The trends in the foreign-born population may have 
been affected by immigration policies to a greater extent than public health interventions. 
This deserves further investigation, because if likely, this link would be important for 
forecasting future trends as well as policy planning, including, for instance, designing 
targeted and acceptable cost-effective interventions or strategies. At the same time, the 
close correlation between rates in the foreign-born population and UK-born ethnic 
minority groups highlights the importance of close monitoring and sustaining TB control 
efforts in foreign-born population within EW. It appears that TB control efforts targeted 
at the UK-born population did not have the expected success over the study period, as 
rates have been stagnating in this population over nearly a quarter of a century, in spite of 
the availability of services and effective treatments. Furthermore, this lack of progress in 
control mainly affect younger age groups, underscoring the fact that there remain pockets 
of sustained transmission in the country that may be difficult to interrupt. If there is any 
chance of progressing towards elimination of TB as a public health problem in EW in the 
near future, such pockets of transmission need to be identified, and the factors that have 
prevented the current control strategy to be effective should be better understood and 
dealt with.  
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Figure 4.1: Distribution of notified TB cases and TB rates in England and Wales in 1983, 
1988, 1993, 1998 and 1999-2014 
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Figure 4.2: Number of TB notifications by place of birth and type of TB (Pulmonary TB 
(PTB) and Extra-Pulmonary TB (EPTB)) in England and Wales 1983-2014 
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Figure 4.3: Age and sex standardised TB notification rates in England and Wales 1983-
2014 by age group, overall, and in UK born and Foreign born populations 
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Figure 4.4: Trends in TB notification rates by ethnic groups in England and Wales 1983-
2014 
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Supplementary tables 
Supplementary table 4.1: Missing data on place of birth and ethnicity in TB 
notifications by reporting years 
Notification 
year  
UK born or 
foreign-born 
(%) 
Self-reported 
ethnicity (%) 
All notifications 131723 9727 (7.4%) 4639 (3.5%) 
1983* 3302 21 (0.6%) 0 (0.0%) 
1988* 2408 51 (2.1%) 4 (0.2%) 
1993* 2705 137 (5.1%) 0 (0.0%) 
1998* 5653 375 (6.6%) 77 (1.4%) 
1999 5692 736 (12.9%) 348 (6.1%) 
2000 6224 921 (14.8%) 388 (6.2%) 
2001 6421 914 (14.2%) 564 (8.8%) 
2002 6858 753 (11.0%) 342 (5.0%) 
2003 6819 627 (9.2%) 295 (4.3%) 
2004 7144 600 (8.4%) 171 (2.4%) 
2005 7891 706 (8.9%) 277 (3.5%) 
2006 7893 809 (10.3%) 286 (3.6%) 
2007 7817 677 (8.7%) 338 (4.3%) 
2008 8023 545 (6.8%) 249 (3.1%) 
2009 8356 570 (6.8%) 348 (4.2%) 
2010 7828 371 (4.7%) 296 (3.8%) 
2011 8389 307 (3.7%) 271 (3.2%) 
2012 8266 298 (3.6%) 186 (2.3%) 
2013 7399 167 (2.3%) 111 (1.5%) 
2014 6635 142 (2.1%) 88 (1.3%) 
*1983, 1988, and 1993 notifications based on national TB surveys, thus only half-year data 
 
67 
 
Supplementary table 4.2: Association between missingness of place of birth and 
notification’s characteristics  
(All notifications included except 3.5% with missing data on ethnicity; N= 127084) 
 
# with 
missing data 
(prevalence 
in %) 
Crude Odds Ratio  
(95% CI) 
p-
value 
Adjusted Odds 
Ratio* (95% CI) 
p-
value 
Sex      
Female 4159 (7.1%)     
Male 5568 (7.6%) 1.12 (1.06; 1.18) <0.001 1.07 (1.02; 1.13) 0.005 
Age group      
0-14 years 470 (6.9%)     
15-29 years 2244 (6.1%) 0.91 (0.80; 1.03)  0.93 (0.81; 1.06)  
30-49 years 3137 (6.6%) 0.97 (0.86; 1.10)  0.95 (0.84; 1.08)  
50-59 years 1142 (8.5%) 1.35 (1.18;1.55) <0.001 1.18 (1.03; 1.35) <0.001 
60-79 years 2062 (9.8%) 1.65 (1.45; 1.87)  1.33 (1.17; 1.52)  
≥80 years 672 (11.7%) 2.08 (1.79;2.41)  1.61 (1.38; 1.87)  
TB type      
Pulmonary  4864 (8.0%)     
Extra-pulmonary 4049 (7.1%) 0.81 (0.77; 0.85) <0.001 0.94 (0.89; 1.00) 0.011 
Both 780 (6.0%) 0.78 (0.71; 0.85)  0.88 (0.81; 0.97)  
Ethnic group      
White 2458 (7.6%)     
Indian 1623 (5.6%) 0.72 (0.68; 0.77)  0.86 (0.82; 0.94)  
Pakistani 774 (3.9%) 0.49 (0.45; 0.53)  0.59 (0.54; 0.64)  
Bangladeshi 173 (3.4%) 0.50 (0.43; 0.59) <0.001 0.63 (0.53; 0.74) <0.001 
Black African 791 (3.3%) 0.41 (0.75; 0.98)  0.54 (0.49; 0.59)  
Black Caribbean 271 (6.6%) 0.86 (0.75; 0.98)  1.04 (0.91; 1.18)  
Other and Mixed 
White/Other 
550 (4.1%) 0.51 (0.47; 0.57)  0.65 (0.59; 0.72)  
*Adjusted for all variables in the table and notification year 
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Supplementary table 4.3: Association between missingness of ethnicity and 
notification’s characteristics  
(All notifications included except 7.4% with missing data on ethnicity; N= 121996) 
 # with 
missing data 
(%) 
Crude Odds 
Ratio (95% CI) 
p-
value 
Adjusted Odds 
Ratio* (95% CI) 
p-
value 
Sex      
Female 2098 (3.6%)     
Male 2541 (3.5%) 0.96 (0.86; 1.06) 0.403 0.96 (0.87; 1.06) 0.394 
Age group      
0-14 years 262 (3.8%)     
15-29 years 1252 (3.4%) 0.97 (0.78; 1.21)  0.77 (0.62; 0.97)  
30-49 years 1664 (3.5%) 0.89 (0.71; 1.10) <0.001 0.70 (0.56; 0.88) <0.001 
50-59 years 477 (3.6%) 0.70 (0.53; 0.91)  0.58 (0.44; 0.76)  
60-79 years 759 (3.6%) 0.64 (0.50; 0.83)  0.58 (0.45; 0.74)  
≥80 years 225 (3.9%) 0.75 (0.54;1.04)  0.70 (0.50; 0.98)  
TB type      
Pulmonary  2195 (3.6%)     
Extra-pulmonary 2097 (3.7%) 0.95 (0.85; 1.05) 0.402 0.83 (0.75; 0.93) <0.001 
Both 347 (2.7%) 0.90 (0.75; 1.08)  0.79 (0.66; 0.95)  
Place of birth      
UK-born 349 (0.9%)     
Foreign-born 1230 (1.4%) 1.54 (1.36; 1.73) <0.001 1.49 (1.31; 1.89) <0.001 
*Adjusted for all variables in the table and notification year 
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Abstract 
Background: Tuberculosis (TB) rates in England are among the highest in developed 
countries and have not declined in over a decade. Poverty has long been known as a driver 
of tuberculosis, although in England, the greatest burden of disease is reported in foreign-
born residents from high TB incidence parts of the world. Little has been done in recent 
years to examine socio-economic trends in TB rates in England, and to disentangle the 
role of deprivation from that of place of birth in the current TB epidemiology.   
Objectives: To measure the overall association between England’s 2008-2012 TB 
notification rates and small area-level deprivation, as well as separately in the UK-born 
and foreign-born populations.  
Methods: Ecological analysis of the association between quintiles of England’s 2010 Index 
of Multiple Deprivation (IMD) rank and TB rates at the Lower-layer Super Output Area 
(LSOA; average population ~1500) level, measured with negative binomial and zero-
inflated negative binomial regression models, adjusting for age, sex, urban/rural area 
classification, and area-level percentage of non-White residents.  
Results: There was a log-linear gradient between area-deprivation levels and TB rates, 
with overall TB rates in the most deprived quintile areas three times higher than the least 
deprived quintile after adjustment for age and sex (IRR=3.35; 95%CI: 3.16 to 3.55), and 80% 
higher (IRR=1.81; 95%CI: 1.71 to 1.91) after further controlling for the urban/rural 
classification and percentage of non-White residents. The association and gradient appear 
stronger in the UK-born than the foreign-born population, with UK-born TB rates in the 
most deprived quintiles about two-and-a-half times higher than the least deprived quintile 
(IRR=2.39; 95%CI: 2.19 to 2.61) after full adjustment, whereas the comparable figure for 
foreign-born subjects was 80% higher (IRR=1.78; 95%CI: 1.66 to 1.91).     
Conclusions: The results suggest that socio-economic deprivation continues to play a 
substantial role in sustaining the TB epidemic in England, especially in the UK-born 
population, and support the case for further investigations into the underlying social- 
determinants of TB.   
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Background 
The tuberculosis (TB) annual notification rates in England remain among the highest in 
high-income countries. Annual rates in England during the past decade have stagnated 
between 12 and 15 per 100,000 persons (1), over four times higher than in the USA (2), and 
two to three times higher than in France, Germany and the Netherlands (3) for example. 
The greatest burden of disease - for instance nearly three-quarters of notified TB cases in 
2015 - is observed among people born out of the United Kingdom, especially in population 
groups originating from parts of the world with high TB incidence and prevalence (1). The 
disproportionate distribution of disease in these population groups is well established, and 
it has received wide attention in terms of both investigations and public health policies 
and actions (4-6). A steady decline in the number of foreign-born TB cases in England has 
been reported in the past five years (1), possibly due to a combination of lower immigration 
from high burden countries and public health measures (e.g. 2012-2013 introduction of 
pre-entry TB screening for 101 countries with high TB incidence (7, 8)). 
Whilst the heightened attention to TB in high-risk foreign-born subjects is justified and 
commendable in light of the greater disease burden in this group, it may have 
overshadowed the fact that TB rates in UK-born subjects have ceased to decline nearly 30 
years ago, with rates increasing from the mid-1980s and plateauing in the past 20 years 
(see manuscript 1). In the UK-born population, TB seems to concentrate mainly in the 
most vulnerable and socio-economically deprived segments of the population, in which 
there is some evidence of ongoing local transmission (1, 9). These stagnant rates in the 
UK-born population of England occur in spite of the country being among the wealthiest 
in the world, and therefore capable of affording and implementing the most effective TB 
control interventions and tools available to eliminate the disease as a public health 
problem. The World Health Organisation (WHO) projections, based on mathematical 
models, further suggest that even in countries with low TB incidence (i.e. annual TB 
notifications <10 per 100,000 people), the implementation of the current array of TB 
control interventions may need to be supplemented by additional measures in order to 
meet the post-2015 global TB strategy goal of reaching pre-elimination levels (defined as 
annual notifications <1 per 100,000) by 2035 and elimination levels (defined as annual 
notifications <1 per million) by 2050 (10). The recommended additional measures include, 
among others, increased efforts and actions to address and reduce the underlying social 
determinants of tuberculosis (10).  
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Social deprivation and poverty are among the oldest known drivers of TB, highlighted in 
part by the correlation between improvements in the standard of living and nutrition, and 
the steady and rapid decline in TB rates and mortality in Western Europe during the first-
half of the 20th century (11), before the large-scale introduction of medical technologies 
like chest X-Ray screening, antibiotic therapy and vaccination (12). Because of the 
resurgence of TB in England in the mid-1980s to early 1990s, several studies attempted to 
examine the potential contribution of social deprivation to reversing the disease trends. 
Using available routine data, several ecological analyses measured the association between 
TB notification rates and area-level deprivation, with most reporting higher TB rates in 
the most deprived areas of the country, and in doing so, helping to draw the attention to 
the disproportionate burden of disease in the most deprived communities, and to 
prioritise and allocate resources; a summary of these studies is presented in Table 5.1. 
However, these previous studies faced the challenge of disentangling the role of 
deprivation to that of place of birth in explaining higher TB rates in deprived areas (13, 14), 
because of the conflation of these two determinants of disease at the area-level (see table 
5.1). The population density of foreign-born subjects, especially from high-TB burden and 
low-income countries, is higher in metropolitan areas where there are more employment 
opportunities, with the greater proportion often residing in deprived areas where 
accommodation may be more affordable, among other reasons.  
Unfortunately, until the introduction of a central TB surveillance system in England in 
1999, the information on the place of birth of notified TB cases was not routinely reported, 
with the data collected systematically only during the 5-yearly national TB surveys (15). 
This limited the ability to separately investigate the association of area-level deprivation 
to TB rates in UK-born and foreign-born subjects. The coalescence between these 
determinants of TB risk may have obfuscated the relationship between deprivation and 
tuberculosis in the UK-born population, raising the question of whether the previously 
reported relationship between TB notification rates and area-level deprivation merely 
reflects the fact that there are more foreign-born subjects at higher risk of TB (thus more 
foreign-born TB cases) residing in the deprived area, with weaker or no real gradient in 
UK-born TB rates across area deprivation levels. It is also notable that the most recent 
study examining this question used data nearly 20 years old (16), predating the 
introduction of the new TB surveillance system and therefore not accounting for changes 
to the TB epidemiology in England in the past two decades. Prior studies may have also 
been limited to some extent by the relatively large geographical area and heterogeneity in 
the population size of the analyses study units. The smallest study unit used by previous 
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research was the electoral wards, with population size varying from under 5000 to over 
26000 persons per ward (17, 18); whereas some studies using units as large as local 
authorities (14) (population estimates in 2001 varying from 35165 in West Somerset to 
990384 in Birmingham). In 2001 the UK Office for National Statistics (ONS) introduced a 
more homogeneous geographical statistical unit for data collection and area-level 
statistics outputs in England, the Output Area (OA), which allows populations to be 
grouped in smaller and more socially-homogenous geographical units of similar size (19).  
As little has been done in recent years to examine socio-economic trends in TB rates in 
England in an era of rapid population movements and travel, and in view of the availability 
of more information than in previous years, this study was designed to investigate the 
current relationship between tuberculosis notification rates between 2008 and 2012 in 
England and area-level deprivation, as well as to attempt to disentangle the potential role 
of place of birth and deprivation by examining this association separately in UK-born and 
foreign-born populations. I also explored the relationship between TB in children aged 0 
to 14 years (a proxy-measure for local TB transmission given most cases likely result from 
recent infection) and area-level deprivation. 
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Table 5.1: Overview of previous ecological studies of the association between TB notification rates and area-level deprivation in England 
First 
Author 
Year  
Setting & Study 
Unit 
Years of TB 
notifications 
Deprivation 
Measure 
Other measures Analysis Results Limitations 
Spence (20) 1993 
33 Electoral Wards 
of Liverpool 
Notifications 
1985-1990 
Townsend† & 
Jarman‡ 
% free school 
meals & % 
council housing 
Correlation 
coefficient 
Strong correlation between 
deprivation and overall TB 
rates (association remain when 
ethnic minorities excluded) 
No distinction 
UK born vs 
Non UK born 
Bhatti (14) 1995 
Local Authorities in 
England and Wales 
(403 in total in 
England & Wales)  
(and Hackney) 
Notifications 
1980-1992 
Jarman 
Census 1991 
None 
Indirect age-
sex 
standardisation 
using national 
rates 
Proportion increase by ethnic 
groups. Increase in 30% poorest 
but not in remainder. Strong 
association with overcrowding 
No distinction 
UK born vs 
Non UK born 
Mangtani 
(21) 
1995 
32 London Borough 
of London 
Notifications 
1982-1991 
Townsend 
and 
Carstairs¥  
Unemployment 
overcrowding 
social class and 
proportion 
migrants 
Indirect 
standardisation 
and Poisson 
regression 
Proportion migrants and 
overcrowding associated with 
TB rates, but not associated 
with trends in TB rates 
No distinction 
UK born vs 
Non UK born 
Tocque (22) 1998 
33 London 
boroughs and 36 
metropolitan 
districts in England 
Notifications 
1991 
Jarman   
Correlation 
coefficient and 
Poisson 
regression 
Positive correlation Jarman and 
TB rates, but less strong 
correlation when immigration 
component removed from 
Jarman index 
No distinction 
UK born vs 
Non UK born 
Hawker (18) 1999 
39 Electoral Wards 
of Birmingham 
Notifications 
1989-1993 
Townsend 
score 
Ethnicity 
Linear 
regression 
Association overcrowding in 
White population but not 
Asians  
No distinction 
UK born vs 
Non UK born 
Tocque (23) 1999 
Council wards in 
Liverpool 
Average 
Annual TB 
rate 1981-85 
and 1991-95 
Jarman  Ethnicity  
Multivariable 
regression 
Positive association TB rates 
and unemployment in 1981, but 
in 1991, overcrowding, elderly 
living alone and proportion 
household with head from new 
commonwealth 
No distinction 
UK born vs 
Non UK born 
Bennett (17) 2001 
Electoral Wards of 
Manchester, 
Liverpool, 
Hospital 
admissions 
1991-1995  
Jarman, 
Townsend 
and Carstairs 
% born in India 
and Pakistan  
Multilevel 
Poisson  
Main explanatory is percentage 
born in India and Pakistan 
No distinction 
UK born vs 
Non-UK born 
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Birmingham and 
Cardiff 
% residences 
overcrowded % 
residence / not 
owner occupied 
Parslow (16) 2001 
Electoral Wards of 
Leeds 
Cases aged 0-
18 years in 
Leeds Chest 
clinic register 
1982-1997 
Carstairs  
Proportion non-
White children 
<19yrs and 
population 
density 
Negative 
binomial 
regression of 
age sex 
standardised 
rates 
TB rates associated with 
ethnicity but not deprivation; 
TB in non-ethnic minority 
associated with deprivation 
No distinction 
UK born vs 
Non UK born 
†Townsend index (24) is an overall deprivation index of material deprivation based on 4 census indicators (% economically active residents aged>16 years, 
% households with no car, % owner occupied houses and % houses with >1 persons-per-room 
¥Carstairs index (25) is an indicator of material deprivation based on 4 census indicators (unemployment among men, car ownership, low social class and 
overcrowding) 
‡Jarman index (26) is a composite measure of deprivation designed to identify underprivileged areas where social factors may be associated with higher 
General Practitioners workload, based on 8 census-derived variables (% old-age pensioners living alone, number of children <5 yeas, % single parent families, 
number of unemployed residents, number of unskilled workers, poor housing, overcrowding [% households with >1 person-per-room], population mobility 
[households who moved residence at least once a year], and % households headed by a person from ethnic minority or born in the new commonwealth) 
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Methods: 
Study design and setting:   
Ecological study investigating the association between TB notification rates in England 
from 2008 to 2012 and small-area measures of deprivation in UK-born and foreign-born 
populations (the term ‘foreign-born’ in this study refer to subjects born out of the UK).  
 
Study unit:  
The unit of analysis was the Lower-layer Super Output Area (LSOA), which consist of the 
aggregation of several neighbouring Output Areas (OAs). The OAs were introduced by the 
Office for National Statistics (ONS) following the UK 2001 census with the aim to improve 
the data collection and reporting of small-area statistics used by local and central 
governments for policy and planning (e.g. data on education, health, employment, crime 
etc.), by providing small geographical units of fairly similar population size that contains 
socially-homogenous households. By comparison, data collection and reporting was 
previously based on enumeration districts of various superficies and population size, 
whose shape and size were determined by data collection requirements rather than social 
homogeneity (19).  
Briefly, OAs contain between 40 and 250 residential households (average ~125), with 
estimated 100 to 625 residents, based on the aggregation of adjacent postcode units 
selected to be socially homogenous. My study units, the LSOAs, are obtained by the ONS 
grouping OAs in order to generate areas roughly similar in population size and socially 
homogeneous (in terms of tenure of household, type of dwelling, and rural urban status). 
LSOAs are designed to have a minimum population of 1000 and a maximum of 3000 
residents, and between 400 and 1200 households (target ~600). They constitute the lowest 
level at which the data used by the ONS to generate area-level deprivation indices are 
aggregated (27). England is currently thus divided by the ONS into 171372 OAs, which are 
grouped into 32844 LSOAs; all LSOAs were included in the analysis.  
 
Data sources: 
TB Notifications for 2008-12 were obtained from the Enhanced Tuberculosis Surveillance 
System (ETS) at Public Health England (PHE). I obtained anonymised information on the 
age, sex, self-reported ethnicity, and UK-born status for each case. Individual residential 
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address postcodes at the time of diagnosis were georeferenced to the corresponding LSOA 
using the ONS geographic codes database. The total number of cases by 5-year age groups, 
sex and place of birth was aggregated for each LSOA. 
Population Data: The ONS census data from 2011 was used to obtain population statistics 
at the LSOA level, including: 
- The resident population by place of birth (overall and disaggregated in UK-born and 
foreign-born); these were used as denominator to obtain LSOA-level rates. 
- The total resident population by sex and 5-year age groups; 
- The total population by ethnic group (in ONS standard classification of self-
reported ethnicity, then dichotomised into White (including White British, 
English, Irish, Scottish, Welsh, and any Other White) versus non-White ethnicity 
(ethnic group other than White, irrespective of country of birth); 
- The sub-total of foreign-born subjects born out of the European Union (EU) 
(henceforth labelled ‘non-EU foreign-born’). This variable was readily available 
from published small-area census statistics; given that England’s resident 
population born in EU countries other than the UK represents about a 33% of the 
foreign-born population, this variable (non-EU foreign-born) was considered 
potentially useful to distinguish and adjust for the foreign-born population 
originating from any of the 27 other EU countries, most of which have relatively 
lower TB burdens compared to other parts of the world.  
Area-level Deprivation Measures: I also obtained from the ONS the most recent (2010) 
version of England’s LSOA-level index of multiple deprivation (IMD) as well as the domain 
specific deprivation indices. The IMD is a multi-dimensional measure that uses 38 distinct 
indicators collected by the ONS at the LSOA-level to assess unmet needs due to the lack 
of resources along seven domains, respectively [1] income deprivation, [2] employment 
deprivation, [3] health deprivation and disability, [4] education, skills and training 
deprivation, [5] barriers to housing and services, [6] crime, and [7] living environment 
deprivation (27). These seven domains represent distinct but strongly correlated forms of 
deprivation that may be experienced by residents of an area. Respective domain-specific 
deprivation scored are constructed using model-based combinations of mutually exclusive 
sets of specific indicators from the total pool 38 indicators. The overall index of multiple 
deprivation (IMD) is obtained by combining the domains scores using specific weight, 
therefore providing a balanced composite deprivation index that account for the various 
aspects of deprivation in the area. The IMD is used to rank LSOA across the country based 
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on their relative deprivation levels, from most deprived (highest scores) to the least 
deprived (lowest scores) (27).   
Other Area-level characteristics: I also obtained for each LSOA its urban/rural 
classification from the ONS 2011 Rural-Urban Definition for Small Area Geographies. 
LSOAs are classified into broad categories taking into account population sparsity, 
respectively Urban (defined as connected built-up areas with 10,000 people or more, with 
sub-groups including [1] major conurbation, [2] minor conurbation, and [3] city and town), 
and Rural (less than 10,000 residents, including [4] town and fringe, [5] village, and [6] 
hamlets and dispersed/isolated dwellings). Documents on the methods and detailed 
classification are available from the ONS (28). For this study, the information was further 
regrouped into three levels, respectively (i) major conurbation, (ii) minor conurbation, 
cities and towns, and (iii) rural areas.  
 
Outcome and Exposure definitions 
Outcome: The main outcomes for this study were the LSOA-level 5-year average annual 
TB notification rates respectively in all resident population, and separately in UK-born and 
foreign-born (non-UK born) subjects. For a subgroup analysis, I also computed TB rates 
in children aged 0 to 14 years, as a proximate for local transmission within England (given 
that TB cases in children are more likely to be a consequence of recent transmission (29), 
and over two-third of under 14-years old TB cases occur in UK-born children (1). 
Exposures: The main exposure of interest was quintile of small- (LSOA-) level index of 
multiple deprivation (IMD) rank.  
Confounders: The statistical analyses were controlled for confounding by age and sex, as 
well as LSOA urban/rural classification. I also adjusted for the area-level proportion of 
non-White, and the proportion of foreign-born residents. 
 
Statistical analysis 
Area-level TB notification rates:  
After cleaning and standard consistency checks, the annual TB notifications over the study 
period were aggregated to obtain the respective numerators for each LSOA (respectively 
overall, UK-born and foreign-born TB cases, and children aged 0-14 years TB cases). Age 
was available for all cases, but about 5% had missing information on whether they were 
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UK-born or not, and they were not included in the analyses stratified by place of birth. 
The denominators to compute area-level TB notification rates were obtained from the 
ONS population data as detailed in the previous section. Robust standard errors were used 
to compute the 95% confidence intervals (95%CI) while accounting for area-level 
clustering. 
Covariates:  
The distribution of the area-level percentage of (i) non-White residents, and (ii) foreign-
born residents born out of the European Union (EU) was examined and used to choose 
cut-offs to transform these variables into categorical variables. I also examined the 
correlation between non-White residents and non-EU foreign-born residents to inform 
adjustment in the multivariable analyses. 
Association between area-level TB notification rates and deprivation level:  
The association between exposure variables and LSOA-level TB rates was measured using 
count data regression models (30), with the log-transformed 5-year population 
denominator as the offset.  
Before investigating the association between the exposures of interest and TB notification 
rates, I first explored which count data regression model was more appropriate to the data. 
A potential problem when modelling area-level rates of a rare disease like TB is the 
overdispersion due to extra-variation in rates between LSOAs. This may lead to a violation 
of the Poisson regression model assumption that the conditional variance of the 
dependent variable is equal to the conditional mean (30, 31). An approach commonly used 
in analyses to deal with overdispersion is to use a Negative Binomial regression model 
instead of a Poisson model (30). For each outcome, I computed the mean number of events 
per analysis unit (LSOA) and the variance to assess deviation from this assumption. I also 
fitted both the Poisson and Negative Binomial regressions to the data and compared the 
models fitness using the log-likelihood based Akaike’s Information Criterion (AIC) and 
Bayesian Information Criterion (BIC). The model with the best fit to the data (smaller AIC 
and BIC) was used for the analysis (30, 31).  
Another potential issue specific to the analysis of foreign-born TB rates is the fact that 
many areas have small to no foreign-born population, and therefore no expected foreign-
born TB cases. This leads to ‘excess’ analysis units with zero counts and further variation 
between clusters; it may also affect the analysis for overall TB rates given that nearly 70% 
of TB cases in England are in foreign born (1). To address this, I used the Vuong Test (32) 
to further compare the Poisson and Negative Binomial models against their respective 
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zero-inflated counterpart with the non-EU foreign-born population used as the predictor 
for ‘excess’ zero counts (consistent with the fact the majority of foreign-born cases are in 
subjects born out of the EU).  
Eventually, the analyses for overall and foreign-born TB rates were done using zero-
inflated negative binomial regression models, with non-EU foreign-born population used 
as the excess zero counts’ predictor, and the UK-born TB rates were analysed using a 
standard negative binomial regression model. All 95% confidence intervals (95%CI) were 
obtained using robust standard errors. 
To measure the association between quintiles of area-level deprivation and LSOA-level TB 
notification rates, I computed crude incidence rate-ratios (IRR) first, then the age-and-sex 
adjusted RRs. I adjusted for confounding by age and sex by including in the model 
parameters  their joint distribution within each LSOA (i.e. male-aged 0-14 years, female-
aged 0-14 years, male-aged 15-64 years, female-aged 15-64 years, and male aged over 64 
years), as suggested by Morgenstern for ecologic studies, to minimise the risk of ecological 
bias due to misspecification of confounders (33). Finally, I fitted a final multivariable 
model that measured the effect of area-level deprivation while further adjusting for non-
White residents in the LSOA, as well as the LSOA’s urban/rural classification. A sub-
analysis of the association between area-level quintiles of deprivation and TB rates in 
children aged 0-14 years was also performed.  
The statistical analyses were done using Stata 14® (StataCorp); the significance testing was 
done using the Wald test.  
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Results 
Nearly 40,000 TB cases were notified in England between 2008 and 2012, for an annual 
average of about 8,000 cases. This corresponded to a 5-year average annual notification 
rate of 15 per 100000 persons, and there was no apparent trend in overall yearly rates over 
that period. The average annual notification rate in UK-born subjects was 4.5 per 100000, 
while the average rate in the foreign-born population was 80 per 100000 persons. The 
distribution of cases and corresponding average annual rates by LSOA characteristics is 
presented in table 5.2. Overall, 71% of TB cases in England over the study period were 
reported from the most deprived two-fifth areas, with this trend similar in UK-born and 
foreign-born populations. However, there were differences between these two groups 
regarding other LSOA characteristics. Major conurbations accounted for 56% of UK-born 
TB cases compared to 70% for foreign-born cases. Nearly half UK-born TB cases were 
reported from areas with <20% non-White population, whereas 60% of foreign-born TB 
cases occurred in areas with ≥40% non-White residents.  This distribution of cases was 
similar in relation to the LSOA percentage of non-EU foreign-born residents. There was a 
strong correlation between LSOAs’ percentages of non-White and percentage of non-EU 
foreign-born residents (Pearson’s correlation coefficient = 0.94; p<0.001), so I only used 
the percentage of non-White subjects (irrespective of country of birth) as covariate in all 
subsequent analyses. 
 
Before fitting regression models to measure the association between area-level TB rates 
and deprivation, I checked for deviations from the standard Poisson regression 
assumption that variance and mean are not too different. The variance of LSOA-level 
overall and foreign-born TB cases count was nearly 5 times higher than the mean, thus 
consistent with large over-dispersion and excess zero counts. The comparison of 
regression models for the association between TB rates and area-level deprivation 
suggested that the zero-inflation negative binomial regression provided a better fit for 
these two outcomes (Vuong test comparing standard to zero-inflation models p<0.001, 
and both AIC and BIC for negative binomial model much lower than for Poisson model) 
table 5.3). For UK-born cases, the variance was only slightly higher than the mean, and the 
results from the Poisson and Negative Binomial regression models were similar; however, 
the AIC and BIC for the Negative Binomial model suggested that the Negative Binomial 
model was marginally better than the Poisson model, thus the former was used for 
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subsequent analyses for UK-born TB rates. The results comparing the regression models 
are reported in table 5.3. 
 
The Overall TB notification rates increased with area-level deprivation, with crude rates 
in the most deprived fifth areas of the country over 5 times higher than the least deprived 
quintile. However, part of this association appeared to be due to variation in the age-and-
sex composition of LSOA, with the association reducing to 3 times higher TB rates in the 
most deprived quintile after adjustment for age-and-sex (table 5.4). The log-linear gradient 
in overall TB rates by deprivation quintile was still present, albeit much weaker once 
controlling additionally for rural/urban area classification and the percentage of non-
White resident in the area. The fully adjusted TB rates varied from 14% increase in the 2nd 
least deprived to 81% higher in the most deprived quintile areas, when compared to the 
least deprived fifth of the country. The same multivariable model, controlling 
simultaneously for age, sex, deprivation, urban/rural classification and percentage of 
White/non-White residents, suggested that the overall notification rates were on average 
about twice as high in urban than rural areas, and nearly 6 times higher in areas with ≥40% 
non-White residents compared to areas with <20% non-White residents (IRR = 5.78, 
95%CI: 5.49 to 6.09).  
 
There were, however, differences in the association between area-level deprivation and TB 
rates in UK-born versus foreign-born populations (see table 5.4). The magnitude and 
gradient of association between deprivation and TB rates was much steeper in the UK-
born population, in which the crude TB rates in the most deprived quintile areas were over 
five times higher than the least deprived quintiles (IRR = 5.19, 95%CI: 4.78 to 5.63), versus 
only about three times higher in the foreign-born population (IRR = 2.78, 95%CI: 2.61 to 
2.96). The difference in the relationship between area-level deprivation and TB rates in 
these two population strata persisted after adjusting for age, sex, rural/urban classification 
and percentage of White/non-White residents. Compared to the least deprived quintile 
areas, the fully adjusted rate-ratios of association between area-level deprivation and TB 
rates in UK-born subjects varied from 2.40 (95%CI: 2.19 to 2.61) in the most deprived 
quintile to 1.21 (95%CI: 1.11 to 1.33) in the 2nd least deprived quintile areas; whereas the 
equivalent figures in the foreign-born population were respectively 1.78 (95%CI: 1.66 to 
1.91) and 1.13 (95%CI: 1.05 to 1.23). The full results are presented in table 5.4. 
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Table 5.2: Tuberculosis cases distribution and 5-year average annual notification rates by LSOA characteristics in England 2008-12 
 UK born Foreign-born All TB cases 
 
Number of 
TB cases  
(column %; 
n= 10184) 
populatio
n at risk 
5-year average 
annual rate per 
100,000 
(95%CI) 
Number of 
TB cases  
(column %; 
n=29524) 
populatio
n at risk 
5-year average 
annual rate per 
100,000 (95%CI) 
Number of 
TB cases  
(column %; 
n=39708) 
population at 
risk 
5-year average 
annual rate per 
100,000 
(95%CI) 
LSOA Quintiles of Index of Multiple Deprivation 
Most deprived  4055 (40) 8574432 9.5 (9.1;9.9) 13053 (44) 2199206 119 (116.0;122.0) 17108 (43) 10773638 31.8 (30.7;32.8) 
2  2431 (24) 8818466 5.5 (5.3;5.8) 8602 (29) 1861055 92.4 (88.9;96.1) 11033 (28) 10679521 20.7 (19.8;21.6) 
3 1617 (16) 9255810 3.5 (3.3;3.7) 4271 (14) 1349267 63.3 (60.5;66.3) 5888 (15) 10605077 11.1 (10.6;11.6) 
4 1173 (12) 9488578 2.5 (2.3;2.6) 2142 (7) 1018227 42.1 (39.4;44.9) 3315 (8) 10506805 6.3 (6.0;6. 7) 
Least deprived 908 (9) 9538031 1.9 (1.8;2.0) 1456 (5) 909384 32.0 (30.2;33.9) 2364 (6) 10447415 4.5 (4.3;4.8) 
Rural / Urban classification of LSOA 
Rural 781 (8) 8642493 1.8 (1.7;1.9) 447 (2) 472892 18.9 (17.0;21.0) 1228 (3) 9115385 2.7 (2.6;2.9) 
Cities/minor 
conurbations 
3707 (36) 22467460 3.3 (3.2;3.4) 8359 (28) 2580276 64.8 (62.7;67.0) 12066 (30) 25047736 9.6 (9.3;10.0) 
Major 
conurbations 
5696 (56) 14565364 7.8 (7.6;8.1) 20718 (70) 4283971 96.7 (94.4;99.1) 26414 (67) 18849335 28.0 (27.3;28.8) 
Percentage of non-White residents in LSOA 
0-19.9% 4985 (49) 37612660 2.7 (2.6;2.7) 5815 (20) 3036658 38.4 (37.2;39.4) 10800 (27) 40649318 5.31 (5.29;5.4) 
20-39.9% 1894 (19) 4480422 8.5 (8.0;8.9) 5851 (20) 1653640 70.8 (68.5;73.1) 7745 (20) 6134062 25.3 (24.5;26.0) 
≥40% 3305 (32) 3582235 18.5 (17.7;19.3) 17858 (60) 2646841 135 (132.0;138.0) 21163 (53) 6229076 67.9 (66.2;69.7) 
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Table 5.3: Comparison of four count-data regression models of the association between 
area-level deprivation and TB notification rates 
 Poisson 
Zero-inflated 
Poisson 
Negative 
Binomial 
Zero-inflated 
Negative 
Binomial 
All England population       (Mean number TB case by LSOA = 1.21; Variance = 6.51) 
Least Deprived  1 1 1 1 
2 1.39 (1.30;1.50) 1.40 (1.30;1.51) 1.39 (1.29;1.49) 1.39 (1.30;1.49) 
3 2.45 (2.29;2.63) 2.29 (2.14;2.44) 2.41 (2.26;2.58) 2.29 (2.15;2.44) 
4 4.57 (4.28;4.87) 3.60 (3.39;3.83) 4.39 (4.12;4.68) 3.74 (3.52;3.98) 
Most Deprived  7.02 (6.62;7.44) 4.82 (4.56;5.09) 6.66 (6.28;7.05) 5.22 (4.94;5.51) 
     
p-value <0.001 <0.001 <0.001 <0.001 
AIC 113707.5 92882.9 88446.2 83753.0 
BIC 113749.5 92941.7 88496.6 83820.2 
Vuong test <0.001 <0.001 
Foreign-Born population       (Mean number TB case by LSOA = 0.9; Variance = 4.98) 
Least Deprived  1 1 1 1 
2 1.31 (1.20;1.43) 1.20 (1.10;1.31) 1.27 (1.17;1.37) 1.19 (1.10;1.29) 
3 1.98 (1.84;2.13) 1.64 (1.52;1.76) 1.83 (1.71;1.96) 1.62 (1.51;1.74) 
4 2.89 (2.69;3.10) 2.19 (2.04;2.35) 2.58 (2.41;2.75) 2.15 (2.02;2.30) 
Most Deprived  3.71 (3.48;3.95) 2.65 (2.48;2.84) 3.41 (3.20;3.62) 2.78 (2.61;2.96) 
     
p-value <0.001 <0.001 <0.001 <0.001 
AIC 62010.2 59288.4 58147.3 56986.8 
BIC 62052.2 59347.2 58197.7 57054.1 
Vuong test <0.001 <0.001 
UK-Born population          (Mean number TB case by LSOA = 0.31; Variance = 0.49) 
Least Deprived  1  1  
2 1.30 (1.19;1.42)  1.30 (1.20;1.43)  
3 1.84 (1.68;2.01)  1.86 (1.84;2.13)  
4 2.90 (2.66;3.15)  3.01 (2.69;3.10)  
Most Deprived  4.97 (4.58;5.38)  5.19 (3.48;3.95)  
     
p-value <0.001  <0.001  
AIC 47865.4  45865.0  
BIC 47907.4  45915.4  
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Table 5.4: Association between LSOA-level deprivation and non-White population and TB notification rates in England in 2008-12 
 Crude Age and Sex adjusted Fully Adjusted†  
 IRR 95%CI p-value IRR 95%CI p-value IRR 95%CI p-value 
Overall population  
Quintiles of LSOA Index of Multiple Deprivation rank  
Least Deprived  1   1   1   
2 1.39 (1.30;1.49)  1.31 (1.22;1.41)  1.14 (1.07;1.21)  
3 2.29 (2.15;2.44) <0.001‡ 1.84 (1.73;1.96) <0.001 ‡ 1.35 (1.27;1.43) <0.001‡ 
4 3.74 (3.52;3.98)  2.58 (2.43;2.74)  1.58 (1.50;1.67)  
Most Deprived  5.22 (4.94;5.51)  3.35 (3.16;3.55)  1.81 (1.71;1.91)  
Percentage of non-White residents in LSOA  
0-19.9% 1   1   1   
20-39.9% 3.31 (3.16;3.47) <0.001 2.89 (2.75;3.04) <0.001 2.60 (2.47;2.73) <0.001 
≥40% 8.7 (8.30;9.12)  6.96 (6.63;7.31)  5.78 (5.49;6.09)  
Rural / Urban classification of LSOA  
Rural 1   1   1   
Cities/minor conurbations 3.15 (2.95;3.37) <0.001 2.01 (1.88;2.16) <0.001 1.79 (1.67;1.91) <0.001 
Major conurbations 6.86 (6.43;7.32)  3.76 (3.50;4.03)  1.92 (1.78;2.06)  
Foreign-born population  
Quintiles of LSOA Index of Multiple Deprivation rank  
Least Deprived  1   1   1   
2 1.19 (1.10;1.29)  1.21 (1.12;1.31)  1.13 (1.05;1.23)  
3 1.62 (1.51;1.74) <0.001‡ 1.57 (1.47;1.69) <0.001‡ 1.34 (1.25;1.44) <0.001 ‡ 
4 2.15 (2.02;2.30)  1.98 (1.85;2.12)  1.57 (1.47;1.68)  
Most Deprived  2.78 (2.61;2.96)  2.38 (2.22;2.54)  1.78 (1.66;1.91)  
Percentage of non-White residents in LSOA  
0-19.9% 1   1   1   
20-39.9% 1.72 (1.62;1.82) <0.001 1.63 (1.54;1.73) <0.001 1.49 (1.41;1.58) <0.001 
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≥40% 3.10 (2.94;3.28)  2.64 (2.49;2.79)  2.28 (2.15;2.42)  
Rural / Urban classification of LSOA  
Rural 1   1   1   
Cities/minor conurbations 2.56 (2.29;2.85) <0.001 2.17 (1.94;2.43) <0.001 1.96 (1.75;2.19) <0.001 
Major conurbations 3.13 (2.79;3.50)  2.56 (2.28;2.87)  1.83 (1.63;2.05)  
UK-born population  
Quintiles of LSOA Index of Multiple Deprivation rank  
Least Deprived 1   1   1   
2 1.30 (1.19;1.43)  1.30 (1.18;1.42)  1.21 (1.11;1.33)  
3 1.86 (1.70;2.04) <0.001‡ 1.72 (1.58;1.89) <0.001‡ 1.45 (1.33;1.58) <0.001 ‡ 
4 3.01 (2.76;3.28)  2.48 (2.27;2.70)  1.77 (1.63;1.93)  
Most Deprived  5.19 (4.78;5.63)  3.90 (3.59;4.24)  2.39 (2.19;2.61)  
Percentage of non-White residents in LSOA  
0-19.9% 1   1   1   
20-39.9% 3.20 (3.01;3.40) <0.001 2.9 (2.71;3.10) <0.001 2.39 (2.24;2.56) <0.001 
≥40% 6.99 (6.62;7.38)  5.96 (5.60;6.34)  4.25 (3.96;4.55)  
Rural / Urban classification of LSOA  
Rural 1   1   1   
Cities/minor conurbations 1.85 (1.70;2.01) <0.001 1.44 (1.32;1.57) <0.001 1.31 (1.20;1.42) <0.001 
Major conurbations 4.52 (4.17;4.91)  3.12 (2.86;3.4)  1.63 (1.49;1.79)  
† Fully adjusted regression models include quintiles of area-level deprivation rank, and further adjusted for age, sex, urban/rural area classification, percentage of 
White/non-White residents 
‡ Test for trend 
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The findings from the sub-group analysis of the association between area-level deprivation 
and TB rates in children aged 0-14 years (used as a proxy-measure for local TB 
transmission) are presented in table 5.5. Overall, the pattern of association was similar to 
that among UK-born subjects. There was a strong gradient of higher TB rates with 
increasing deprivation levels, with the crude TB rates in children ≤14 years old living in the 
most deprived quintile areas of the country about 10 times higher compared to those in 
the least deprived areas (IRR=10.07, 95%CI: 7.76 to 13.06). After adjusting for the 
urban/rural area classification and the percentage of White/non-White residents, there 
was still good evidence of association, albeit weaker, between area-level deprivation and 
TB rates in children ≤14 years old; fully adjusted TB rates in the two most deprived quintile 
areas were between 2 and 3 times higher than the least deprived quintile areas.  
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Table 5.5: Association between area-level deprivation and TB notification rates in children aged 0-14 years in England in 2008-12 
 TB notifications Crude Fully Adjusted† 
 
TB 
cases 
Population 
aged 0-14 years 
Annual TB rate 
(per 100,000) 
IRR 95%CI p-value IRR 95%CI p-value 
Quintiles of LSOA Index of Multiple Deprivation rank  
Least Deprived  77 1793732 0.86       
2 94 1698737 1.11 1.29 (0.92;1.80)  1.06 (0.76;1.49)  
3 220 1752179 2.51 2.89 (2.15;3.88) <0.001‡ 1.60 (1.19;2.16) <0.001‡ 
4 520 1931600 5.38 6.14 (4.69;8.05)  2.23 (1.68;2.95)  
Most Deprived  1053 2308561 9.12 10.07 (7.76;13.06)  2.84 (2.14;3.78)  
Percentage of non-White residents in LSOA  
0-19.9% 443 6986089 1.27       
20-39.9% 372 1117089 6.66 5.27 (4.45;6.25) <0.001 3.53 (2.95;4.23) <0.001 
≥40% 1149 1381631 16.60 13.05 (11.35;14.99)  7.10 (6.00;8.39)  
Rural / Urban classification of LSOA  
Rural 28 1470602 0.38       
Cities/minor 
conurbations 
524 4437751 2.36 6.04 (3.96;9.20) <0.001 2.85 (1.85;4.39) <0.001 
Major conurbations 1412 3576456 7.90 19.49 (12.9;29.44)  3.50 (2.27;5.41)  
†Adjusted for quintiles of LSOA IMD rank, percentage of non-White resident population and urban/rural area classification 
‡Test for trend 
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Discussion 
These analyses suggest that over the 5-year study period (2008-2012), TB notification rates 
in England were positively associated with small-area level deprivation even after 
controlling for age, sex, urban/rural differences and the area-level proportion of non-
White residents. However, this relationship appeared stronger in the UK-born population 
compared to foreign-born, with TB notification rates in UK-born subjects living in the 
most deprived quintile areas of the country nearly two-and-a-half times higher than the 
least deprived quintile areas after adjustment for confounding. By comparison, TB rates in 
foreign-born subjects from the most deprived quintile areas were just about 80% higher 
than the least deprived quintile areas. Area-level deprivation was also strongly associated 
with higher TB rates in children aged 0-14 years old. 
 
An advantage of the current study over previous ecological analyses of the relation of 
deprivation to TB rates in England was the availability and use of LSOAs as study unit. The 
smaller and similar population size (average 1500 residents) of these statistical units, 
combined to the fact that the ONS designed LSOAs specifically to be more socially 
homogenous, allowed individuals within study units to be less dissimilar with respect to 
their deprivation status (my key exposure of interest), hence less misclassification. This 
has probably helped minimise the risk of ecological bias in measuring the association 
between area-level deprivation and the risk of TB (30, 34). By comparison, previous 
ecological studies have used larger and more heterogeneous aggregation levels, ranging 
from electoral wards (population varying from 5000 to 26000 per wards) (16, 17, 20) to local 
authorities (35,000 to nearly 1,000,000 residents per unit) (14), hence more vulnerable to 
misclassification of exposure. Another strength of this analysis was the use of exact 
population count as denominators to calculate rates, with numbers obtained from a recent 
population census. This may have helped to avoid some pitfalls of population estimates, 
which typically tend to underestimate small groups like foreign-born populations, hence 
overestimating rates in those groups. A possible limitation of this study could be the 
under-notification of TB cases, which could have led to slight underestimation of TB rates. 
An audit of the TB surveillance system between 1999-2002 using the capture-recapture 
method estimated about 15% under-reporting, but improving with time (35). The audit did 
not explore potential difference in under-reporting between UK-born and foreign-born 
populations, making it difficult to predict the likely impact of any under-notification on 
my findings. It is plausible that under-notification is more frequent in UK-born 
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population, helped by the under-notification of post-mortem cases in the elderly, and 
differential clinical suspicion index (36). However, under-notification of TB cases would 
lead to an underestimation rather than overestimation of the association of area-level 
deprivation and TB rates, which means that the estimates presented here are likely 
conservative. 
 
The measure of deprivation used here, the Index of Multiple Deprivation (IMD), was 
designed to measure how the lack of resources along seven domains, income, 
employment, health and disability, education skills and training, barriers to housing and 
other services, crime, and living environment, experienced by individuals, may affect wide 
ranging aspects of their living conditions, including health outcomes (27). Several studies 
have shown that the IMD correlate well with various health inequalities, including all-
cause mortality (37) and several hazardous health habits (e.g. smoking, alcohol drinking) 
(38). Prior to the introduction of the IMD, the most commonly used area-level measures 
of deprivation used in studies assessing the relationship to TB rates included the Jarman 
index (26), the Townsend score (24) and the Cartstair score (25). The Jarman Index was 
developed from a set of eight census-derived variables identified by a survey of a random 
sample of GPs as part of an exercise aimed at identifying under-privileged areas where 
social factors may lead to increase GP workloads (26). The Townsend and Carstairs scores 
on the other hand, were composite measures of area-level deprivation based on combining 
4 census-derived indicators (24, 25). One improvement of IMD in measuring area-level 
deprivation compared to previous measures is that it is based on smaller geographic areas 
of similar population size and specifically selected to include socially homogenous 
households (27); whereas the census-based indicators used for former measures of 
deprivation were based on either enumeration districts or census wards, which had larger 
population and wider variation in size (for example England was formerly divided by the 
ONS in 9265 census wards versus about 32000 LSOAs currently). Another advantage of 
the IMD is the collection at the small-area (LSOA) level of 32 separate census-based 
indicators to capture different aspects of deprivation, providing better resolution than 
previous measures (27). A study found that the IMD maintained a stronger and more 
consistent correlation to health inequality compared to the Townsend score both in urban 
and rural areas (39). 
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The respective roles of social deprivation and immigration from high TB parts of the world 
in explaining the resurgence of TB in England have been the object of much debate (13). 
Most authors have argued that most of the disease resurgence is related to immigration 
from high-TB parts of the world, but some are also of the opinion that similar to 
comparable low-TB incidence settings, poverty and social deprivation have played an 
additional role in the failure of TB rates to decline since the mid-1980s (40) . Whilst it is 
true that the greater burden of disease in England nowadays rests with foreign-born 
populations, my results suggest that deprivation plays a greater role in differential TB rates 
in UK-born populations compared to foreign-born populations. These results contrast 
with the findings of Bennet et al who reported that in their analyses of TB rates in electoral 
wards in Manchester, Liverpool, Birmingham and Cardiff, variations in rates were 
explained by the proportion of residents born in India and Pakistan, and not by area-level 
deprivation (17). I contend that the difference to my results is explained by the fact that 
their analyses did not separately examine the association of deprivation and TB rates in 
UK-born and foreign-born subjects, especially in light of the fact their study was set in 
major conurbations with high proportion of foreign-born subjects. The weaker association 
between deprivation and TB rates in foreign-born populations in my study is most likely 
due to the fact the risk of disease is mostly associated with the higher TB burden in place 
of origin of many foreign-born subjects in England, and their ties to these areas, with 
deprivation only playing a smaller role. On the other hand, the stronger association 
between deprivation and TB in UK born populations is consistent with the historical link 
between TB and poverty, with greater prevalence of deprivation-related TB risk factors in 
poorer areas. These may include living in overcrowded (and possibly poorly ventilated) 
dwellings, as well as poorer nutritional status for example, both associated with higher risk 
of TB infection as well as progression to disease (29). These results are consistent with 
findings from the previous studies by Mangtani et al who reported an association between 
higher TB rates and overcrowding in London boroughs (21), as well as Hawker et al who 
found that overcrowding was associated with TB rates in the White population in 
Birmingham, but not the Asian population (18). Tocque et al also reported a positive 
association between TB rates in Liverpool council wards and unemployment, a known 
predictor of financial status and related circumstances (housing, nutritional status etc.) 
(23). Furthermore, it was found in surveys that other health determinants associated with 
higher risk of TB, including for instance tobacco smoking, history of prison stay, and 
history of homelessness, are more prevalent in socially deprived population subgroups 
(38). The strong association between area-level deprivation and TB rates in children aged 
94 
 
0-14 years also found in my study provides some support to the hypothesis that deprivation 
remains an important determinant of TB risk in UK-born populations. Most TB cases in 
children result from recent Mycobacterium tuberculosis (Mtb) infection, thus suggesting 
that there is perhaps more recent transmission in the most deprived areas. However, part 
of this association is also probably explained by the fact that a proportion of children born 
in the UK to foreign-born parents have an increased risk of TB due to their family ties to 
high TB-burden parts of the world.  
 
In summary, the results presented here are the first in over 15 years examining variations 
in TB rates across gradients of area-level deprivation, and the first since the introduction 
of the centralised TB surveillance system, as well as the current high-resolution measure 
of area-level deprivation. Despite their limitations, the findings suggest that deprivation 
continues to play a role in sustaining the TB epidemic in the UK-born population in 
England, and deserve further attention. Further studies are warranted at the individual-
level to investigate which deprivation-related determinants of health are related to the risk 
of TB, and how they may affect this risk. Such studies may be helpful in designing and 
planning interventions that may address such social determinants of TB, and help progress 
towards the aim of TB elimination in the near future. The results should also contribute 
to raising the awareness of the disproportionate burden of TB in the UK-born populations 
residing in the most deprived areas. 
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Abstract 
Background: England tuberculosis (TB) rates have been stagnant in the UK-born 
population for over a quarter of a century, especially among young adults. There is 
evidence from ecological studies that deprivation remains a risk factor. However, in this 
setting, few studies have recently investigated the association between poverty-related 
social determinants of health inequality (SDH) at the individual-level and tuberculosis 
disease, as opposed to infection.  
Objectives: To measure the association between individual socio-economic status and 
some social determinants of health, and TB, while taking into account the clustering of 
social risk factors in subjects, and to estimate the potential population impact.  
Methods: Secondary analyses of a nationwide case-control study targeted at UK-born 
White adults aged 23 to 38 years at diagnosis of their first TB episode, and randomly 
selected age-and-sex frequency-matched community-based controls. Data on some SDH 
(education level, household overcrowding, tobacco smoking, alcohol use, drugs use, and 
history of homelessness and prison) were collected during face-to-face interviews using a 
Computer-Assisted Personal Interview. Statistical analyses using logistic regression 
models was informed by a theoretical formal causal framework (Directed Acyclic Graph) 
of plausible inter-relation between the measured social determinants. 
Results: Overall, 681 TB cases and 1183 controls were recruited. A strong association 
between education level and TB was noted, with risk of TB about four times higher in 
subjects with GCSE O-levels or below compared to those with degree or higher (OR=3.94; 
95%CI: 2.74; 5.67) after controlling for age, sex, BCG vaccination and long (3 months) 
stays in Africa or Asia. After simultaneously adjusting for all measured social 
determinants, as well as BCG vaccination and long stays in Africa or Asia, higher TB risk 
was also associated with tobacco smoking, use of drugs, especially injectable drugs 
(OR=5.67; 95%CI: 2.68; 11.98), history of homelessness, and deprivation in the area of 
residence. Population Attributable Fraction (PAF) estimates suggest that tobacco 
cessation and class-A drug use prevention could respectively help prevent 18% and 15% TB 
cases in the target population. 
Conclusions: The results provide insight into some mechanisms through which 
deprivation affects the risk of TB in the study population, and support the argument for 
improved approaches to TB control efforts, such as integrated health and social services 
in high-risk young adult populations.  
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Background 
Tuberculosis largely remains a disease of social exclusion and inequality, affecting 
disproportionately on the poor and most vulnerable segments of the population with an 
estimated 90% of cases worldwide reported from low and lower-middle income countries 
(1). In several low-burden settings, although the majority of cases are currently reported 
among migrants from high incidence countries, a substantial proportion of TB due to 
transmission within the native population appears to be concentrated in the more 
deprived and marginalised groups (2-4). Such deprivation includes income poverty, as well 
as multiple social disadvantages such as lower education, reduced access opportunities to 
good health care, and lower accommodation and living standards. Some behaviours 
harmful to health may also be more common in deprived populations (5), including for 
example alcohol abuse (6, 7), tobacco smoking (8), and use of controlled drugs (9).  
Until recently, TB control strategies emphasised medical technologies (including 
preventive treatment and vaccination, early and better diagnosis, effective treatment, and 
management of co-morbidities), with less focus on addressing the underlying social 
determinants (10). However, the newly adopted WHO strategy to eliminate TB as a public 
health problem by 2035 recognises that the pace of decline required to reach this target 
cannot be achieved without also addressing the social determinants of TB, a priority area 
now embedded within the three pillars of the 2015 global end-TB strategy (11, 12). This 
strategy is also relevant to low-TB incidence countries, which are closer to TB elimination, 
and where additional efforts are required to interrupt transmission, notably among the 
vulnerable and hard-to-reach populations in whom it is highest. An initial step to 
addressing these social determinants in these countries is the proper mapping and 
understanding of the associated risk (3). Although TB is a classic disease of poverty, the 
pathways (underlying social determinants) through which poverty affects the risk of TB 
have not received much attention in recent times.  
TB rates in the native UK-born population have not declined in more than two decades, 
especially among young adults (see manuscript 1), and in 2014, 60% of notified TB cases in 
England who had at least one of the social risk factors homelessness, drug use, alcohol 
abuse, or history of prison stay were aged 15-44 years (13). Pulmonary TB, the infectious 
form of the disease, was the most common form reported among those with at least one 
of these risk factors, and nearly one in ten had prior history of TB. This group was also 
more likely to have drug-resistant TB than those with no social risk factors, and to have 
negative treatment outcome. Also, 75% of UK-born cases with any of those social risk 
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factors were from White ethnic background, even though only 62% of all UK-born cases 
were from White ethnicity (13). These statistics underline the importance of 
understanding and addressing social determinants of TB in the UK-born population to TB 
control efforts. 
Few studies have measured the potential increase in risk of TB associated with specific 
social determinants in low-incidence settings. For some potential risk factors like 
homelessness and prison stay, many studies are limited to documenting their prevalence 
among TB patients, or alternatively, the prevalence of TB disease or latent infection in 
these risk groups. The majority of studies of the association between poverty/deprivation 
and TB in low-incidence countries are ecological in nature, comparing notification rates 
across socio-economic levels of geography (14) (see also manuscript 2). Most comparative 
studies at the individual level have focused on either contrasting patients’ characteristics 
by groups (e.g. native vs foreign born, age groups, and drug sensitive vs drug resistant), or 
comparing the association between these social risk factors and treatment outcome. 
Furthermore, the fact that such social risk factors tend to cluster in individuals provides 
an additional challenge, which needs to be properly accounted for when measuring their 
respective effect. This has been a limitation to several available studies examining this 
question. For example, it is known that the proportion of smokers is higher among alcohol 
drinkers; however, of the eight studies in which the association of alcohol drinking to risk 
of TB was measured in the past 40 years, only two adjusted for tobacco smoking, an 
established factor increasing the risk  of TB (15). 
This paper reports the results of a case-control study in which the association between 
individual socio-economic status and a range of social determinants of health, and the risk 
of tuberculosis were measured among UK-born young adults from White ethnic 
background. A causal Directed Acyclic Graph (DAG) is posited as the formal framework 
within which the respective potential effect of risk factors is estimated while accounting 
for the presence of others. 
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Methods 
Study design and setting: 
This was a community-based case-control study conducted between 2012 and 2014 across 
England, with controls frequency-matched to cases on birth cohort and sex. The data 
collected and used for the present analyses were secondary to the primary aim of the main 
study, which was to estimate the duration of BCG effectiveness against tuberculosis 
between 10 and 30 years after vaccination (16).,  
 
Participants 
Cases were individuals born in the United Kingdom (UK) and diagnosed with their first 
episode of active tuberculosis at age 23 to 38 years old between years 2003 and 2012 (hence 
born between 1965 and 1989), and notified to the national enhanced tuberculosis 
surveillance system (ETS) (13). This age-group inclusion criteria was determined by the 
primary objective of the study, notably estimating BCG effectiveness 10 to 25 years after 
vaccination in a population in which the median age at vaccination was 13 years old. The 
study was restricted to the White ethnic group in which the overall risk of tuberculosis is 
comparable to that of the general population, while the risk of TB in subjects from several 
minority ethnic groups in England is known to be higher and are likely to have different 
socio-economic drivers. 
Controls were subjects from the same (White) ethnic background as cases and born in the 
UK between the years 1965 and 1989, and never diagnosed with, or treated for tuberculosis 
up to the time of inclusion in the study. Controls were frequency-matched to cases on sex 
and birth cohort ±2 years) and sampled from the same communities where cases had been 
reported. 
Exclusion criteria:  
 Cases with known HIV infection were excluded, as their risk of TB is higher than the 
general population. The same criterion was not applied to controls as it was impractical 
to exclude in the field. However, the HIV prevalence in the general population in 
England is very low (overall population prevalence 1.5 per 1,000), and much lower 
among UK born subjects and in the White ethnic group (17). 
 Cases living in state institutions at the time of data collection, notably in prisons were 
also excluded, because of practical difficulties to arrange access to these persons at the 
time of the data collection. 
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Sampling design: 
Cases: All eligible TB cases across England notified to the Enhanced Tuberculosis 
Surveillance System (ETS) between 2003 and 2012 were identified and invited to take part 
to the study. Tuberculosis is a notifiable disease by law in the UK, and the ETS is the 
national TB surveillance system run by Public Health England (PHE), formally known as 
the Health Protection Agency (HPA).  
Controls: Approximately 1200 controls were required to achieve the primary objective for 
which the data was initially collected. They were selected at random from the community 
using a three-stage self-weighted sampling scheme, thus allowing wide geographic 
coverage while optimising logistical efficiency. The sampling frame included the UK Office 
for National Statistics (ONS) Super Output Area (SOA) hierarchical geographies and the 
small-user Postal Address File for England. This file contains the list of all residential 
addresses within each postcode unit (PCD) in England. PCDs are grouped by the ONS into 
Output Areas (OA) using an automated process that allow for social homogeneity between 
resident households. The OAs are aggregated in SOAs, a level suitable for statistical 
reporting while preserving the anonymity of residents (SOAs count on average 125 
households, with an average population of 300). Clusters of SOAs form Lower layer SOAs 
(LSOA - average 600 households and 1500 residents), and LSOAs are grouped into Middle 
layer SOAs (MSOA – average 3000 households and 7500 residents) (18). Taking into 
account the methods and response rate from the Health Survey for England 2004 (19) and 
ONS LSOA mid-2010 population estimates (20), it was estimated that approximately 9400 
addresses needed to be screened in order to recruit enough controls (based the 
assumption that overall about 1 in 7-8 residential addresses would be yield an eligible 
control that accepted an invitation to participate), with a maximum of one eligible person 
invited to take part to the study if any in the household. To achieve wide geographic 
coverage, but at the same time maintain travel distances reasonable for cost-efficient 
screening, the sampling scheme was designed to include a single residential address from 
each sampled postcode unit, and a total of seven addresses per LSOA. The sampling steps 
were as follows: 
(i) The first stage was the selection of 449 of Middle layer Super-Output areas 
(MSOA) from the 6781 total across England, with probability proportional 
to the size (PPS) of their 2010 mid-year 25-49 years population estimates. 
(ii) The second stage was the selection of three Lower layer LSOAs in each 
MSOA sampled in the first stage, by simple random sampling (SRS). 
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MSOAs each contain on average five LSOAs of roughly similar population 
size.  
(iii) The third stage was the selection of seven residential addresses from each 
LSOA by simple random sample (SRS) using the small-user Postal Address 
File. To ensure an equal geographical spread of selected addresses within 
each LSOA, seven distinct postcode units were randomly sampled in each 
LSOA, then one address per postcode unit. LSOAs have on average of 30 
postcode units (PCD), with each PCD containing about 15 residential 
addresses. 
 
Permissions 
The study obtained ethics clearance from the NHS Research Ethics Service (REC 
11/H1102/11) and LSHTM Research Ethics Committee (Approval 5996), and was also 
granted NHS Research and Development authorisation through Public Health England  
(PHE, formerly HPA). Contact details of eligible study participants with history of TB 
episode notified to the ETS were obtained from PHE, in line with its National 
Information Governance Board (NIGB) health and social care approval to retain and 
analyse national surveillance data for public health purposes under Section 251 NHS Act 
2006.  
 
Field procedures and data collection 
Cases and controls’ individual interviews were conducted in their home by trained and 
experienced interviewers from the National Centre for Social Research (NatCen), a not-
for-profit independent organisation with over 40-year experience in social survey and 
research in the UK.  
The contact details from all eligible cases were obtained from the HPA and they were sent 
postal invitations to take part to the study, with the ability to opt-out (by prepaid postal 
return slip or Freephone hotline). NatCen’s interviewers subsequently visited cases at their 
addresses, a signed informed consent was obtained and data was collected using a personal 
face-to-face interview. 
An advance invitation was also mailed to the residential addresses selected to be screened 
for controls, with similar opt-out options as cases. The addresses were then visited by field 
workers and screened for eligible controls. In households with one or more eligible 
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subjects, one person was offered participation to the study, and data was collected by face-
to-face interview after a signed informed consent was obtained.  
NatCen’s interviewers conducted the face-to-face interviews using the same computer 
assisted questionnaire and standard-operating procedures for both cases and controls. All 
questions used a standard script and were close-ended, and the questionnaire was tested 
prior to the fieldwork. 
After the field data collection, participants’ demographic information was used to obtain 
additional information from the ETS and area-level statistics from the ONS public 
databases. 
 
Variables and data sources 
The outcome of interest was the first episode of any form (pulmonary or non-pulmonary) 
of active tuberculosis diagnosed between age 23 and 38 years old. The information was 
retrieved from the ETS. In addition to checks in the ETS, controls were also asked during 
the interview if they were ever treated for tuberculosis and excluded. 
Independent variables: During the face-to-face interview, interviewers collected 
information on a range of known and potential determinants of risk of tuberculosis, which 
are called in this report ‘independent variables’. These included: 
(a) Socio-demographic information, including the date of birth, sex, residential 
postcode and highest educational level achieved. The residential postcode was 
linked to ONS public database to obtain the LSOA-level index of multiple 
deprivation. LSOAs represent the lowest level in the hierarchy of ONS statistical 
geographies for which the information on deprivation is available in England (21). 
(b) Lifestyle variables, notably duration, frequency and quantity of tobacco smoking, 
alcohol drinking, as well as Class B/C drugs (e.g. Cannabis, Benzodiazepines, Qat, 
Glue, Solvents, Speed or other amphetamines etc.) and Class A drugs (e.g. Ecstasy, 
Cocaine, crack, Heroin, LSD, Psychedelic (e.g. “magic” mushrooms).  
(c) Other determinants of the risk of TB, including BCG vaccination status, history of 
homelessness and prison stay (including in the UK or abroad), household 
overcrowding and history of long stays in parts of the world with high TB 
incidence. 
 
Measures to deal with bias 
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Selection bias:  
All eligible TB cases notified to the ETS between 2003 and 2012 across England were invited 
to participate. Likewise, the sampling design for control recruitment used a multi-stage 
self-weighted scheme to select eligible controls across England at random, while ensuring 
a wide and fairly distributed geographical coverage.  
Study participants were not told that the study was directly related to TB to minimise self-
selection; the study title and information materials used the general term “Lung health”, 
and several questions were introduced to discuss other common lung diseases, notably 
asthma and pneumonia.  
Efforts were also made to ensure cases and controls had the same opportunities to take 
part in the study. Field workers used the same contact pattern for cases and control 
addresses, with several contact attempts, including at least one visit at different times of 
the day (morning, afternoon and evening) as well as days of the week (week-days and 
week-end). 
Information bias: 
The interviewers were aware of the case versus control status of participants because of 
the design of the fieldwork. However, they were trained to administer the interview in a 
similar fashion. Furthermore, all questions had a standard script that interviewers had to 
read, with no personal interpretation possible, and responses were close-ended. 
Interviewers also had a mix of cases and controls in their respective fieldwork package. 
The study participants were blinded to the study hypotheses as discussed in the section 
above. To minimise social-desirability bias when collecting information on lifestyle 
variables and other sensitive matters, this specific data was collected in a separate section 
of the computer-assisted questionnaire directly completed by the participant, and then 
electronically locked in a way that the information was neither visible nor accessible to 
the interviewer.  
 
Study size 
A total of 681 cases and 1183 controls contributed data for this study. The sample size was 
based on the main objective of the study for which the data were initially collected (16). 
Assuming that 10% of the sample was an inflation to allow control for confounding, I 
computed that I would have over 80% power to detect odd ratios (OR) ≥1.5 for exposures 
with 15% or higher prevalence in the control group, and OR ≥ 1.8 for exposures with 
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prevalence of 5% or higher in the control group (figure 6.1). The power calculations are 
based on a double-sided likelihood ratio test (LRT), with 5% type-1 error threshold. 
 
 
Figure 6.1: Expected study power as a function of the OR to detect possible the 
association between a risk factor and TB, given the available sample size 
 
Statistical Analysis 
Variables and data management 
Distal determinants of socio-economic status 
 Educational level: participants’ highest educational attainment was grouped 
respectively by (1) Degree level, teaching qualification or other higher education 
equivalent [~17 years of formal education starting about age 5 year], (2) General 
Certificate of Education (GCE) A levels or equivalent level [~14-17 years of education], 
(3) GCE O levels or equivalent [~12-13 years of education], and (4) Lower than O levels 
[<12 years of education]. 
 Small-area level deprivation: participants’ residential postcode addresses were linked 
to the ONS public data to obtain information on the LSOA-level index of multiple 
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deprivation (IMD), including the deprivation score and ranking. The IMD ranks were 
grouped in quintiles of deprivation based on the nation-wide ranking of LSOAs. 
 Household overcrowding: Information on the number of residents in the participant’s 
household was obtained and the number of bedroom or rooms used for sleeping 
purposes. The information was used to calculate the average number of persons per 
bedroom (ppb); this is one of the common indicators of household overcrowding used 
for health and policy planning (22, 23). The ppb was then transformed this into a binary 
variable (i) < 2 ppb, or (ii) ≥2 persons per bedroom. 
Lifestyle variables:  
 Alcohol history: Participants’ typical drinking pattern was captured using the 
frequency-quantity approach. They were asked if they consumed any alcohol whether 
currently or in the past (in which case they were asked when they stopped). The self-
assessed information on the frequency and typical quantity of alcohol consumption was 
also collected using the first 2 questions of the standard 3-items AUDIT-C score (24) 
([never, less than monthly, monthly, 2-4 times a month, 1-2 times a week and >=4 times 
a week] for frequency, and [none, 1-2, 3-4, 5-6,7-9, >=10 UK standard drink units] for 
quantity). This information was then combined as follows to derive an estimated 
maximum typical alcohol intake per week: 
 The highest boundary of the reported frequency was used as an estimate of 
frequency of alcohol consumption per week (e.g. the category on average 
2-4 times a month was considered as 4 times a month; and 1-2 times a week 
considered as 2 times a week). 
 The midpoint of the reported quantity of alcohol consumed in a typical 
occasion was converted into grams of alcohol (in England, one standard 
drink unit corresponds on average to 8 grams/10ml of pure alcohol). Thus 
if a subject reported drinking for example 3-4 units in a typical occasion, 
this was converted to 3.5 * 8 = 28g of pure alcohol on a typical occasion. 
 The information on frequency and quantity was subsequently combined 
into average consumption in grams of alcohol per week, and then grouped 
into categories (never drinker, 1-40g/week [>0 to 5 units per week] g/week, 
41-112g/week [>5 to 14 units/week], and ≥112g/week [>14 units per week]).  
People who had stopped drinking 5 years or more ago represented a very small group 
(2.8%) and were classified according to their typical consumption when there were 
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drinking. Only 4.5% of the study sample reported never drinking alcohol, and they 
were merged with the lowest consumption group. 
The choice of a 5 units (40 grams) per week cut-off for the lower risk category was 
informed by the Health Survey for England 2011 findings that most people in England 
who drink only do so one or two days a week (25). The cut-off of 14 units (112 grams) 
per week for the higher risk category reflects the current UK guidelines that drinking 
above that level may have deleterious effects on health, irrespective of gender (26).  
The literature on measurement of alcohol consumption suggests that quantity-
frequency methods tend to underestimate alcohol consumption, as they are less likely 
to capture occasions or periods of excessive drinking (27, 28). There is further evidence 
from England that people tends to underestimate the content of self-poured drinks, 
thus home drinking (29). However, for the purpose of my analysis, this was a 
convenient and conservative estimate of  levels of drinking in study participants. 
 Tobacco smoking: The current and past tobacco smoking habits were ascertained in 
all participants. Questions were asked about the fact, as well as the duration of 
smoking and typical number of cigarettes per day. About 20% (213/1154) of current and 
past smokers reported starting to smoke before age 16 years, the age at which it was 
legal to purchase cigarettes in the UK between 1908 and 2007. The annual survey of 
smoking, drinking and drugs in young people in England revealed that between 1982 
and 2005, the proportion of schoolchildren who regularly smoke at least one cigarette 
per week was very low in 11 and 12 years old (0 to 2%) whereas this was much higher in 
children aged 13,14 and 15 years (respectively 5 to 10%, 12 to 19% and 20 to 30%) (30). 
Furthermore, the 2014 survey reports that 46% of children who smoke at least one 
cigarette per week reported purchasing cigarettes themselves in shops in spite of it 
being illegal (30). Therefore, for those who reported starting to smoke before age 13 
years, only the duration of smoking from age 13 years onwards was included in the 
analyses.  
To estimate the lifetime tobacco consumption for each participant, the duration and 
frequency-quantity of tobacco smoking was combined into cigarette pack-years. This 
is a standard unit where 1 pack-year correspond to smoking an average of 20 cigarettes 
per day for 1 year, 10 cigarettes per day for 2 years, or alternatively 40 cigarettes per day 
for 6 months. Subjects were classified into (1) Never smoker, (2) Past smokers, (3) 
Occasional and daily smokers <10 packs-year, (4) daily 10-19 and (5) >=20 pack-years. 
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The past smoker category only included subjects who reported stopping to smoke for 
more than a year. 
 Drug use: Participants were asked about past and current usage of class A, B and C 
controlled substances. Subjects were classified according to whether they (1) currently 
used, or had last used them (2) 1-10 years or (3) more than 10 years ago, or (4) never, 
respectively for class A, and class B and/or C drugs; injectable class A drugs were a 
separate category.  
 History of homelessness: Participants were asked if they had ever been homeless, 
and the longest duration they spent homeless. They were grouped in (1) never been 
homeless, (2) homeless for ≤12 weeks, and (3) homeless for >12 weeks.  
 History of prison stay: The questionnaire also enquired if they had ever been in 
prison in the UK or abroad, and were categorised in a binary variable respectively (1) 
any history of prison stay (either in the UK or abroad) or (2) never been in prison. 
Other determinants of TB risk 
 Age/Birth cohort: Participants were grouped in 5-year birth cohorts. The use of birth 
cohorts allows to simultaneously account for any effect on the risk of TB of two 
temporal dimensions, notably calendar time and age.  
 BCG vaccination: BCG status was established by inspection of participants’ upper 
arms for the characteristic BCG vaccination scar, and a consistent history of BCG 
vaccination. 
 Long stays in high TB incidence areas: Participants were asked about visits with 
durations ≥3 months abroad. For simplicity and consistent with the global 
epidemiology of TB, stays in Africa and Asia were classified as higher risk for TB 
infection compared to stays in The Caribbean, Central or South America, Eastern 
Europe and other regions. 
Conceptual framework 
In order to inform the statistical analyses strategy, a conceptual causal framework of the 
hypothesised relation of the variables of interest to the risk of tuberculosis as well as to 
each other, was posited based on background knowledge. Following the social model of 
health proposed by Dahlgren and Whitehead in 1991 (31) (figure 6.2), the variables were 
grouped into:  
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(1) Distal social determinants of health: including educational level, area-level 
deprivation in place of residence and household overcrowding. 
(2) Intermediate social determinants of health, notably tobacco smoking, alcohol 
drinking and drug misuse, as well as history of homelessness and prison stay; 
(3) Matching variables (age/birth cohort, sex) as well as a priori determinants of 
TB risk, including BCG vaccination and long stays (≥3 months) in high TB-
incidence parts of the world (Africa and Asia). 
 
Figure 6.2: Dahlgren and Whitehead social model of health 
(Source Dahlgren and Whitehead, 1991)(31) 
The relation between variables and tuberculosis was represented in a causal directed 
acyclic graph (DAG) in figure 6.3. This is a graph in which the observed (measured) 
variables are represented as ‘nodes’, and the hypothesised causal relation between these 
variables is conceptualised in the form of directed arrows, with the graph being acyclic i.e. 
arrows always going in the same direction, from a presumed cause (also called ‘ancestor’ 
variable) towards a presumed effect (also called ‘descendant’ variable), thus no effect is 
causing itself (no feedback cycle). Within the framework, the direct association between 
a variable and TB is represented in the graph by a direct arrow (or ‘directed path’) from 
that variable to TB; under the assumptions underlying the DAG, this direct arrow 
represents an estimate of the presumed direct ‘causal’ effect of that variable on the risk of 
TB, i.e. the effect that is not mediated through any of the other observed variables in the 
framework. Therefore, DAGs require explicit assumptions regarding the presumed causal 
relation between any pair of variables (nodes); these assumptions are very simplistic and 
can be limited by contemporary knowledge. However, the DAGs are conceptually useful 
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to identify and control for mechanisms through which spurious associations between a 
variable and tuberculosis may arise in the multivariable analyses, including backdoor 
paths (defined as ‘non-causal open’ paths that go from a ‘descendent’ variable (or an 
effect) towards an ‘ancestor’ variable (a cause), and may therefore give rise to a non-causal 
‘spurious’ association) (32). For example, assume there was no real cause-to-effect 
association between drug use and TB in my study, but that there were separate causal 
associations between education level and drug use, and between education level and TB; 
a model measuring the association between drug use and TB in such study sample without 
adjusting for education level would show an association, albeit non-causal, because of the 
‘backdoor’ path from drug use to education level, then from education level to tuberculosis 
(figure 6.3). However, if the backdoor path was ‘blocked’, by adjusting for education level 
in the statistical model, there would be no association between drug use and TB.  
In the DAG, it was hypothesised that the highest educational level attained could affect 
employment and income in later life, hence the individual socio-economic status, and 
through this, influence the choice of area of residence (area-level deprivation) and type of 
accommodation (including overcrowding). The educational level and socio-economic 
status may also affect the risk of tuberculosis in part through their (indirect) effect on 
intermediate social determinants of health (including lifestyle risk factors), and via other 
pathways for which no measurements were made in this study (direct effect). It was also 
assumed that all associations between TB and the variables represented in the DAGs may 
be confounded by BCG vaccination status and long stays in high TB incidence parts of the 
word, two known risk factors for TB. These two variables were not represented in the DAG 
for visual convenience, but were treated as a priori confounders in the analyses. 
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Figure 6.3: Directed Acyclic Graph (DAG) of hypothesised relation between social 
determinants and tuberculosis. 
Note: The socio-economic status (SES) is depicted in a dash-lined cloud to indicate that this variable is 
not directly observed, but is assumed to be one effect of the educational level. Thus, the dash red arrows 
indicate that the association between SES and the intermediate social determinants of health is not 
directly measured in this framework. The relationship between education level and SES is represented 
in the DAG to explicitly assume that education level has a dual effect on the intermediate social 
determinants, by itself and via its effect on the socio-economic status. The assumption allows one to 
see back-door paths between these intermediate variables and TB that do not include education level, 
thus could otherwise have been missed. The variables BCG and ‘long stay in high-TB parts of the world’ 
are known independent risk factors for TB and considered a priori confounders for these analyses. They 
are included in all adjusted analyses and not represented in this DAG. 
 
Descriptive analyses 
The distribution of all independent variables by case and control status was tabulated and 
examined, including missing data. The characteristics of study participants with data 
missing for at least one variable were described and compared to those with complete 
data. To inform the multivariable model building, the correlation between related 
variables was also examined, especially between lifestyle variables (use of tobacco, alcohol 
and controlled drug), as well as history of prison and homelessness.   
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Associations of socio-economic and lifestyle indicators and tuberculosis  
Two groups of logistic regression models were built. The first group of models was 
designed to measure the overall association (‘total effect’) of education level – the most 
distal indicator of socio-economic level in my conceptual framework - and tuberculosis. 
The second group of models measured the respective associations between tuberculosis 
and the more proximal (intermediate) social determinants of health inequality in the 
conceptual framework – some of which are assumed to mediate part of the overall effect 
of socio-economic deprivation on TB risk.  
For each group of models, a baseline and adjusted regression models were fitted, 
respectively to estimate the ‘crude’ and adjusted odds ratios. The ‘crude’ estimates were 
obtained using regression models in which the frequency-matching variables (sex and 
birth cohort [in 5-year bands]) were forced (the ‘baseline models). Therefore, the phrase 
‘crude estimates’ in this chapter indicates age and sex-adjusted measures. The models in 
which birth cohort was fitted as a categorical variable were compared to linear; the former 
provided a better fit and there was strong evidence of departure from linearity, therefore 
birth cohort was fitted as a categorical variable in all regression models. The adjusted 
models for each group of variables were based on the DAG as described below: 
 In the first model measuring the overall adjusted effect of educational level (including 
that possibly mediated through the intermediate social determinants), a logistic 
regression model was fitted, in which in addition to age and sex, there was further 
adjustment for the a-priori confounders (BCG status and long stays in high TB areas). 
 The second model measured the ‘direct’ fully adjusted respective association between 
TB and more proximal risk factors in the DAG, including area-level deprivation, 
household overcrowding, and the other intermediate social determinants. This model 
was adjusted for the matching variables age and sex, the a-priori confounders, as well 
as all ‘nodes’ (variables) from the DAG that needed to be blocked (i.e. controlled for) 
to adjust for confounding to only measure the ‘direct’ association between each 
determinant and TB (i.e. non-spurious and not ‘mediated’ through any other observed 
variable in the DAG). The appropriate fully adjusted model based on the DAG 
eventually included all the variables, as well as educational level. When building the 
model, multi-collinearity was checked when simultaneously including correlated 
variables, by looking at changes in the standard errors and confidence intervals. Two 
variables (use of class B/C drugs vs use of class A drugs) with strong correlation and 
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evidence of multi-collinearity were fitted in turn in the model to measure their 
association to TB.  
One caveat with DAGs is the simplistic assumption on the direction of cause-to-effect 
sequence between some variables. For example, alcohol abuse can contribute to causing 
homelessness in some subjects, but homelessness can also increase the risk of alcohol 
abuse. The assumptions on temporal sequence in my DAG and the resulting regression 
model were informed by the literature as much as possible. For example, while many ex-
prisoners initiated drug use in prison, drug use also increases the risk of incarceration; 
however, a survey of substance abuse among prisoners in England and Wales has shown 
that the rates of drug use and dependence is high prior to incarceration (33, 34), with 75% 
heroin users and nearly 9 in 10 users of other class A drugs users reporting initiating drug 
use prior to incarceration (35). This explains my DAG’s assumption regarding the most 
common direction of association between drug use and prison in my study sample. The 
same applies to alcohol abuse and homelessness; the directed path in the DAG is 
consistent with a survey of substance use in homeless people in England, in which 
substance use, including alcohol, was among the most common reasons contributing to 
becoming homeless (36).  
The main analyses were restricted to observations with complete data for all variables in 
the DAG (complete case-analysis). All significance testing in regression models were done 
using likelihood ratio test (LRT). A test for trend was also conducted for ordered 
categorical variables in which the level-specific estimates suggested a trend. The statistical 
analyses were done using Stata 14.0. 
 
Missing data 
As a sensitivity analysis, the multiple imputation by chained equation (MICE) procedure 
was used to impute values to missing data and the analyses above repeated. The multiple 
imputation model included all putative variables included in the fully adjusted model, as 
well as the case/control status. The predictive models used were respectively logistic 
regression for binary variables (BCG status, person-per-bedroom, history of prison stay), 
ordered logistic regression for ordered categorical variables (smoking status, alcohol 
drinking and educational level), and multinomial logistic regression model for other non-
ordered categorical variables (history of homelessness, class A and class B/C drug use). 
Twenty datasets were imputed, on which the same regression models as for the complete-
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case analyses were repeated. Rubin’s rules were used to combine estimates across imputed 
datasets, and obtain the ‘imputed’ ORs and 95% confidence intervals (95%CI). 
 
Population attributable fractions (PAF): 
For the important modifiable risk factors, the information on their frequency in the study 
population was combined with the magnitude of association to TB to approximate the 
PAF. This was used to explore the theoretical impact that various interventions on specific 
risk factors may have in my target population.  
The PAFs were estimated by using the proportion of cases exposed and the adjusted ORs 
(aORs) using the formula PAF = ∑pi’(aORi – 1)/aORi, where pi’ is the proportion of cases 
with exposure level i for a specific risk factor, and aORi is the adjusted odds ratio for level 
i of that risk factor (37). This formula assumes that my aORs approximate risk ratios (rare 
disease assumption) and that they provide reasonable estimates of each risk factor’s causal 
effect on tuberculosis. There is a further assumption that the respective prevalence of 
exposure in the sampled cases are comparable to that in all cases. Finally, an implicit 
assumption of the logistic regression (used to obtain risk factors’ aORs) is that their effects 
are multiplicative, not additive. Therefore, the individual PAFs cannot be combined to 
obtain a ‘joint PAF’ of any combination of risk factors.   
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Results 
Characteristics of study participants 
The characteristics and distribution of various risk factors in cases and controls is 
presented in table 6.1. There was 9% more female control participants than cases, but the 
distributions by birth cohorts were comparable in cases and controls. Eighty-eight percent 
(1618/1864) of participants had complete data for all key variables; the most missing data 
were found in alcohol drinking (3%), tobacco smoking (3%) and educational level (3%).  
Over 40% cases lived in the most deprived fifth of the country, and one in five also reported 
no education at O-level equivalent or above, compared to one in twenty controls. Lifestyle 
risk factors were fairly common among cases, with over a quarter smoking daily with 
lifetime consumption greater than 10 pack-years versus one in eight controls, 18% cases 
reporting drinking above the recommended limit of 14 units per week compared to 11% 
controls, and one in ten cases had a history of using injectable class A drugs versus 1% 
controls. A very strong correlation was also found between using class B and C drugs, and 
using class A drugs (Spearman correlation coefficient = 0.76). The clustering of social risk 
factors was also more common in cases than in controls; for example, 7% cases reported 
both using class A drug, and history of homelessness and prison stay, compared to only 
1% controls (figure 6.4)  
 
Figure 6.4: Venn diagram of the prevalence of history of class A drug use, homelessness 
and prison stay in cases and controls 
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Table 6.1: Characteristics study participants 
 
Variable 
Cases (%)  
(n=681) 
Controls (%) 
(n=1183) 
Sex 
Female 345 (51%) 710 (60%) 
Male 336 (49%) 473 (40%) 
Birth cohort 
1965-1969 65 (10%) 175 (15%) 
1970-1974 179 (26%) 318 (27%) 
1975-1979 216 (32%) 263 (22%) 
1980-1984 152 (22%) 264 (22%) 
1985-1989 69 (10%) 163 (14%) 
Education level 
None 132 (19%) 75 (6%) 
O level, GCE or GCSE 208 (31%) 366 (31%) 
A level, SCE Higher  91 (13%) 250 (21%) 
Degree or Teaching degree 218 (32%) 461 (39%) 
missing 31 (5%) 31 (3%) 
BCG vaccination status 
BCG vaccinated 509 (75%) 1024 (87%) 
Unvaccinated 164 (24%) 154 (13%) 
missing 8 (1%) 5 (0.4%) 
Stay of 3 months or more in High TB-incidence areas (Africa or Asia) 
No 610 (90%) 1126 (95%) 
Yes 71 (10%) 57 (5%) 
Small area-level deprivation 
Least deprived quintile 64 (9%) 238 (20%) 
2nd quintile 101 (15%) 236 (20%) 
3rd quintile 107 (16%) 237 (20%) 
4th quintile 131 (19%) 236 (20%) 
Most deprived quintile 278 (41%) 236 (20%) 
Persons per bedroom 
<2 person per bedroom 587 (86%) 1104 (93%) 
≥2 persons per bedroom 77 (11%) 77 (7%) 
missing 17 (3%) 2 (0.2%) 
Tobacco smoking 
Never smoked 191 (28%) 508 (43%) 
Past smoker 94 (14%) 215 (18%) 
Occasional/Daily <10 pack-years  202 (30%) 277 (23%) 
Daily 10-19.9 pack-years 119 (17%) 106 (9%) 
Daily ≥20 pack-years 57 (8%) 47 (4%) 
missing 18 (3%) 30 (3%) 
Typical Alcohol consumption 
Do not drink alcohol 36 (5%) 49 (4%) 
Drink up to 40g (5 units)/week 324 (48%) 658 (56%) 
Drink 41-112g (5-14 units)/week 172 (25%) 300 (25%) 
Drink >112g (>14 units)/week 120 (18%) 130 (11%) 
missing 29 (4%) 46 (4%) 
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Class B and C drugs misuse  
Never used any 378 (56%) 818 (69%) 
Last used >10 years ago 63 (9%) 135 (11%) 
Last used 1-10 years ago 95 (14%) 106 (9%) 
Used <1 year ago 130 (19%) 93 (8%) 
missing 15 (2%) 31 (3%) 
Class A drugs misuse  
Never used any 426 (63%) 921 (78%) 
Last used >10 years ago 44 (6%) 88 (7%) 
Last used ≤10 years ago 128 (19%) 131 (11%) 
Used injectable class A drugs 66 (10%) 12 (1%) 
missing 17 (2%) 31 (3%) 
History of homelessness and sleeping rough 
Never 556 (82%) 1104 (93%) 
≤12 weeks 61 (9%) 43 (4%) 
>12 weeks 57 (8%) 25 (2%) 
missing 7 (1%) 11 (1%) 
History of prison in UK and/or abroad† 
Never been in prison 593 (87%) 1132 (96%) 
Stayed in prison† 83 (12%) 35 (3%) 
missing 5 (1%) 16 (1%) 
†including 10 (1.5%) cases and 2 (0.2%) controls with history of prison stay abroad 
 
 
Association between distal social determinants (education level, 
area-level deprivation in place of residence, and household 
overcrowding) and tuberculosis 
In the baseline model, the ‘crude’ odds of TB  in subjects with none or lower than O-level 
and equivalent educational level was nearly four times higher than in those with degree-
level education (OR=3.84; 95%CI=2.70 to 5.47), whereas the risk seemed comparable to 
baseline in subjects with education at GCE O and A-level equivalent. This pattern of 
association remained unchanged after adjusting for age, sex, BCG vaccination status and 
long stays in high TB areas (table 6.2). 
There was also a strong association between area-level index of multiple deprivation 
(IMD) and TB, with a risk of TB nearly twice and four times higher in subjects respectively 
from the most deprived fourth and fifth quintiles compared to those in the least deprived 
fifth areas. These associations remained strong, albeit slightly attenuated after adjustment 
for confounding by other variables (respectively [aOR=1.74; 95%CI=1.16 to 2.59] for the 2nd 
most deprived quintile and [aOR=3.30; 95%CI=2.23 to 4.88] for the most deprived 
quintile). The risk of TB was nearly doubled in those living in overcrowded housing when 
controlling for age and sex; but the OR was smaller after further adjustment for 
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confounding (aOR=1.42; 95%CI=0.95 to 2.12) (detailed results in table 6.3). Most of the 
confounding in these analysis was due to the a priori confounders BCG vaccination and 
stays of 3 months or more in high TB incidence parts of the world, and the ‘backdoor paths’ 
through education level (see supplementary table 6.1).  
 
 
Table 6.2: Overall association between Education level and tuberculosis 
 
 Variable Baseline model*  Adjusted model** 
Complete Case analysis (n = 1638; 578 cases and 1060 controls) 
 OR 95%CI 
p-
value  
aOR 95%CI 
p-
value  
Degree or Teaching 
degree 
1   1   
A level, SCE Higher 0.78 (0.58;1.06)  0.79 (0.58;1.08)  
O level, GCE or GCSE 1.19 (0.93;1.53) <0.001 1.28 (0.99;1.66) <0.001 
None 3.84 (2.70;5.47)  3.94 (2.74;5.67)  
MICE*** Imputed datasets (n = 1864; 681 cases and 1183 controls) 
Degree or Teaching 
degree 
1   1   
A level, SCE Higher 0.82 (0.61;1.10)  0.85 (0.63;1.15)  
O level, GCE or GCSE 1.30 (1.02;1.65) <0.001 1.41 (1.10;1.81) <0.001 
None 4.21 (2.92;5.65)  4.21 (2.99;5.92)  
*Baseline model adjusted for age (birth cohort) and sex 
**Adjusted model: Educational level adjusted for age, sex, BCG vaccination status and stays ≥3 months in high 
TB incidence areas (Africa or Asia). Other variables not included in model because assumed to be mediators in 
causal framework. 
***MICE = Multiple Imputation using Chained Equations 
 
Association between tuberculosis and intermediate social 
determinants and other risk factors  
Focusing on the intermediate social determinants of health (table 6.3), the strongest 
association after adjusting for confounding was found between TB and misuse of class A 
injectable drugs, with over five times increase in the risk of TB (aOR=5.67; 95%CI=2.68 to 
11.98) as compared to people who never misused class A drugs. The risk of TB was also 
about 50% higher in those who reported using either non-injectable class A or class B and 
C drugs within the past 10 years. After controlling for confounding, there was also strong 
evidence (p=0.008) of a mild dose-effect association between tobacco smoking and TB, 
including 17%, 25%, 61% and 72% higher risk of TB respectively in past smokers, and 
subjects smoking occasionally or less than 10 pack-years daily, 10-19.9 pack-years, and 20 
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or more pack-years, compared to non-smokers. The typical weekly levels of alcohol 
consumption reported in this study sample were not associated with TB.  
The risk of TB in subjects reporting a history of homelessness of up to 12 weeks and over 
12 weeks were respectively 66% (aOR=1.66; 95%CI=0.99 to 2.79) and double that of those 
with no such history (aOR=2.01; 95%CI=1.11 to 3.63); meanwhile the association observed 
between history of prison stay and TB in the baseline model (OR=3.88; 95%CI=2.49 to 
6.04) disappeared once all variables were controlled for (aOR=1.34;95%CI=0.79 to 2.28). 
There was no single variable explaining most of the confounding by itself, with most of 
the associations disappearing only after the simultaneous inclusion in the multivariable 
model of tobacco smoking, drug use, alcohol use, history of homelessness, and education 
level. 
For the other risk factors investigated, subjects who reported stays with duration of 3 
months or more in Africa or Asia were nearly three times as likely to have TB (aOR=2.67; 
95%CI=1.74 to 4.08), whereas the risk of TB was halved in those who had received BCG.  
Finally, consistent with the causal diagram hypotheses that part of the association between 
education level and tuberculosis is mediated by some intermediate variables, the four-fold 
higher odds in subjects with none or lower than O-level compared to those with degree-
level education (OR=3.94; 95%CI=2.74 to 5.67) was attenuated  to an OR=1.76 (95%CI=1.16 
to 2.68) after controlling for all intermediate social determinants.  
 
Missing data 
The characteristics of the 226 (12%) subjects with data missing for at least one variable 
were compared to those 1638 (88%) with complete data for all variables. Fifteen percent 
(103/681) of cases had missing data compared to 10% (123/1060) in controls (p=0.003). The 
distribution and association of missingness to other variables is reported in the 
supplementary table 6.2. Broadly, those with missing data were slightly less educated, 
more deprived, heavier tobacco smokers and alcohol drinkers; they were also more likely 
to have a history of homelessness. However, they were comparable to those with no 
missing data with regards to other characteristics (including age, sex, BCG status, long 
stays abroad, drug use and history of prison). 
The findings did not appear to be affected by the missing data, with the results from 
statistical analyses after multiple imputation of missing data similar to those of the 
complete case analyses, but with narrower confidence intervals (see table 2 for education 
level and supplementary table 6.3 for other variables).   
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Table 6.3: Association between intermediate social determinants and tuberculosis∞ 
 
Variable Baseline model†  Fully adjusted Model‡ 
n = 1638; 578 cases 
and 1060 controls 
OR 95%CI 
p-
value  
OR 95%CI 
p-
value 
Quintiles of Index of multiple deprivation 
Least deprived quintile 1 -  1 -  
2nd quintile 1.70 (1.16;2.51)  1.76 (1.18;2.64)  
3rd quintile 1.60 (1.09;2.35) <0.001 1.51 (1.01;2.27) <0.001 
4th quintile 1.95 (1.34;2.85)  1.74 (1.16;2.59)  
Most deprived quintile 4.38 (3.07;6.24)  3.30 (2.23;4.88)  
Persons per bedroom (ppb) 
<2 ppb 1   1   
≥2 ppb 2.01 (1.40;2.88) <0.001 1.42 (0.95;2.12) 0.091 
Tobacco smoking 
Never smoked 1 -  1 -  
Past smoker 1.33 (0.98;1.82)  1.17 (0.83;1.65)  
Occasional / <10pk-yr 1.89 (1.45;2.46) <0.001 1.25 (0.92;1.69) 0.008* 
Daily 10 to 19.9 pk-yr  2.67 (1.90;3.75)  1.61 (1.09;2.38)  
Daily ≥20 pk-yr 3.49 (2.18;5.59)  1.72 (0.98;3.01)  
Typical Alcohol drinking 
Non-drinker/ ≤40g/wk  1 -  1 -  
41-111g/wk 0.98 (0.77;1.25) 0.015 1.00 (0.76;1.3)  
≥112g/wk 1.54 (1.13;2.10)  1.06 (0.75;1.51) 0.936 
Class B/C drug misuse 
Never 1 -  1 -  
>10 years ago 0.88 (0.62;1.25)  0.73 (0.49;1.08) 0.004 
1-10 years ago 1.94 (1.40;2.7) <0.001 1.55 (1.07;2.23)  
<1 year ago 2.78 (2.00;3.85)  1.49 (1.00;2.20)  
Class A drug misuse 
Never 1 -  1 -  
>10 years ago 0.91 (0.6;1.38)  0.72 (0.45;1.14)  
≤10 years ago 1.91 (1.42;2.57) <0.001 1.51 (1.07;2.12) <0.001 
Injectable 10.57 (5.44;20.53)  5.67 (2.68;11.98)  
BCG vaccination status 
No 1 -  1 -  
Yes 0.45 (0.35;0.57) <0.001 0.51 (0.38;0.68) <0.001 
Stay of 3 months or more in High TB-incidence areas (Africa or Asia) 
No 1 -  1 -  
Yes 2.27 (1.54;3.34) <0.001 2.67 (1.74;4.08) <0.001 
History of homelessness 
Never 1 -  1 -  
≤12 weeks 2.92 (1.86;4.59) <0.001 1.66 (0.99;2.79) 0.005* 
>12 weeks 4.35 (2.56;7.40)  2.01 (1.11;3.63)  
History of prison stay 
No 1 -  1 -  
Yes 3.88 (2.49;6.04) <0.001 1.34 (0.79;2.28) 0.273 
∞The associations between TB and the a priori confounders BCG vaccination and long stays in high TB 
incidence parts of the world are also reported in the table 
†Baseline model is controlling for frequency-matching variables birth cohort and sex 
‡Fully adjusted model further controls for education level and all the variables presented in the table 
*p-value of test for trend 
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Potential population impact of TB risk factors 
The information on the likely frequency of modifiable risk factors in the target population 
and their ‘net’ adjusted association to TB was combined to approximate risk-factors-
specific population attributable fractions (PAFs) as described in the statistical analyses 
section; the results are presented in table 6.4. While the association of TB to tobacco 
smoking was relatively weak, the high prevalence suggested that preventing this habit 
could help avoid about 18% TB cases in my target population. Similarly, interventions to 
prevent misuse of class A drugs could help avoid 15% TB cases, with about 8% by reducing 
injectable drug A abuse. The calculations also suggest that school BCG vaccination may 
have helped prevent about 12% cases in this population, and reducing homelessness could 
reduce 7.6% TB notifications. The respective effect of these risk factors is not assumed to 
be additive; therefore, the joint PAF for any combination of risk factors is not the sum of 
their respective PAFs, and the results presented should not be interpreted as such. 
 
Table 6.4: Estimates of Tuberculosis Population Attributable Fraction for specific risk 
factors 
Risk Factor/Levels at 
risk 
# 
Exposed 
Cases  
% Exposed 
Cases  
(N=578) 
aOR 
Level 
specific 
PAF 
Total Risk 
Factor PAF* 
Tobacco smoking 
Past smoker 91 16% 1.17 2.3%  
Occasional / <10pk-yr 173 30% 1.25 6.0% 18% 
Daily 10 to 19.9 pk-yr  96 17% 1.61 6.4%  
Daily ≥20 pk-yr 47 8% 1.72 3.3%  
Class A drug misuse 
<10 yrs 110 19% 1.51 6.4% 14.7% 
Injectable 57 10% 5.67 8.2%  
Class B/C drug misuse 
1-10 years ago 84 15% 1.55 5.3% 11.6% 
<1 year ago 109 19% 1.49 6.2%  
BCG 
Unvaccinated 140 24% 1.96 11.8% 11.8% 
Stay of 3 months or more in High TB-incidence areas (Africa or Asia) 
Yes 62 11% 2.67 6.9% 6.9% 
History of homelessness 
≤12 weeks 50 9% 1.66 3.6% 7.6% 
>12 weeks 46 8% 2.01 4.0%  
    *PAF = ∑pi’(aORi – 1)/aORi, where pi’ is the proportion of cases with exposure level i for a specific risk 
factor, and aORi is the adjusted odds ratio for level i of that risk factor 
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Discussion 
Summary main findings  
This study represents to my knowledge the first attempt at using a formal causal 
framework to examine how the association between individual socio-economic status 
(SES) and tuberculosis (TB) in the native population from a high-income and low-TB 
burden setting may be explained by some aspects of the social determinants of health. 
This causal framework allowed us to make explicit assumptions on the inter-relation 
between these determinants, and therefore to control for mutual confounding when 
measuring their respective association to TB. Using the educational level as an indicator 
for individual SES, I found that amongst UK-born White adults in England, the risk of TB 
is higher in lower SES groups, with four times greater odds of TB among those with none 
or education level below O-level, compared to those with A-level and above. My analyses 
also suggested that in the target population, some of this association between socio-
economic status and TB could be explained through the place of residence (based on 
small-area level of deprivation), tobacco smoking, misuse/abuse of controlled drugs, as 
well as homelessness. The other social determinants of health inequalities measured in the 
study (household overcrowding, alcohol drinking and history of prison stay) were only 
weakly associated with TB after adjusting for these risk factors. The analysis also showed 
that BCG vaccination halved the risk of TB in those vaccinated, whereas travels for 3 
months or more in high-TB burden parts of the world was associated with more than a 
doubling in the risk of disease. The estimates of population impact suggested that 
interventions targeting tobacco smoking and drug misuse (especially class A drugs) may 
contribute to substantially reducing the burden of tuberculosis in the target population.  
 
Overall SES (using Educational level as an indicator) and risk of 
tuberculosis  
There are studies supporting the idea that in low-incidence settings, poverty and lower 
SES remain associated with greater risk of Mtb infection (14), as well as delay to diagnosis 
and treatment (38), and poorer treatment outcome and mortality (39). However, there is 
less data on the association between individual SES and the risk of TB disease. Most studies 
addressing this specific question have been ecological by design, thus focusing on 
variations in the distribution of disease across gradients of deprivation or poverty at area-
level (40). These studies have been helpful to highlight areas of greater burden and where 
more resources are needed for control efforts, but they have only provided limited insight 
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on how individuals SES relates to their risk of disease, including within poor areas where 
the burden of disease is higher. My results that the risk of TB is nearly four-fold higher in 
individuals with none or lower education level, irrespective of intermediate determinants 
such as tobacco smoking and drug use, is consistent with the few published studies that 
have measured the association between an individual-level indicator of SES and TB 
disease, even though the direct comparison between my results and those studies is 
complicated by the variation in the indicators used to measure individual SES. In their 
case-control study of risk factors of TB in Adults in Washington in 1988-90, Buskin et al. 
used family income, years of education and housing conditions to create a composite 
binary SES variable; they found that the risk of TB in lowest SES category was about four 
times higher than that of the highest SES group (41). Another case-control study in 
Greenland in 2004-06 using occupation as the proxy-measure for SES, also observed that 
TB was four times more likely in unemployed subjects compared to those in work or 
studies (42). The similarity of these results to ours despite the use of different indicators 
confirms the hypothesis that lower SES is an important risk factor for active TB in this 
study population. 
It also reflects the close correlation between educational level and SES in developed 
countries. It has been argued that education level is a good indicator of SES, because it is 
greatly determined by parental SES, as well as a strong predictor of future employment 
and earnings, therefore taking into account both early life influences and adulthood SES 
(43); it is also relatively easy to measure accurately, therefore minimising measurement 
error. The higher risk of disease in subjects from lower SES status is probably a composite 
consequence of an increased risk of exposure to and infection by Mtb, and a higher 
probability of progression to disease once infected. However, it is unlikely that lower SES 
directly causes these, but instead, SES determines the distribution of more proximal risk 
factors, including social determinants, which in turn can affect the risk of infection and 
disease. The suggestion fits with the WHO Commission on Social Determinants of Health 
(CSDH) framework which postulates that the pathways through which socio-economic 
stratification result in health inequalities is by causing unequal distribution of social 
determinants of health in the society (44, 45). 
 
Risk factors associated with increased risk of TB 
The extent to which selected social determinants of health inequality (SDH) explain the 
association between individual’s SES and the risk of TB in my study population was 
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investigated within a causal framework that allowed simultaneous exploration of their 
respective potential effects. After taking into account all other variables and potential 
pathways between SES and TB in my framework, there was evidence that the higher risk 
of TB related to lower SES was explained in part by tobacco smoking, drug misuse, history 
of homelessness, and area-level deprivation, whereas the evidence of association between 
TB and respectively alcohol drinking, history of prison stay, and household overcrowding 
was no longer apparent once controlling for the other pathways in this dataset.  
The association found between tobacco and tuberculosis is consistent with results from 
four of five previous studies in the UK in which this was measured, including two case-
control studies in which current smokers were found to be on average 60% more likely to 
develop TB than non-smokers (46, 47); A similar result was recently reported from a US 
study (48). Two previous systematic reviews of the association between tobacco smoking 
and tuberculosis found overall nine studies in developed countries (8 case-control and 1 
cross-sectional studies), of which six reported evidence of association with odds ratios 
between 1.6 and 3.9 for current smokers compared to non-smokers (49, 50). The fact that 
the effect of lower SES on the risk of TB is mediated through tobacco smoking is not 
surprising; studies have consistently found that the prevalence of tobacco smoking is 
higher among subjects from lower SES background, and that the age at initiation of 
smoking is much younger (8, 30). The various harmful effects of tobacco smoking on 
health are well documented, including on the immune system (51, 52). It is biologically 
plausible that the tobacco-related loss of mucosal immunity in the respiratory tract 
increases the risk of Mtb infection in smokers, even at lower exposure doses; and the 
impairment of both innate and adaptive immune responses by tobacco can lead to higher 
risk of disease in infected individuals. The plausibility of a direct effect of tobacco smoking 
on the risk of TB is supported further by the dose-effect observed in my study, with the 
risk in daily smokers higher than in occasional and past smokers.       
Regarding drug use, although a number of studies in recent times have reported a greater 
prevalence of Mtb infection (TST positive tests) among drug users than the general 
population, there is scant evidence on the association between drug use and TB disease 
(53, 54). In my study, subjects who admitted to using either of class C, B or non-injectable 
class A drugs in the past 10 years were about 50% more likely to develop TB, and the risk 
in those admitting to using injectable class A drugs was much higher, nearly 5 times that 
of non-drug users after controlling for other proximal risk factors. In 1971, well before the 
HIV pandemic, Reichman et al. reported that the prevalence and incidence of TB among 
drug users in Harlem, New York were respectively 9 and 10 times higher than that of its 
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general population (55), which is consistent to the unadjusted estimates obtained for the 
association between use of injectable drugs and TB in my study. In the same analyses, 
these authors found that the TST rates in the drug-user population were similar to the 
general population of Harlem, which supports the hypothesis that drug use may be 
independently associated with increased risk of developing TB disease after infection (55).  
In the context of low TB incidence in most developed countries in contemporary times, 
the higher prevalence of Mtb infection reported among drug users could also still be due 
to higher probability of exposure and transmission among drug users, for example as a 
result of frequenting or congregating in spaces with inadequate ventilation. Two studies 
respectively in the USA (56) and the UK (57) have found that smear positive TB is nearly 
twice more frequent among drug users than other forms of TB, and delays to diagnosis are 
more frequent, which may both contribute to more transmission in this population group. 
However, the biological mechanisms through which drug use may increase the risk of TB 
are not clear. There are studies suggesting drug use may impair the immune system (58), 
and it has been speculated that pulmonary damage is related to some forms of drug abuse, 
for example frequent smoking of crack-cocaine and other inhaled drugs, may affect 
alveolar macrophages (59) (58). It is also possible that co-infection with HIV and under-
nutrition may contribute to the much higher risk in those using injectable drugs. Recent 
Mtb infection, which is likely in these risk groups given frequent exposure, is also in itself 
a strong risk factor of disease, with nearly 5-10% risk of TB in the 2-5 years following 
infection, as compared to much lower risk over the rest of a lifetime (60).   
The higher prevalence of a number of lifestyle behaviours hazardous to health among 
homeless people, especially those sleeping rough, is well documented; such behaviours 
include tobacco smoking, drug use and harmful alcohol drinking (36, 61). This is evident 
in my study, because the association between homelessness and TB is nearly halved after 
controlling for these other risk factors; for instance, the 4 times higher risk of TB in those 
reporting being homeless for more than 12 weeks compared to those who have never been 
homeless dropped to twice the risk after additional controlling for the other factors. 
However, even after taking into account the other social determinants, there was still good 
evidence that history of homelessness was independently associated to a higher risk of TB. 
This is likely explained by the role of other factors frequent in homeless subjects that were 
not accounted for in my study, for example poorer nutritional status, which contributes 
to weakening the immune system, as well as greater likelihood of exposure to subjects 
with infectious TB.  
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In my analysis, the risk of TB was also higher in those in general living in deprived areas, 
even after controlling for other risk factors and social determinants (up to three times 
increase in those living in the most deprived quintile areas). The IMD-based measure of 
deprivation most likely captures aspects of poverty that affects the risk of TB through 
pathways other than the social determinants measured in my study. Two of the seven 
domains that are included in the composite IMD, barriers to housing and services, and 
living environment deprivations, capture aspects of the living environment that may affect 
the risk of infection, including for instance quality of housing and household 
overcrowding (21). The IMD also measures income and employment deprivation (21), 
which are associated with nutritional status and health frailty, and through that may affect 
the risk of disease.  
 
Risk factors with weak evidence of an association with TB 
The association between alcohol drinking and TB in this study population was consistent 
with the results of the sole previous UK study in which this was measured (62), but was 
weaker than reported in several other studies. Subjects who reported regularly drinking 
on average 14 units or more per week, were only about 50% more likely to have TB than 
non-drinkers, and alcohol was no longer associated with TB after adjusting for other social 
determinants, whereas a previous systematic review of the literature reported a pooled 
relative risk of nearly three times more TB among drinkers (15). Although the comparison 
of various studies is complicated by variation in the definitions and classification of alcohol 
abuse, the difference probably reflects the duration of exposure, as my study population 
was mainly relatively younger adults (23 to 38 years), hence less likely to have been 
exposed to chronic harmful drinking long enough to affect their immunity, while several 
of the studies reporting stronger association included older adults, and/or on subjects with 
recorded diagnosis of alcohol abuse (15). Also, the fact that several prior studies did not 
always control for some confounders may have contributed to overestimating the alcohol-
related relative risk of TB; for example, a cohort study in Canada reported an adjusted 
relative risk of 3.12 (95%CI 1.26-7.72), but did not control for tobacco smoking (63), 
whereas another cohort in Finland in which the analysis were adjusted for tobacco 
smoking found no association (64).    
Household overcrowding and history of prison stay were both strongly associated with TB 
in my baseline model, but these associations were weaker after adjusting for other 
variables. It is documented that overcrowding may increase the risk of Mtb exposure and 
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infection (65, 66), and the higher prevalence of LTBI among prisoners has been noted in 
several surveys (67); the strong association with TB after controlling for age and sex, is 
consistent with the fact that recent infection is in itself a strong risk factor for disease (60). 
The weaker association between overcrowding and TB after additional adjustment for 
other determinants in my study sample may reflect the fact that subjects living in 
overcrowded households are more likely to be from lower SES, and could therefore also 
be at higher risk of exposure to other TB risk factors, for example tobacco smoking. A 
similar reasoning could be held regarding the association between TB and history of prison 
stay. For example the prevalence of tobacco smoking, drug use and homelessness among 
ex-prisoners is higher than the general population (33, 34); and as discussed in the previous 
section, both drug use and homelessness can increase the risk of TB e.g. via poor 
nutritional status, including in infected ex-prisoners. Alternative explanations for the 
weak evidence of association between TB and history of prison stay after adjustment could 
include the underreporting of other risk factors like drug use and history of homelessness 
in the control group, which may have caused overestimation of their association with TB, 
and in turn an underestimation of the association between history of prison and TB. It is 
also possible that the overall association between history of prison stay and TB was 
underestimated in my study sample due to under-reporting of prison stay among cases, 
and the analysis not taking into account parameters like the duration of prison stay and 
time since last prison stay. 
 
Study strengths and limitations 
One caveat of using a formal causal framework in my study is that it requires relatively 
simplistic causal assumptions for the complex relationship between the various social 
determinants. For example, while drug users are at higher risk of prison stay, many ex-
prisoners develop their addiction during their prison stay (34, 35). However, in my 
analyses, the assumptions were made to obtain conservative estimates for all associations 
investigated. Another frailty that my study share with many observational designs based 
on recall of exposure, was the difficulty in ascertaining the precise temporal sequence 
between participants’ exposure to some of the risk factors and Mtb infection and TB. This 
is mitigated to some extent by the fact that some of the risk factors investigated tend to 
be correlated in time, in that recent exposure status is a relatively good predictor of past 
exposure status. Furthermore, reverse causality is not a major concern for the relationship 
of TB to the determinants of health measured in this study.  
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A difficulty inherent to investigating social determinants of a disease like tuberculosis that 
disproportionately affects socially marginalised and deprived segments of the population 
is that cases with the highest levels of exposure (at highest risk) can be difficult to trace 
and enrol in the study. Reasonable efforts were made to find and include such individuals; 
for example, attempts were made (including some successful) to contact eligible notified 
cases who are still homeless, but with known contact details at shelters or temporary 
accommodations. Likewise, the sections of the questionnaire collecting data on socially-
sensitive habits and history, including tobacco, alcohol and drug use, history of 
homelessness and prison stay were collected confidentially using a self-administered 
computer assisted software which allowed the participants to enter the information 
themselves in confidence and electronically locked it so it was not accessible to the 
interviewer; this was not only to minimise bias in reporting of the information, but also to 
ensure equal chance of participation to the study of people with higher exposure levels. 
However, overall the proportion of cases that could successfully be contacted was lower 
in the most deprived area than in the least deprived areas. The study was also restricted to 
people who had their first ever notified episode of TB, thus not including those with 
relapse who may have higher prevalence of some of the risk factors of interest. Another 
issue related to the retrospective ascertainment of exposures is the measurement accuracy; 
the misclassification of some variables may have contributed to underestimate some 
associations. It is therefore possible overall that the associations between TB and of some 
of the social determinants of health investigated here may have been underestimated, and 
my results are relatively conservative.  
 
Conclusions and recommendations 
Despite of their limitations, the results presented here provide some insights into some of 
the mechanisms through which social deprivation affects the risk of TB in the adult native 
population of a low-incidence developed country. As noted in introduction, the TB rates 
have been stagnating in the native adult UK population for nearly a quarter of a century, 
in spite of the scaling up of control efforts in recent years, and new threats have emerged, 
not least the spread of multi-drug resistant TB strains. The new global TB strategy adopted 
by the WHO in 2015 recognises that additional actions are needed to complement the 
current TB control and prevention tools to progress towards elimination, including 
addressing the underlying social determinants of TB (3).  Although further studies are 
needed to build a stronger the body of evidence to make policy recommendations, the 
potential impact of interventions addressing some of the social determinants investigated 
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should be noted. The population attributable fraction estimates based on my conservative 
analyses suggest that interventions like tobacco smoking cessation in white UK born 
young adults may help reduce up to a fifth of TB cases in the target population, while drug 
addiction treatment could help avert nearly 15% disease. A recent UK-based qualitative 
study has highlighted the need to integrate care across a number of social and health 
services to address the complex needs of TB patients in order to achieve better treatment 
outcome (68). My results provide further arguments in support of such integrated 
approach, as it could also help prevent cases and reduce the burden of disease among 
vulnerable groups, and at the same time improve the cost-effectiveness of combined 
public health  interventions by pooling resources.     
135 
 
References 
1. World Health Organization. Global tuberculosis report 2015 - 20th Edition 2015. 
Available from: 
http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf?ua=1. 
2. Lonnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M. Drivers of 
tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med. 
2009;68(12):2240-6. 
3. Lonnroth K, Migliori GB, Abubakar I, D'Ambrosio L, de Vries G, Diel R, et al. 
Towards tuberculosis elimination: an action framework for low-incidence countries. Eur 
Respir J. 2015;45(4):928-52. 
4. European Centre for Disease Prevention and Control / WHO Regional Office for 
Europe. Tuberculosis surveillance and monitoring in Europe 2016. Stockholm: European 
Centre for Disease Prevention and Control; 2016. Available from: 
http://ecdc.europa.eu/en/publications/publications/ecdc-tuberculosis-surveillance-
monitoring-europe-2016.pdf. 
5. Poulton R, Caspi A, Milne BJ, Thomson WM, Taylor A, Sears MR, et al. 
Association between children's experience of socioeconomic disadvantage and adult 
health: a life-course study. Lancet. 2002;360(9346):1640-5. 
6. Caldwell TM, Rodgers B, Clark C, Jefferis BJ, Stansfeld SA, Power C. Lifecourse 
socioeconomic predictors of midlife drinking patterns, problems and abstention: 
findings from the 1958 British Birth Cohort Study. Drug Alcohol Depend. 2008;95(3):269-
78. 
7. Jefferis BJ, Manor O, Power C. Social gradients in binge drinking and abstaining: 
trends in a cohort of British adults. J Epidemiol Community Health. 2007;61(2):150-3. 
8. Casetta B, Videla AJ, Bardach A, Morello P, Soto N, Lee K, et al. Association 
between cigarette smoking prevalence and income level: a systematic review and meta-
analysis. Nicotine Tob Res. 2016. 
9. Reinherz HZ, Giaconia RM, Hauf AM, Wasserman MS, Paradis AD. General and 
specific childhood risk factors for depression and drug disorders by early adulthood. J 
Am Acad Child Adolesc Psychiatry. 2000;39(2):223-31. 
136 
 
10. Lonnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, et al. 
Tuberculosis control and elimination 2010-50: cure, care, and social development. 
Lancet. 2010;375(9728):1814-29. 
11. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO's 
new end TB strategy. Lancet. 2015;385(9979):1799-801. 
12. The 67th World Health Assembly Executive Board. Global strategy and targets 
for tuberculosis prevention, care and control after 20152014. Available from: 
http://apps.who.int/gb/ebwha/pdf_files/EB134/B134_R4-en.pdf?ua=1. 
13. Public Health England. Tuberculosis in England: 2015 (presenting data to end of 
2014) report version 1.1.: Public Health England,; 2015. Available from: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/492431/
TB_Annual_Report_v2.6_07012016.pdf. 
14. Lienhardt C. From exposure to disease: the role of environmental factors in 
susceptibility to and development of tuberculosis. Epidemiol Rev. 2001;23(2):288-301. 
15. Lonnroth K, Williams BG, Stadlin S, Jaramillo E, Dye C. Alcohol use as a risk 
factor for tuberculosis - a systematic review. BMC Public Health. 2008;8:289. 
16. Mangtani P, Nguipdop-Djomo P, Keogh R, Sterne JA, Abubakar I, Smith PG, et al. 
The duration of protection of school-age BCG vaccination in England: a population -
based case-control study. . Submitted. 2016. 
17. Health Protection Agency. HIV in the United Kingdom: 2012 Report. London, UK: 
Health Protection Services, Colindale; 2012. Available from: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/335452/
HIV_annual_report_2012.pdf. 
18. Office for National Statistics. A beginner's guide to UK geography: Census 
geography 2011 [cited 2011]. Available from: http://www.ons.gov.uk/ons/guide-
method/geography/beginner-s-guide/census/index.html. 
19. Becker E, Boreham R, Chaudhury M, Craig R, Deverill C, Doyle M, et al. Health 
Survey for England 2004 volume 2: Methodology and documentation. Joint Health 
Survey Unit National Centre for Social Research, 2006. 
20. Office for National Statistics. Population estimates for UK, England and Wales, 
Scotland and Northern Ireland, Mid-2010 2011 [cited 2011]. Available from: 
137 
 
http://www.ons.gov.uk/ons/rel/pop-estimate/population-estimates-for-uk--england-
and-wales--scotland-and-northern-ireland/mid-2010-population-estimates/index.html. 
21. Office for National Statistics, editor. The English Indices of Deprivation 
20072008. 
22. Blake KS, Kellerson RL, Simic A. Measuring overcrowding in housing: a report for 
the US department of housing and urban development, Office of policy development and 
research2007. Available from: 
https://www.huduser.gov/publications/pdf/measuring_overcrowding_in_hsg.pdf. 
23. Office of the Deputy Prime Minister. The impact of overcrowding on health and 
education: a review of the evidence and literature. London, UK2004. Available from: 
http://dera.ioe.ac.uk/5073/1/138631.pdf. 
24. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol 
consumption questions (AUDIT-C): an effective brief screening test for problem 
drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use 
Disorders Identification Test. Arch Intern Med. 1998;158(16):1789-95. 
25. Joint Health Surveys Unit. Health Survey for England 2011, Volume 1: Health, 
Social care and Lifestyles. London: National Centre for Social Research & University 
College London; 2012. Available from: 
http://content.digital.nhs.uk/catalogue/PUB09300/HSE2011-All-Chapters.pdf. 
26. Department of Health. UK Chief Medical Officers’ Alcohol Guidelines Review: 
Summary of the proposed new guidelines. London, UK: Department of Health; 2016. 
Available from: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/489795
/summary.pdf. 
27. Del Boca FK, Darkes J. The validity of self-reports of alcohol consumption: state 
of the science and challenges for research. Addiction. 2003;98 Suppl 2:1-12. 
28. Dawson DA. Methodological issues in measuring alcohol use. Alcohol Res 
Health. 2003;27(1):18-29. 
29. Alcohol Guidelines Review – Report from the Guidelines development group to 
the UK Chief Medical Officers (published January 2016 with the consultation on the 
language and understanding of the UK Chief Medical Officers low-risk alcohol 
guidelines). Department of Health; 2015. Available from: 
138 
 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/545739/
GDG_report-Jan2016.pdf. 
30. National Centre for Social Research, National Foundation for Educational 
Research. Smoking, Drinking and Drug Use Among Young People in England - 2014: 
Health and Social Care Information Centre; 2015. Available from: 
http://content.digital.nhs.uk/catalogue/PUB17879. 
31. Dahlgren G, Whitehead M. Policies and Strategies to Promote Social Equity in 
Health - Background document to WHO Strategy paper for Europe1991 September 1991. 
Available from: https://core.ac.uk/download/pdf/6472456.pdf. 
32. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. 
Epidemiology. 1999;10(1):37-48. 
33. Singleton N, Farrell M, Meltzer H. Substance misuse among prisoners in England 
and Wales. Int Rev Psychiatry. 2003;15(1-2):150-2. 
34. Singleton N, Farrell M, Meltzer H. Substance misuse among prisoners in England 
and Wales: Further analysis of data from the ONS survey of psychiatric morbidity among 
prisoners in England and Wales carried out in 1997 on behalf of the Department of 
Health: Office for National Statistics,; 1999. Available from: 
https://www.ons.gov.uk/ons/rel/psychiatric-morbidity/substance-misuse-among-
prisoners/substance-misuse-among-prisoners/substance-misuse---among-prisoners.pdf. 
35. Boys A, Farrell M, Bebbington P, Brugha T, Coid J, Jenkins R, et al. Drug use and 
initiation in prison: results from a national prison survey in England and Wales. 
Addiction. 2002;97(12):1551-60. 
36. Fountain J, Howes S. Home and Dry? Homelessness and Substance Use. London, 
UK: The National Addiction Centre; 2002. Available from: 
http://www.crisis.org.uk/data/files/publications/HomeDry.pdf. 
37. Bruzzi P, Green SB, Byar DP, Brinton LA, Schairer C. Estimating the population 
attributable risk for multiple risk factors using case-control data. Am J Epidemiol. 
1985;122(5):904-14. 
38. French CE, Kruijshaar ME, Jones JA, Abubakar I. The influence of socio-economic 
deprivation on tuberculosis treatment delays in England, 2000-2005. Epidemiology & 
Infection. 2009;137(4):591-6. 
139 
 
39. Alvarez JL, Kunst AE, Leinsalu M, Bopp M, Strand BH, Menvielle G, et al. 
Educational inequalities in tuberculosis mortality in sixteen European populations. Int J 
Tuberc Lung Dis. 2011;15(11):1461-7, i. 
40. Tocque K, Doherty MJ, Bellis MA, Spence DP, Williams CS, Davies PD. 
Tuberculosis notifications in England: the relative effects of deprivation and 
immigration. International Journal of Tuberculosis & Lung Disease. 1998;2(3):213-8. 
41. Buskin SE, Gale JL, Weiss NS, Nolan CM. Tuberculosis risk factors in adults in 
King County, Washington, 1988 through 1990. Am J Public Health. 1994;84(11):1750-6. 
42. Ladefoged K, Rendal T, Skifte T, Andersson M, Soborg B, Koch A. Risk factors for 
tuberculosis in Greenland: case-control study. Int J Tuberc Lung Dis. 2011;15(1):44-9. 
43. Galobardes B, Shaw M, Lawlor DA, Lynch JW, Davey Smith G. Indicators of 
socioeconomic position (part 1). J Epidemiol Community Health. 2006;60(1):7-12. 
44. Solar O, Irwin AA. A Conceptual Framework for action on the Social 
Determinants of Health. Social Determinants of Health Discussion Paper 2 (Policy and 
Practice). . Geneva, Switzerland: World Health Organization; 2010. Available from: 
http://apps.who.int/iris/bitstream/10665/44489/1/9789241500852_eng.pdf?ua=1. 
45. Hargreaves JR, Boccia D, Evans CA, Adato M, Petticrew M, Porter JD. The social 
determinants of tuberculosis: from evidence to action. Am J Public Health. 
2011;101(4):654-62. 
46. Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other 
associated factors, and the risk of tuberculosis. Arthritis Rheum. 2006;55(1):19-26. 
47. Lowe CR. An association between smoking and respiratory tuberculosis. Br Med 
J. 1956;2(5001):1081-6. 
48. Smith GS, Van Den Eeden SK, Baxter R, Shan J, Van Rie A, Herring AH, et al. 
Cigarette smoking and pulmonary tuberculosis in northern California. J Epidemiol 
Community Health. 2015;69(6):568-73. 
49. Slama K, Chiang CY, Enarson DA, Hassmiller K, Fanning A, Gupta P, et al. 
Tobacco and tuberculosis: a qualitative systematic review and meta-analysis. Int J Tuberc 
Lung Dis. 2007;11(10):1049-61. 
50. Lin HH, Ezzati M, Murray M. Tobacco smoke, indoor air pollution and 
tuberculosis: a systematic review and meta-analysis. PLoS Med. 2007;4(1):e20. 
140 
 
51. Stampfli MR, Anderson GP. How cigarette smoke skews immune responses to 
promote infection, lung disease and cancer. Nat Rev Immunol. 2009;9(5):377-84. 
52. U.S. Department of Health and Human Services. Other Specific Outcomes - 
Immune Function and Autoimmune Disease. 2014  [cited July 2016]. In: The Health 
Consequences of Smoking: 50 Years of Progress: A Report of the Surgeon General 
[Internet]. Atlanta (GA), USA: U.S. Department of Health and Human Services, Centers 
for Disease Control and Prevention, National Center for Chronic Disease Prevention and 
Health Promotion, Office on Smoking and HealthReports of the Surgeon General, [cited 
July 2016]; [545-71]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24455788. 
53. Deiss RG, Rodwell TC, Garfein RS. Tuberculosis and illicit drug use: review and 
update. Clinical Infectious Diseases. 2009;48(1):72-82. 
54. Nava-Aguilera E, Andersson N, Harris E, Mitchell S, Hamel C, Shea B, et al. Risk 
factors associated with recent transmission of tuberculosis: systematic review and meta-
analysis. International Journal of Tuberculosis & Lung Disease. 2009;13(1):17-26. 
55. Reichman LB, Felton CP, Edsall JR. Drug dependence, a possible new risk factor 
for tuberculosis disease. Arch Intern Med. 1979;139(3):337-9. 
56. Oeltmann JE, Kammerer JS, Pevzner ES, Moonan PK. Tuberculosis and substance 
abuse in the United States, 1997-2006. Archives of Internal Medicine. 2009;169(2):189-97. 
57. Story A, Bothamley G, Hayward A. Crack cocaine and infectious tuberculosis. 
Emerging Infectious Diseases. 2008;14(9):1466-9. 
58. Friedman H, Newton C, Klein TW. Microbial infections, immunomodulation, and 
drugs of abuse. Clin Microbiol Rev. 2003;16(2):209-19. 
59. Baldwin GC, Tashkin DP, Buckley DM, Park AN, Dubinett SM, Roth MD. 
Marijuana and cocaine impair alveolar macrophage function and cytokine production. 
Am J Respir Crit Care Med. 1997;156(5):1606-13. 
60. Rieder HL. Epidemiologic basis of tuberculosis control. Paris: International 
Union Against Tuberculosis and Lung Disease; 1999. 
61. Shanks NJ, George SL, Westlake L, al-Kalai D. Who are the homeless? Public 
Health. 1994;108(1):11-9. 
62. Tocque K, Bellis MA, Beeching NJ, Syed Q, Remmington T, Davies PD. A case-
control study of lifestyle risk factors associated with tuberculosis in Liverpool, North-
West England. European Respiratory Journal. 2001;18(6):959-64. 
141 
 
63. Moran-Mendoza O, Marion SA, Elwood K, Patrick D, FitzGerald JM. Risk factors 
for developing tuberculosis: a 12-year follow-up of contacts of tuberculosis cases. 
International Journal of Tuberculosis & Lung Disease. 2010;14(9):1112-9. 
64. Hemila H, Kaprio J, Pietinen P, Albanes D, Heinonen OP. Vitamin C and other 
compounds in vitamin C rich food in relation to risk of tuberculosis in male smokers. Am 
J Epidemiol. 1999;150(6):632-41. 
65. Chapman JS, Dyerly MD. Social and Other Factors in Intrafamilial Transmission 
of Tuberculosis. Am Rev Respir Dis. 1964;90:48-60. 
66. Drucker E, Alcabes P, Bosworth W, Sckell B. Childhood tuberculosis in the 
Bronx, New York. Lancet. 1994;343(8911):1482-5. 
67. Baussano I, Williams BG, Nunn P, Beggiato M, Fedeli U, Scano F. Tuberculosis 
incidence in prisons: a systematic review. PLoS Med. 2010;7(12):e1000381. 
68. Craig GM, Zumla A. The social context of tuberculosis treatment in urban risk 
groups in the United Kingdom: a qualitative interview study. Int J Infect Dis. 2015;32:105-
10. 
 
 
 
 
142 
 
Supplementary table 6.1: Association between tuberculosis, and area-level deprivation 
in place of residence and household overcrowding  
 
 Baseline model*  Adjusted model 1** Adjusted model  2** 
 OR 95%CI 
p-
value 
OR 95%CI 
p-
value 
OR 95%CI 
p-
value 
Quintiles of Index of multiple deprivation 
Least deprived 
quintile 
1 -  1 -  1 -  
2nd quintile 1.70 (1.16;2.51)  1.87 (1.26;2.79)  1.76 (1.18;2.64)  
3rd quintile 1.60 (1.09;2.35) <0.001 1.60 (1.07;2.38) <0.001 1.51 (1.01;2.27) <0.001 
4th quintile 1.95 (1.34;2.85)  1.94 (1.31;2.87)  1.74 (1.16;2.59)  
Most deprived 
quintile 
4.3
8 
(3.07;6.24)  3.82 (2.60;5.60)  3.30 (2.23;4.88)  
Persons per bedroom (ppb) 
<2 ppb 1 -  1 -  1 -  
≥2 ppb 2.01 (1.40;2.88) <0.001 1.67 (1.14; 2.44) 0.009 1.42 (0.95;2.12) 0.091 
*Baseline model adjusted for matching variables birth cohort and sex 
** Adjusted model 1 further adjusted for a priori confounders BCG status and long stay (≥3 months) 
in Africa or Asia, and Education level 
*** Adjusted model 2 control for all variables in the table and in the adjusted model 1, as well as 
tobacco smoking, drug use, alcohol drinking, history of homelessness, and history of prison stay. 
Note: This supplementary table illustrates that most of the confounding in measuring the 
association between the variables presented in the table and TB was due to education level and the a 
priori confounders.   
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Supplementary table 6.2: Characteristics of subjects with and without missing data, 
and association to missingness 
Variable Missing data 
(%) (n=226) 
Complete data 
(%) (n=1638) 
Crude OR (95%CI) p-value 
TB status 
Controls 123 (54%) 1060 (65%) -  
Cases 103 (46%) 578 (35%) 1.53 (1.16;2.03) 0.003 
Birth cohort 
1985-1989 25 (11%) 207 (13%) -  
1980-1984 49 (22%) 367 (22%) 1.10 (0.66;1.84)  
1975-1979 52 (23%) 427 (26%) 1.01 (0.61;1.67) 0.219 
1970-1974 75 (33%) 422 (26%) 1.47 (0.91;2.38)  
1965-1969 25 (11%) 215 (13%) 0.96 (0.54;1.73)  
Sex 
Female 118 (52%) 937 (57%) -  
Male 108 (48%) 701 (43%) 1.22 (0.93;1.62) 0.157 
Education level 
Degree level 51 (31%) 628 (38%) -  
A level, SCE Higher 25 (15%) 317 (19%) 0.97 (0.59;1.60)  
O level, GCE or GCSE 59 (36%) 515 (31%) 1.41 (0.95;2.09) 0.020 
None 29 (18%) 178 (11%) 2.00 (1.23;3.26)  
Small area-level deprivation 
Least deprived quintile 34 (15%) 268 (26%) -  
2nd quintile 29 (13%) 308 (19%) 0.74 (0.44;1.25)  
3rd quintile 28 (12%) 316 (19%) 0.70 (0.41;1.18) <0.001 
4th quintile 44 (19%) 323 (20%) 1.07 (0.67;1.73)  
Most deprived quintile 91 (40%) 423 (26%) 1.69 (1.11;2.59)  
Persons per bedroom (ppb) 
<2 ppb 184 (89%) 1507 (92%) -  
≥2 ppb 23 (11%) 131 (8%) 1.44 (0.90;2.30) 0.142 
BCG vaccination status 
Unvaccinated 41 (19%) 277 (17%) -  
BCG vaccinated 172 (81%) 1361 (83%) 0.85 (0.59;1.23) 0.401 
Stay of 3 months or more in High TB-incidence areas (Africa or Asia) 
No 212 (94%) 1524 (93%) -  
Yes 14 (6%) 114 (7%) 0.88 (0.50;1.57) 0.666 
Tobacco smoking 
Never smoked 48 (27%) 651 (40%) -  
Past smoker 24 (13%) 285 (17%) 1.14 (0.67;1.90)  
<10 pack-years  56 (31%) 423 (26%) 1.80 (1.20;2.69) <0.001 
10-19.9 pack-years 34 (19%) 191 (12%) 2.41 (1.51;3.86)  
≥20 pack-years 16 (9%) 88 (5%) 2.46 (1.34;4.53)  
Typical Alcohol consumption 
≤ 40g (5 units)/week 76 (50%) 991 (61%) -  
41-112g (5-14 units)/week 43 (28%) 429 (26%) 1.31 (0.88;1.93)  
>112g (14 units)/week 32 (21%) 218 (13%) 1.91 (1.23;2.97) 0.017 
Class B and C drugs misuse 
Never used any 104 (58%) 1092 (67%) -  
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Used >10 years ago 20 (11%) 178 (11%) 1.18 (0.71;1.95)  
Used 1-10 years ago 24 (13%) 177 (11%) 1.42 (0.89;2.28) 0.062 
Used <1 year ago 32 (18%) 191 (12%) 1.76 (1.15;2.69)  
Class A drugs misuse  
Never used  122 (69%) 1225 (75%) -  
used >10 years ago 15 (8%) 117 (7%) 1.29 (0.73;2.27)  
used ≤10 years ago 31 (17%) 228 (14%) 1.37 (0.90;2.07) 0.355 
Used injectable class A  10 (5%) 68 (4%) 1.48 (0.74;2.94)  
History of homelessness 
Never 174 (84%) 1486 (91%) -  
≤12 weeks 19 (9%) 85 (5%) 1.91 (1.13;3.21) 0.012 
>12 weeks 15 (7%) 67 (4%) 1.91 (1.06;3.42)  
History of prison stay 
Never been in prison 187 (91%) 1538 (94%) -  
Stayed in prison 18 (9%) 100 (6%) 1.48 (0.88;2.50) 0.158 
 
 
  
145 
 
Supplementary table 6.3: results of the sensitivity analyses of the association between 
distal and intermediate determinants and TB after multiple imputation for missing data 
(fully adjusted model‡) 
 
Variable Complete case Multiple imputation 
 OR 95%CI 
p-
value  
OR 95%CI 
p-
value 
Quintiles of Index of multiple deprivation 
Least deprived quintile 1 -  1 -  
2nd quintile 1.76 (1.18;2.64)  1.64 (1.12;2.41)  
3rd quintile 1.51 (1.01;2.27) <0.001 1.54 (1.05;2.26) <0.001 
4th quintile 1.74 (1.16;2.59)  1.87 (1.29;2.73)  
Most deprived quintile 3.30 (2.23;4.88)  3.30 (2.29;4.75)  
Persons per bedroom (ppb) 
<2 ppb 1   1   
≥2 ppb 1.42 (0.95;2.12) 0.091 1.34 (0.92;1.95) 0.128 
Tobacco smoking 
Never smoked 1 -  1 -  
Past smoker 1.17 (0.83;1.65)  1.01 (0.73;1.41)  
Occasional / <10pk-yr 1.25 (0.92;1.69) 0.008* 1.24 (0.93;1.65) 0.004* 
Daily 10 to 19.9 pk-yr  1.61 (1.09;2.38)  1.61 (1.12;2.32)  
Daily ≥20 pk-yr 1.72 (0.98;3.01)  1.66 (0.99;2.76)  
Typical Alcohol drinking 
Non-drinker/ ≤40g/wk  1 -  1 -  
41-111g/wk 1.00 (0.76;1.3)  1.10 (0.86;1.43)  
≥112g/wk 1.06 (0.75;1.51) 0.936 1.20 (0.86;1.67) 0.494 
Class B/C drug misuse 
Never 1 -  1 -  
>10 years ago 0.73 (0.49;1.08) 0.004 0.74 (0.51;1.06) 0.004 
1-10 years ago 1.55 (1.07;2.23)  1.52 (1.07;2.16)  
<1 year ago 1.49 (1.00;2.20)  1.43 (0.99;2.07)  
Class A drug misuse 
Never 1 -  1 -  
>10 years ago 0.72 (0.45;1.14)  0.79 (0.51;1.22)  
≤10 years ago 1.51 (1.07;2.12) <0.001 1.46 (1.05;2.02) <0.001 
Injectable 5.67 (2.68;11.98)  5.36 (2.63;10.90)  
BCG vaccination status 
No 1 -  1 -  
Yes 0.51 (0.38;0.68) <0.001 0.51 (0.39;0.67) <0.001 
Stay of 3 months or more in High TB-incidence areas (Africa or Asia) 
No 1 -  1 -  
Yes 2.67 (1.74;4.08) <0.001 2.63 (1.76;3.94) <0.001 
History of homelessness 
Never 1 -  1 -  
≤12 weeks 1.66 (0.99;2.79) 0.005* 1.51 (0.94;2.41) 0.008* 
>12 weeks 2.01 (1.11;3.63)  1.88 (1.09;3.23)  
History of prison stay 
No 1 -  1 -  
Yes 1.34 (0.79;2.28) 0.273 1.45 (0.88;2.38) 0.144 
‡Fully adjusted model controls for sex, birth cohort, education level and all the variables presented in the table 
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ABSTRACT
Objective: Assess the current BCG vaccination
policies and delivery pathways for immunisation in
Primary Care Trusts (PCTs) in England since the 2005
change in recommendations.
Design: A survey of key informants across PCTs using
a standardised, structured questionnaire.
Setting: 152 PCTs in England.
Results: Complete questionnaires were returned from
127 (84%) PCTs. Sixteen (27%) PCTs reported
universal infant vaccination and 111 (73%) had
selective infant vaccination. Selective vaccination
outside infancy was also reported from 94 (74%)
PCTs. PCTs with selective infant policy most frequently
vaccinated on postnatal wards (51/102, 50%), whereas
PCTs with universal infant vaccination most frequently
vaccinated in community clinics (9/13, 69%; p=0.011).
To identify and flag up eligible infants in PCTs with
targeted infant immunisation, those who mostly
vaccinate on postnatal wards depend on midwives and
maternity records, whereas those who vaccinate
primarily in the community rely more often on various
healthcare professionals.
Conclusions: Targeted infant vaccination has been
implemented in most PCTs across the UK. PCTs with
selective infant vaccination provide BCG vaccine via a
greater variety of healthcare professionals than those with
universal infant vaccination policies. Data on vaccine
coverage would help evaluate the effectiveness of
delivery. Interruptions of delivery noted here emphasise
the importance of not just an agreed, standardised, local
pathway, but also a named person in charge.
INTRODUCTION
Tuberculosis (TB) remains a public health
problem in England. After a century of con-
sistent decline in the incidence and annual
infection risk, the incidence of TB has been
rising since the late 1980s.1 TB is concen-
trated within certain groups of the population
(including migrants from high-prevalence
countries, prisoners, homeless persons and
other marginal populations) and in urban
areas.2
Since the 1950s, immunisation with the
BCG vaccine, which has been shown to be
highly effective in the UK population,3 has
been a part of TB control efforts in England.
The routine policy had been primarily to
administer the BCG vaccine to all tuberculin-
negative schoolchildren aged 10–14 years. In
some areas BCG was given during infancy
and it was recommended that it should also
be given to ‘children of immigrants in whose
communities there is a high incidence of
TB’, among other high-risk groups.4 In 2005,
this policy was replaced by a targeted immun-
isation programme directed at children with
high risk of TB exposure.
The change in policy came after several
years of discussion in the independent gov-
ernment advisory committee, the Joint
Committee of Vaccination and Immunisation
( JCVI). In the 1990s, it was estimated that
due to the low TB incidence, universal school-
age vaccination was no longer cost-effective.5
Universal BCG vaccination, however,
remained policy largely because the inci-
dence was rising slowly and health authorities
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were unsure about the impact that the emerging HIV epi-
demic could have on TB epidemiology.5 6 In 2005, after
the HIV epidemic had stabilised and the UK had already
fulﬁlled the criteria of the International Union Against
Tuberculosis and Lung Diseases (IUATLD) to stop
routine immunisation (which recommends different pol-
icies for different levels of TB, based on economic apprai-
sals and the balance between the beneﬁts and risks of
BCG vaccination),7 the JCVI recommended stopping uni-
versal school-age vaccination and replacing it with a tar-
geted infant vaccination programme.5
As part of this targeted infant programme, it is agreed
that universal vaccination is the most effective way to
reach all eligible children in areas of the country with
TB incidence ≥40 per 100 000 person-years (pyrs). In
areas with TB incidence <40 per 100 000 pyrs, a selective
approach is recommended to immunise only infants at
high risk, that is, if their parents or grandparents origin-
ate from a country with an incidence ≥40 per 100 000
pyrs, if travelling to a high-incidence country for 3 or
more months or when in contact with a TB case. In add-
ition, children of any age at high risk of TB should be
vaccinated at suitable opportunities.8
In view of possible organisational changes in the NHS
and given the current TB epidemiology in the country,
we considered it important and timely to assess the BCG
vaccine policy and the main vaccine delivery pathways
across the commissioning bodies for community and
hospital care (Primary Care Trusts, PCTs) in England.
METHODS
A standardised, mostly closed-ended structured question-
naire was designed (available from the authors). The
questionnaire covered the vaccination policy inside and
outside infancy, eligibility criteria and their documenta-
tion, delivery pathways and constraints to service deliv-
ery. The questionnaire was piloted in four London PCTs.
In November 2010, we contacted all 152 PCTs in
England. Immunisation leads and other staffs involved
in TB control and BCG vaccination implementation
were electronically mailed a copy of the questionnaire
and a web-link to an internet equivalent created using
the survey engine SurveyMonkey. As delivery of BCG
vaccine involves a chain of activities and responsibilities,
respondents were asked to gather information from
other key informants as needed. A reminder was sent
after 4 weeks. After an additional 4 weeks, we contacted
non-respondent PCTs by telephone to gather the infor-
mation required.
At completion of the active data collection, as an add-
itional data check, between August 2011 and September
2011, we searched PCTs’ websites and related NHS
sources for publicly available documents on their
current BCG vaccination policy. We assessed the agree-
ment between the information on these publicly avail-
able documents and the data collected from the survey.
We compared distribution frequencies using a χ2 test or
Fisher’s exact test where appropriate. For each variable,
we only included observations for which data were
available.
RESULTS
Between November 2010 and March 2011, 123 question-
naires representing 129/152 PCTs (85%) were returned:
72 (59%) as electronic documents and 51 (41%) via the
internet survey. No difference in TB notiﬁcation rates was
found between responding and non-responding PCTs
(data not presented). We found publically available
current BCG policy documents for 114 (88%) of the 129
PCTs. Two (2%) PCTs were excluded from subsequent
analysis because their BCG policy could not be deter-
mined from the responses. Sixteen (13%) PCTs reported
universal infant vaccination and 111 (87%) selective
infant vaccination. The agreement with publically avail-
able BCG policy documents was high, with only three
(2%) PCTs reporting a policy that was different from the
information in these documents. Responses from these
three PCTs to more detailed questions in the question-
naire were consistent with a selective infant vaccination at
that time.
Three PCTs reported changing their policy between
2006 and 2011; one PCT followed the national recom-
mendation and changed from targeted infant vaccin-
ation to universal infant vaccination as TB incidence
exceeded 40 per 100 000 pyrs; one PCT changed to uni-
versal infant vaccination, although their TB incidence
was <40 per 100 000 pyrs but justiﬁed doing so because
of a borderline TB rate, high TB rates in neighbouring
areas and high population mobility; one PCT had a uni-
versal infant vaccination programme prior to 2006,
although their TB incidence was below the threshold,
and changed to targeted infant vaccination.9
Some PCTs reported vaccination policies that did not
reﬂect the JCVI recommendations. Six PCTs reported tar-
geted infant vaccination despite having a 3-year average
TB incidence ≥40 per 100 000.9 Documents obtained
from the websites, however, of three of these PCTs, state
that they implement universal infant BCG vaccination.
Six of the 16 PCTs reporting universal vaccination had
3-year average TB incidence ≤40 per 100 000.9 They were
all in or close to major conurbations.
Vaccination during infancy
PCTs with a selective infant BCG vaccination policy
administer BCG via a wider range of healthcare provi-
ders than PCTs with universal infant BCG vaccination
(table 1). PCTs with selective policy most frequently
offer vaccination on postnatal wards (51/102, 50%) but
also vaccinate in community (24/102, 24%) and hospital
clinics (27/102, 26%); PCTs with universal policy more
frequently offer vaccination in community clinics (9/13,
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69%) and less frequently on postnatal wards (4/13,
31%, p=0.011).
All PCTs that vaccinate primarily on postnatal wards
do so during the infants’ ﬁrst month of life, whereas
only 13/37 (35%) PCTs that mainly vaccinate in commu-
nity clinics do so in the infants’ ﬁrst month of life
(p<0.001).
BCG vaccination receipt in infancy is documented in
various ways across PCTs, and this did not depend on
the vaccination policy (table 1). It is most consistently
documented in the Red Book (119/123, 97%) and in
the Child Health Information Systems (114/123, 93%).
It is also noted in other registers and notes (table 1),
but always in combination with either or both of the
former two (ﬁgure 1).
Selective infant vaccination
In the 111 PCTs with selective infant vaccination, 71%
reported routinely assessing eligibility for BCG. They all
offer BCG vaccination to children with parents or grand
parents born in countries with TB incidence ≥40 per
100 000 pyrs (table 2). Six PCTs reported that travel to a
high-incidence country for 3 or more months is not an
eligibility criterion; and two PCTs reported that contact
with a TB case is not a selection criterion either.
Two main BCG delivery pathways were apparent from
the information on identiﬁcation and primary place of
immunisation, but with considerable overlap. Where
midwives are primarily responsible for identifying eligible
infants, they are more frequently vaccinated on postnatal
wards (37/56, 66%) than when eligibility is ﬂagged by
general practitioners (GPs), health visitors (HVs) or pae-
diatricians (12/44, 27%; p<0.001). Conversely, in PCTs in
which eligible infants are primarily ﬂagged up by GPs,
HVs or paediatricians, they are more frequently vacci-
nated in community clinics (32/44, 73%) than when
midwives identify them (19/56, 34%; p<0.001). In line
with these delivery pathways, when infants are identiﬁed
by midwives or vaccinated on postnatal wards, their eligi-
bility is most frequently ﬂagged up in maternity records,
whereas when infants are identiﬁed by GPs, HVs or pae-
diatricians or when they are vaccinated in community
clinics, various systems are used with no clear preference
(table 3).
Vaccination outside of infancy
Vaccination outside infancy was reported in 94/127
(74%) PCTs. In 14/94 (14%) PCTs vaccination outside
of infancy is offered to preschool children only, in 9/94
Figure 1 Principal systems used to document BCG
vaccination and their combinations in Primary Care Trusts
with infant vaccination policy (N=123).
Table 2 Selection criteria employed to decide eligibility
for BCG vaccination in 111 Primary Care Trusts with a
targeted infant vaccination policy
n (%)*
Infant of parents born in country with incidence
>40 per 100000
107 (100)
Contact with TB 93 (87)
Prolonged travel 94 (88)
Parental request 14 (13)
Insecure accommodation 13 (12)
Socially deprived 2 (2)
Asylum seeker/refugees 2 (2)
*Four observations with missing data.
TB, tuberculosis.
Table 1 Place where BCG is primarily administered and
systems reported to document BCG vaccination in 127
Primary Care Trusts with infant vaccination policy
Selective
infant
vaccination
Universal
infant
vaccination
n (%) n (%)
Place of primary BCG
administration
N=102* N=13**
Postnatal ward 51 (50) 4 (31)
At home 0 0
At community clinic 24 (23) 9 (69)
At chest clinic 17 (17) 0
At hospital paediatric clinic 10 (10) 0
Systems in use for BCG
documentation
N=107*** N=16
Antenatal/maternity records 43 (40) 5 (31)
Birth notification records 15 (14) 2 (12)
Paper log books held by
midwives
6 (6) 1 (6)
Child health information
system
100 (93) 14 (88)
School health records 27 (25) 5 (31)
GP 50 (46) 3 (19)
Red Book 103 (96) 16 (100)
Discharge letters 37 (35) 2 (12)
GP, general practitioner.
*Nine, **three and ***four missing values for those variables.
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(9%) to schoolchildren only and in the remaining PCTs
to both groups. HVs are most frequently involved in
identifying eligible preschool children (51/85, 51%).
GPs alone were mentioned by 3/85 (4%) PCTs but 33/
85 (36%) PCTs reported that both GPs and HV identify
eligible preschool children. A similar pattern was seen
for the identiﬁcation of school children: school nurses
alone identify eligible school children in 56/80 (70%)
PCTs, GPs alone in 9/80 (11%) PCTs and in 15/80
(19%) PCTs both school nurses and GPs identify school
children.
All PCTs offering vaccination outside infancy reported
assessing previous BCG immunisation in eligible chil-
dren using at least one of the criteria recommended by
the Green Book. Sixty-four of 94 (68%) PCTs use a com-
bination of reliable parental recall, documentary evi-
dence and presence of a scar as evidence of previous
BCG vaccination. Seventy of 94 (18%) PCTs use the
combination of a BCG scar and reliable recall; whereas
13/94 (14%) consider only one criterion as sufﬁcient
evidence.
Logistic constraints hindering BCG administration
Of all PCTs, 26/127 (20%) reported periods between
2005 and 2010 during which they could not administer
BCG due to logistic constraints. The most frequent
reasons are vaccine supply shortage and lack of trained
health workers (including access to training) to adminis-
ter the vaccine. One PCT reported various episodes
where no BCG could be administered as a result of a
pending business case over who was to carry out BCG vac-
cination when the previously appointed community
paediatrician retired. A similar problem was reported in a
different PCT reporting unclear responsibilities after the
adult respiratory department stopped seeing paediatric
patients. In one PCT, BCG could not be administered
over a 2-year period due to the absence of funding agree-
ments and was only reintroduced after a school outbreak.
DISCUSSION
Six years after its introduction, the 2005 recommenda-
tion for BCG vaccination has been implemented in the
vast majority of England PCTs. All surveyed PCTs have
an infant vaccination policy in place, but a quarter of
these PCTs do not report offering vaccination outside
infancy. Selective infant vaccination mostly takes place
on the postnatal ward and during the ﬁrst month of life
whereas universal infant vaccination mainly happens in
community clinics and after the ﬁrst month of life. In
PCTs with a selective infant vaccination policy, this
survey found greater variation in the organisation of
BCG vaccine delivery.
We were unable to gather information from 15% of
the PCTs. However, TB notiﬁcation rates between
responding and non-responding PCTs were similar, sug-
gesting results presented are not likely to be biased.
Since the JCVI issued their recommendations in 2005,
there has been an ongoing discussion about how to
deﬁne areas of high TB incidence in the context of the
policy.10–12 Universal infant vaccination is, for oper-
ational reasons, recommended in PCTs where the TB
incidence is ≥40 per 100 000 pyrs, as it is agreed that
this is the most efﬁcient way to reach all infants at high
risk of TB in such areas. Nevertheless, the cut-off inci-
dence for targeted infant vaccination is debated as chil-
dren in PCTs with an incidence <40 per 100 000 pyrs
can still be at high risk of TB.13
In this survey, six PCTs in or close to urban areas
reported vaccinating all infants, although their
PCT-speciﬁc incidence is <40 per 100 000 pyrs. This
could indicate that some PCTs in urban areas are consid-
ering regional incidence to inform their policies, rather
than PCT-speciﬁc incidence. Nevertheless, it remains
uncertain if this strategy ensures that the maximum
number of eligible children are being immunised, and if
it is more cost-effective than a PCT-speciﬁc informed tar-
geted vaccination policy. Further analysis of the economic
efﬁciency of regional BCG vaccination is required.
Surveys of BCG vaccination policies and practices in
England and Wales in 1982 and 1992 indicated consider-
able variations across health districts.14 15 In 1992, 15 of
the 186 health districts in England had already stopped
their routine school immunisation programme; 148
offered BCG to selected groups of neonates and ﬁve dis-
tricts routinely gave BCG to all their neonates.15 Today,
variation in local BCG vaccination policies is lower but
the organisation of BCG delivery remains highly vari-
able. We ﬁnd that PCTs commission a wide range of
healthcare providers to deliver the vaccine. This hetero-
geneity across PCTs also demands a high level of organ-
isation between PCTs if services such as maternity care
straddle PCT borders. Hospitals may not be
co-terminous with PCTs and hence infants from PCTs
with different policies and practices can be born in the
same hospital. In this light, it is of concern that many
PCTs do not have service-level agreements to organise
BCG administration either within the PCT or across
Table 3 Systems in use to flag up infants’ eligibility for
BCG vaccination stratified by main responsible for
identification in 111 Primary Care Trusts with targeted
infant vaccination
Systems used to
flag up eligibility
Identification
primarily by
midwives*
Identification
primarily by
GP, HV or
paediatrician*
N=51 N=38
Maternity records 43 (84%) 14 (37%)
Baby’s hospital notes 28 (55%) 18 (47%)
Red Book 25 (49%) 22 (56%)
Birth notification records 10 (20%) 6 (16%)
Child health information
system
10 (20%) 6 (16%)
*Twenty-two observations with missing data.
GP, general practitioner; HV, health visitor.
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boundaries.4 This and the complexity of managing a
localised service could also explain why some PCTs were
unable to deliver BCG during periods where service pro-
viders changed.
The commissioning of BCG may become more complex
if it becomes the responsibility of Clinical Commissioning
Consortia. In its current form, the suggested changes to
the NHS structure could lead to consortia responsible for
overlapping geographical areas. If services are not
commissioned across boundaries and responsibilities are
not clearly assigned, the current heterogeneity in policies
and practices could increase and seriously compromise
the targeted infant vaccination. Infant hepatitis B vaccin-
ation is another selective programme, being given to
infants of mothers screened antenatally and found to be
positive for hepatitis B carriage. It works best when there is
an identiﬁed person in each area, who is responsible for
coordinating the programme.16 This model should be
considered for the BCG programme.
While the structural organisation of the NHS poses
challenges for the 2005 recommendations, the imple-
mentation of a targeted vaccination policy is, in its self,
demanding.17 Hence, it is vital to monitor the imple-
mentation to assure high vaccination coverage. Good
data on BCG immunisation coverage are complicated to
assemble in PCTs with targeted infant vaccination where
the denominator is unclear. Data from audits, however,
show that vaccination coverage in areas with targeted
infant vaccination can be low18 and that even in PCTs
with high coverage, it can vary greatly between maternity
units19 and ethnic groups.20 We ﬁnd that a wide range
of healthcare professionals are involved in the identiﬁca-
tion of eligible children. It is therefore conceivable that
infants are not identiﬁed due to unclear responsibilities.
In addition, our ﬁndings suggest that some health pro-
fessionals involved in the BCG vaccination programme
might be unfamiliar with recommended eligibility cri-
teria; this could contribute to low coverage rates.21 A
standardised pathway to identify eligible infants, with
clear responsibilities and roles and regular training of
staffs involved, could contribute to high vaccination
coverage in PCTs with selective vaccination policy.22 23
In addition to the correct identiﬁcation of infants at
risk, assuring that the vaccine is administered is another
challenge of a targeted vaccination policy.17 22 Half of
the PCTs vaccinate on postnatal wards—a vaccine deliv-
ery pathway associated with high vaccination coverage in
local audits.22–24 The other half, however, vaccinate in a
community setting or clinics which in this survey was
associated with vaccination at an older age. The differ-
ent delivery pathways probably reﬂect local circum-
stances. Immunising newborns in postnatal wards may
be more optimal in conditions in which the workload is
manageable at that level, with either a relatively lower
number of eligible newborns or a sufﬁcient number of
skilled personnel to administer BCG. Vaccinating in the
community might be more effective in areas with higher
numbers of eligible newborn (especially if universal
BCG vaccination) and limited number of trained staffs
to administer the vaccine in postnatal wards. However,
the latter could mean a higher risk of attrition as
parents may not return their children to immunisation
appointments, as reported in previous audits.23 25 A
study in South London found that parents would be
more interested if the vaccine was accessible on a
‘drop-in’ basis from community clinics18 in such areas.
Another aspect that might affect efﬁcient delivery is
that the most commonly used systems for documentation
of BCG receipt are often not the systems used to ﬂag up
eligibility. Aligning the systems used to identify eligible
children with the system used to document BCG vaccin-
ation could be an effective way to ensure that identiﬁed
infants receive the vaccine and a means to estimate cover-
age.24 Also, BCG vaccination was not delivered with other
routine infant vaccinations possibly because of the need
for speciﬁc training for an intradermal vaccination. The
addition of BCG vaccination to offer of other routine
infant vaccinations in speciﬁc regions could be another
way of ensuring coverage of those at risk.
The 2005 BCG policy for the UK also recommends
vaccinating previously unvaccinated children who are at
high risk of TB. Despite the policy, a quarter of all PCTs
do not report vaccinating outside infancy. Although the
absence of vaccination outside infancy may conserve
resources in areas with low levels of migration, some
PCTs in urban centres with presumably high levels of
migration do not report vaccinating outside infancy.
This suggests that greater efforts are needed to
strengthen targeted BCG vaccination outside infancy.
In conclusion, a targeted infant BCG vaccination has
been implemented in most PCTs across England, either
as part of postnatal hospital care or a community vaccin-
ation programme separate from other childhood vacci-
nations via a number of locally agreed healthcare
professionals. Information to assess coverage would be
useful to monitor successful provision of an effective
measure to prevent childhood TB.
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ABSTRACT
BCG uptake among infants in England has not been
measured since targeted infant vaccination replaced
universal schoolchildren vaccination in 2005, mainly
because of the challenges in deﬁning denominators.
We estimated uptake between 2006 and 2008 by
dividing number of BCG doses administered to infants by
number of all live births (where BCG vaccination is
universal) or ethnic minority/Eastern Europeans live births
(where infant-BCG vaccination is selective). Weighted
average uptake was 68% (95% CI 65% to 71%),
slightly higher in primary care trusts with universal (72%
(95% CI 64% to 80%)) than selective (66% (95% CI
61% to 70%)) policy; and also 13% higher in areas
vaccinating in postnatal wards compared with
community settings.
INTRODUCTION
England’s policy since 1953 of universal BCG vac-
cination of schoolchildren was replaced in 2005 by
targeted immunisation of infants at higher risk of
disease. Selective immunisation of eligible infants in
PCTs with annual tuberculosis (TB) incidence <40/
100 000, notably those with family ties to high
TB-incidence countries and universal vaccination of
all neonates in PCTs with annual TB incidence
≥40/100 000 is recommended. It is essential that
the performance of the BCG vaccination pro-
gramme, like other components of TB control
efforts, is continuously and rigorously monitored
and evaluated. This is challenging in the current
programme because appropriate denominators to
measure infant-BCG uptake are not routinely avail-
able, especially in areas with selective vaccination.
METHODS
We estimated the 2006–2008, 3-year average
infant-BCG uptake in each PCT by dividing the
number of BCG doses in children aged ≤1 year by
the number of eligible delivered live births (accord-
ing to local BCG policy). The average national
uptake was calculated using each PCT’s eligible
population as weights. Live-birth information per
ethnic group and PCT of residence was obtained
from the Ofﬁce for National Statistics (ONS). We
obtained BCG dose numbers from the National
Health Service Information Centre (NHS-IC)
annual reports, based on PCTs’ returns of immun-
isation activities (KC50 forms). For PCTs with uni-
versal BCG, uptake was in all live births. For PCTs
with selective BCG vaccination, the eligible popula-
tion was live births to parents born in countries
joining the European Union (EU) since 2004 and
non-EU European countries (mostly former Soviet
Union) and to ethnic minority parents.
We also investigated how BCG uptake at
PCT-level differed by current (universal or select-
ive) vaccination policy, primary place of vaccine
delivery (postnatal ward versus community setting)
and provision of infant-BCG since the 1970 to the
1980 s. Multiple linear regression was used,
weighted by the population eligible for BCG,
adjusting for PCT-level age-standardised and sex-
standardised TB incidence, and for ONS PCT-level
Index of Multiple Deprivation, and proportion of
ethnic minority among live births.
Using Stata V.12.0 for analyses, means were com-
pared by t test and analysis of variance (ANOVA) as
appropriate. Proportions were compared using
Fisher’s exact test. Signiﬁcance testing in the regres-
sion models was conducted by using ANOVA.
RESULTS
Twenty-eight of 151 (19%) PCTs had data on
number of infant-BCG doses that were missing for
at least 1 year, between 2006 and 2008, and were
excluded from analyses. Their characteristics were
not different from the 123 PCTs included (see
online supplementary table S1). The 3-year average
BCG uptake varied from 5% to 100%, with a
weighted average of 68% (95% CI 65% to 71%)
across the 123 PCTs. BCG uptake was on average
higher in PCTs with universal (72% (95% CI 64%
to 80%)) than selective (65% (95% CI 62% to
70%)) vaccination policy (p=0.21) (see table 1).
Thirty PCTs (24%) had uptake lower than 50%
(respectively 3/17 (18%) with universal and 27/106
(25%) with selective policy).
At univariable analysis, uptake was roughly 11%
(95% CI 4% to 18%) higher in areas that offered
infant-BCG vaccination since 1980 (p=0.004) and
9% higher (95% CI 2% to 16%; p=0.01) in PCTs
that vaccinate primarily on postnatal wards com-
pared with those doing so in community settings.
There was also evidence of higher uptake in the
most deprived areas (p=0.008) and those with
high TB incidence (p=0.001). After controlling for
PCT-level TB incidence, deprivation rank and pro-
portion of ethnic minority live births, uptake was
10% (95% CI 2% to 18%; p=0.01) higher in
PCTs that provided infant-BCG since the 1970s–
1980s than those that did not and 13% (95% CI
6% to 20%; p<0.001) higher in areas immunising
primarily in postnatal wards compared with com-
munity settings. Results were similar when analyses
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were restricted either to PCTs with universal or selective policy,
respectively. When adjusting for all factors, uptake was not dif-
ferent between universal and selective policy PCTs (p=0.38)
(see online supplementary table S2 for details).
DISCUSSION
We present the ﬁrst estimates of infant-BCG uptake in England
since the 2005 change in policy from routine universal BCG
vaccination of schoolchildren to infant-BCG. For the past
8 years, no denominator has been readily available for continu-
ous monitoring of uptake.
We used numerator data (BCG doses) from the NHS-IC,
which carefully assess the data for validity, including checking of
unusual year-on-year variations. We only analysed PCTs that
have reported BCG doses every year from 2006 to 2008; but as
they are estimates the results should be treated with some
caution. The denominators used to calculate uptake were only
available for a limited number of years (2005–2008) to assess
uptake in areas with a selective policy that included infants born
to parents from ethnic minorities and to parents from European
countries with annual TB rate >40/100 000 (mostly Eastern
Europe and the former Soviet Union); they constitute the main
population groups targeted by the infant-BCG programme.
Although these data are imperfect, we believe the results pro-
vided fair approximations of infant-BCG uptake in the eligible
population, especially given the current paucity of alternative
data sources in England. These estimates provide a useful
insight in the effectiveness of the delivery of BCG under the
current BCG vaccination programme in England.
Targeted infant immunisation is challenging to implement and
monitor, in areas where only selected groups are vaccinated. It
requires close coordination between antenatal services, which
usually identify eligible infants before birth and childhood
vaccination services that administer the vaccine after birth.
Collaboration between commissioning bodies is also important;
coterminous PCTs may have different local policy or delivery
systems, yet share areas covered by the same maternity wards.
Several European countries have reported drops in BCG vaccin-
ation uptake after switching from universal to targeted policy. In
Sweden, uptake among eligible infants dropped from over 95%
to 2% when universal neonatal BCG was replaced by a targeted
programme in 1975.1 Similarly, in France coverage fell from
77% to 58% in 2007.2 This highlights the need to closely
monitor BCG uptake.
It could be argued that 68% infant-BCG uptake within
3 years of the policy change reﬂects fairly successful implemen-
tation of the new guidance in most areas in spite of the limited
data monitoring. We speculate that experience of infant-BCG
pre-2005 in several PCTs contributed to the smooth transition
from routine schoolchildren vaccination; this is supported by
higher uptake in areas that offered infant-BCG since the 1980s.
By 1991, 82% (153/186) English health districts already offered
some infant-BCG services although there was much variability
on targeted groups.3 Contributing factors could also include
increased awareness and allocation of more resources to TB
control activities around the study period. In the 2009 national
tuberculosis survey, 60% (67/112) PCTs reported an increase in
the funding of their TB services and 74% (83/112) routinely
carried TB health promotion and awareness raising activities.
The average uptake hides the heterogeneity between areas.
Our estimate implies roughly one in three infants at high risk
for tuberculosis did not receive BCG vaccine over the study
period, and one in four PCTs had uptake lower than 50%,
including three with universal infant-BCG policy. This does not
reﬂect a wider problem with vaccine delivery services in some
PCTs; BCG uptake was not correlated to routine infant
Table 1 Three-year average BCG uptake* (2006–2008) and association with Primary Care Trust (PCT)-level characteristics
Variables
Average BCG uptake (%)
(95% CI)
Unadjusted β coefficient†
(95% CI) p Value
Adjusted β coefficient‡
(95% CI) p Value
Current infant BCG policy
Selective (n=106) 65.6 (61.6 to 69.5) — 0.073 — 0.38
Universal (n=17) 71.6 (63.7 to 79.5) 6 (−0.6 to 12.7) 4.2 (−5.3 to 13.6)
Past infant BCG policy
No previous infant BCG (n=53) 60.0 (54.4 to 65.6) — 0.004 — 0.013
Infant BCG since 1980s (n=66) 71.0 (66.7 to 75.1) 10.9 (3.6 to 18.2) 9.9 (2.1 to 17.6)
Index of multiple deprivation
Most deprived (n=40) 73.0 (68.1 to 77.8) — 0.008 — 0.07
Moderately deprived (n=42) 62.5 (56.4 to 68.7) −10.4 (−17.8 to −3.0) −9.5 (−17.6 to −1.2)
Least deprived (n=41) 62.7 (55.6 to 69.7) −10.3 (−19.1 to −1.5) −2.5 (−15.7 to 10.8)
Age-and-sex standardised 3-year average annual TB incidence (per 100 000 person-years)
0–19.9 (n=84) 65.2 (61.2 to 69.2) — 0.001 — 0.015
20–39.9 (n=25) 62.5 (54.0 to 71.0) −2.7 (−10.5 to 5.1) −5.6 (−20.9 to 9.8)
40+ (n=14) 76.5 (68.8 to 84.2) 11.3 (3.4 to 19.2) 7.6 (−10.2 to 25.4)
Percentage ethnic minority among 2006–2008 live-births
0–19.9% (n=72) 63.8 (58.2 to 68.8) — 0.16 — 0.87
20–39.9% (n=25) 64.8 (67.6 to 77.6) 0.9 (−9.3 to 11.2) −3.7 (−17.6 to 10.2)
40%+ (n=26) 70.9 (64.1 to 77.7) 7.0 (−1.6 to 15.7) −3.4 (−21.4 to 14.7)
Primary place of infant BCG vaccination
Community settings (n=48) 63.5 (58.2 to 68.8) — 0.01 — 0.0005
Postnatal ward (n=54) 72.6 (67.6 to 77.6) 9.1 (1.86 to 16.3) 12.9 (5.9 to 20.0)
*Twenty-eight PCTs excluded because they had missing data for infant-BCG doses at least 1 year over the study period.
†For categorical variables, the β coefficient represents the respective difference between average coverage in each stratum and the baseline category.
‡Adjusted for all other variables in the table.
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immunisations in PCTs during the study period (see online
supplementary ﬁgure S1). PCTs with longer experience of
infant-BCG pre-2005 had higher uptake. PCTs vaccinating pri-
marily in postnatal wards also had better uptake than in com-
munity settings (mostly clinics). Immunisation of eligible
newborns before they leave hospital may be easier than having
parents return later on. An audit found that 40% newborns
who left hospital without BCG did not attend later appoint-
ments.4 However, the effectiveness of a postnatal strategy will
depend on adequate numbers of trained staff in postnatal wards
relative to the number of eligible newborns. A study in areas
with high number of eligible newborns found that the high staff
turnover and brief neonatal stay affected BCG uptake in post-
natal wards.5 ‘Drop-in’ vaccination clinics have been suggested
as an alternative to circumvent the issue of low attendance in
community settings, and the idea has since been used in several
areas. In summary, the organisation of vaccine delivery can
affect uptake, and while local circumstances should be taken
into account, continuous monitoring is essential in shaping
services.
The absence of denominators is the main impediment to
adequately measure BCG uptake to monitor the BCG vaccin-
ation programme in England; the absence of rigorous data of
number of vaccine doses given could also improve. As part of
his 2004 action plan for stopping tuberculosis in England, The
Chief Medical Ofﬁcer recommended the effective monitoring of
BCG immunisation; it is worrying that over 8 years later, this
has not yet been implemented. Collection through the Cover of
Vaccination Evaluated Rapidly programme of the number of
BCG doses administered is under discussion. These efforts
should be welcomed by policy makers and supported by com-
missioners and healthcare providers who have the responsibility
to collect and provide accurate information. It is also essential
that suitable denominators are collected as part of these efforts,
notably in areas with selective infant-BCG vaccination. The
monitoring system implemented for the hepatitis B vaccine,
which is also only administered to selected groups of infants,
could be used as a model. In such a system, for instance, it
would be statutory for midwives in areas with selective vaccin-
ation policy to ﬂag and notify pregnant women whose newborn
will be eligible for BCG, with linkage of information to
maternities and the local child health information system. In an
era of tuberculosis re-emergence, emergence of
multidrug-resistant strains, with tuberculous meningitis and
miliary cases still reported among UK-born children, adequate
monitoring of the BCG vaccination programme is critical to
ensure its future performances, especially in the context of
recent structural changes to the NHS.
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Additional table 1: Characteristics of PCTs not included in final multiple regression 
models (because of missing information on at least one variable in the model) 
Variable PCTs not in final models (Total=21) 
PCT in final 
models 
(Total=102) 
p-values 
Vaccination policy (%)* 
Universal (n = 17) 5%  16% 0.30 
Selective (n=106) 95% 84%  
Index of Multiple Deprivation* 
Most deprived (n=40) 38% 32%  
Moderately deprived (n=42) 33% 34% 0.53* 
Least deprived (n=41) 29% 34%  
Age-and-sex standardised 3-year average TB incidence (per 100,000)* 
0-19.9 (n=84) 86% 65%  
20-39.9 (n=25) 6% 22% 0.23 
>=40 (n=14) 5% 13%  
*Column percentages 
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Additional table 2: Comparison of mean infant-BCG uptake by primary place of 
immunisation, stratified by current vaccination policy 
Current infant BCG policy / 
Primary place of infant BCG 
vaccination 
Uadjusted beta 
coefficient 
(95%CI) 
p-value Adjusted beta 
coefficient** 
(95%CI) 
p-value 
Universal 
Community settings (n=10) -  -  
Postnatal ward (n=6) 1.2 (-17.7 to 20.1) 0.90 14.4 (-12.4 to 41.1) 0.26 
Selective 
Community settings (n=38) -  -  
Postnatal ward (n=48) 19.5 (11.6 to 27.4) <0.0001 18.3 (9.3 to 27.3) <0.0005 
**Adjusted for all other variables in the main model: past infant BCG policy, PCT-level index of multiple 
deprivation, standardised 3-year average TB incidence, and ethnic minority population in the birth cohort. 
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Additional figure 1: Scatter plot of average DPT coverage* in infants against BCG 
uptake between 2006 and 2008 in PCTs included in the study 
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Scatter plot of DPT coverage against BCG in infants from 2006 to 2008
 
 
*Data from NHS Information Center Immunisation statistics annual report 
 
This scatter plot suggests that there is no association between infant-BCG uptake and that of 
other routine infant vaccines within PCTs. Therefore, low BCG uptake in some PCTs is most 
likely not due to wider difficulties with infant-vaccines delivery services. 
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Articles
Duration of BCG protection against tuberculosis and change 
in eﬀ ectiveness with time since vaccination in Norway: 
a retrospective population-based cohort study 
Patrick Nguipdop-Djomo, Einar Heldal, Laura Cunha Rodrigues, Ibrahim Abubakar, Punam Mangtani
Summary
Background Little is known about how long the BCG vaccine protects against tuberculosis. We assessed the long-term 
vaccine eﬀ ectiveness (VE) in Norwegian-born individuals.
Methods In this retrospective population-based cohort study, we studied Norwegian-born individuals aged 12–50 years 
who were tuberculin skin test (TST) negative and eligible for BCG vaccination as part of the last round of Norway’s 
mandatory mass tuberculosis screening and BCG vaccination programme between 1962 and 1975. We excluded 
individuals who had tuberculosis before or in the year of screening and those with unknown TST and BCG status. We 
obtained TST and BCG information and linked it to the National Tuberculosis Register, population and housing 
censuses, and the population register for emigrations and deaths. We followed individuals up to their ﬁ rst tuberculosis 
episode, emigration, death, or Dec 31, 2011. We used Cox regressions to estimate VE against all tuberculosis and just 
pulmonary tuberculosis by time since vaccination, adjusted for age, time, county-level tuberculosis rates, and 
demographic and socioeconomic indicators.
Findings Median follow-up was 41 years (IQR 32–49) for 83 421 BCG-unvaccinated and 44 years (41–46) for 
297 905 vaccinated individuals, with 260 tuberculosis episodes. Tuberculosis rates were 3·3 per 100 000 person-years 
in unvaccinated and 1·3 per 100 000 person-years in vaccinated individuals. The adjusted average VE during 40 year 
follow-up was 49% (95% CI 26–65), although after 20 years, the VE was not signiﬁ cant (up to 9 years VE [excluding 
tuberculosis episodes in the ﬁ rst 2 years] 61% [95% CI 24–80]; 10–19 years 58% [27–76]; 20–29 years 38% [–32 to 71]; 
30–40 years 42% [–24 to 73]). VE against pulmonary tuberculosis up to 9 years (excluding tuberculosis episodes in the 
ﬁ rst 2 years) was 67% (95% CI 27–85), 10–19 years was 63% (32–80), 20–29 years was 50% (–19 to 79), and 30–40 years 
was 40% (–46 to 76).
Interpretation Findings are consistent with long-lasting BCG protection, but waning of VE with time. The vaccine 
could be more cost eﬀ ective than has been previously estimated
Funding Norwegian Institute of Public Health and London School of Hygiene & Tropical Medicine.
Introduction
BCG, the sole tuberculosis vaccine licensed for use in 
human beings, is an important part of tuberculosis control 
eﬀ orts.1 It provides, on average, 86% protection against 
miliary and meningeal tuberculosis in children.2–4 It also 
protects against pulmonary tuberculosis, although its 
eﬀ ect varies geographically and seems higher further from 
the equator,5–7 ranging, for instance, from no evidence of 
protection in the Indian Tuberculosis Prevention Trial up 
to an eﬃ  cacy of 78% in the British Medical Research 
Council trial.7 Reasons for such variability7,8 include good 
eﬃ  cacy if vaccination is done before infection with 
Mycobacterium tuberculosis or sensitisation by environ-
mental mycobacteria.7,9 BCG might also protect against 
tuberculosis infection itself,10,11 suggesting a greater con-
tribution to tuberculosis control than that previously 
assumed, although understanding of the immunological 
basis of BCG-derived protection remains low.12
BCG is one of the commonest vaccines, but the 
duration of eﬀ ect against tuberculosis is unclear, even 
though this information could aﬀ ect vaccination policies. 
The substantial decrease in tuberculosis incidence in the 
1980s to 1990s led several countries to move from 
universal vaccination of infants (most western European 
countries) or schoolchildren (eg the UK and Norway) to 
targeted vaccination of infants at high risk of tuberc-
ulosis;13 whether BCG protection will last until young 
adulthood when the risk of pulmonary tuberculosis and 
transmission to others is high is unclear. Improved 
understanding of long-term changes in BCG protection 
might also be useful not only to develop and test new 
tuberculosis vaccines, but also to adapt vaccination 
schedules. BCG booster vaccine candidates are designed 
on the premise of enhancement of weak or waned pre-
existing BCG-derived protection.14 Other tuberculosis 
vaccine candidates (recombinant BCG or other atten-
uated mycobacterium-based vaccines) are em pirically 
inspired or derived from BCG,14 and the performance of 
BCG can inform their potential eﬀ ect.
BCG protection can last for up to 15 years.15 Little 
information exists beyond that period because studies 
have either relatively short follow-up or few events if 
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follow-up is long. Follow-up of participants in the Native 
American and Alaska Natives BCG trial16 showed 
signiﬁ cant BCG protection up to 40 years after vacc-
ination, although these ﬁ ndings have not yet been 
substantiated elsewhere. We used a retrospective 
population cohort from Norway from which well 
preserved information from the tuberculin skin test 
(TST) and BCG status was available, with reliable linkage 
to good tuberculosis surveillance from 1962 to 2011, to 
assess BCG eﬀ ectiveness for 40 years in the general 
population and a European setting.
Methods
Study design and population
In this retrospective population-based cohort study, we 
studied Norwegian-born individuals aged 12–50 years 
who were TST negative to whom intradermal BCG 
vaccination was oﬀ ered as part of the nationwide 
Norwegian mandatory mass tuberculosis screening and 
BCG vaccination programme that took place between 
1948 and 1975.17–19 We only included those screened 
during the last round of the programme, which took 
place between 1962 and 1975, when data were com-
puterised and all tuberculosis cases were compulsorily 
reported to the central National Tuberculosis Register 
(established in 1962). We excluded individuals who had 
tuberculosis before or in the year of screening, and those 
with unknown TST and BCG status. We did not include 
those younger than 12 years because they were not 
routinely oﬀ ered BCG unless they had been in contact 
with a person with tuberculosis. We did not speciﬁ cally 
exclude immunocompromised indivi duals; immuno-
suppression was not a speciﬁ c con traindication for BCG 
vaccination during the study period because HIV 
infection was not yet present and most immuno-
suppressant drugs were not yet present or widely used. 
Furthermore, no clear reason exists why occurrence of 
these factors (if any) during follow-up should aﬀ ect 
tuberculosis rates in vaccinated and unvaccinated people 
diﬀ erently.
Research in context
Evidence before this study
All ten published randomised trials of BCG were reviewed for 
evidence for the duration of BCG eﬃ  cacy against tuberculosis 
by Sterne and colleagues in 1998. This review was 
complemented by a comprehensive systematic review by 
Abubakar and colleagues in 2012, which also included all 
observational studies. Abubakar and colleagues searched for 
articles in electronic medical databases up to May 31, 2009 
(including MEDLINE, Embase, Cochrane Central Register, and 
others), and in trial registers and grey literature sources. Search 
terms for disease were “TB”, “tuberculosis”, “tubercle bacill*”, 
“M. tuberculosis complex”, “M. bovis”, “M. africanum”, 
“M. canetti”, “M. microti”, and “M. tuberculosis”, and for 
intervention were “BCG vaccine”, “BCG”, “BCG vacc*”, 
“BCG imm*”, and “Bacillus Calmette”. Details of all databases 
searched are published in the report. We repeated the search 
strategy in MEDLINE, Embase, Cochrane Central, and Web of 
Knowledge, but identiﬁ ed no new additions. Authors of the 
most recent review suggested that BCG is, on average, eﬀ ective 
against tuberculosis if given to individuals not already infected 
with Mycobacterium tuberculosis or sensitised by environmental 
mycobacteria, and the vaccine can protect for 10–15 years. 
Pooled VE estimates (against all forms of tuberculosis disease) 
from trials were 60% (95% CI 37–74) for 0 to less than 5 years, 
56% (17–76) for 5 to less than 10 years, and 46% (18–64) for 
10–15 years. Seven of the ten trials provided some data for 
follow-up beyond 15 years after vaccination, but investigators 
of only one noted evidence of protection, whereas the others 
had too few events for meaningful estimates. Abubakar and 
colleagues also identiﬁ ed 22 relevant observational studies 
(consisting of ﬁ ve cohort, ﬁ ve case-population, nine case-
control, and three cross-sectional studies), of which only four 
had some data for BCG eﬀ ectiveness up to 20 years after 
vaccination. Authors of three of these studies suggested 
decreasing but persisting protection 15–20 years after 
vaccination. Overall, evidence is consistent with signiﬁ cant 
BCG-derived protection against tuberculosis for 10–15 years 
after vaccination, with waning over time; however, the vaccine 
eﬀ ect beyond that period is uncertain.
Added value of this study
Long-term follow-up of participants in the Native American 
and Alaska Natives BCG trial suggested that BCG could protect 
against tuberculosis for up to 60 years. Our study is, to our 
knowledge, only the second (and the ﬁ rst from western 
European countries) in which some of these ﬁ ndings are 
replicated. Our results suggest a BCG protection of about 50% 
during 40 years, with some evidence of about 40% 
eﬀ ectiveness 30–40 years after vaccination. The consistency 
between results from these two settings strengthens the 
hypothesis that BCG-derived immunity could persist for much 
longer than 10–15 years as previously assumed.
Implications of all the available evidence
A longer duration of protection than that currently thought 
would imply that BCG is potentially more cost eﬀ ective and 
beneﬁ cial than was previously estimated. This ﬁ nding could be 
relevant if countries revise their BCG vaccination policies in 
response to changing tuberculosis epidemiology, especially in 
low-incidence countries. The potentially long-lived eﬀ ect of 
BCG should be investigated and taken into account in 
development of new tuberculosis vaccines, especially in view of 
our low understanding of immunity to M tuberculosis. The 
duration and changes in levels of BCG-derived protection would 
also be relevant to scheduling of vaccination if the new family 
of BCG-booster vaccines was successfully developed and 
introduced.
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We obtained ethical clearance from the Norwegian 
Research Ethics Committee (reference number 2012/755/
REK nord).
Procedures
In the tuberculosis screening and BCG vaccination 
programme, participants were screened for tuberculosis 
in mobile units, consisting of chest radiography and a 
TST with use of the adrenalin von Pirquet (aP) method,18 
which was standard in Norway until 2004. Screening 
campaigns were repeated every 2–10 years depending on 
local tuberculosis incidence. Overall attendance for the 
tuberculosis screening and BCG vaccination programme 
was 80–85%; the rest did not attend because they had 
been screened in another programme (about 5%—eg, as 
a military recruit), because they were ill or temporarily 
absent (5–10%), or because of an unknown reason (about 
5%).17 School leavers (13–14 years of age) with a negative 
TST were also oﬀ ered vaccination through the annual 
school screening programme.
Tuberculin skin testing with the aP method was done 
using Danish Old Tuberculin at a concentration 
corresponding to about 70% of the international standard 
from 1947 to 1953, which was subsequently doubled from 
1954 to improve sensitivity.19 A positive reaction was 
deﬁ ned by an induration of 4 mm or larger. BCG was 
manufactured at the Bergen State BCG Laboratory 
(Bergen, Norway) using the Swedish Gothenburg strain.20 
Liquid BCG was used until 1959, progressively replaced 
by freeze-dried BCG between 1959 and 1973,21 with 
standardisation between the two formulations done by 
routine comparison of postvaccination TST induration 
size in schoolchildren.22 From 1973, BCG was provided 
from Statens Serum Institute, Copenhagen, Denmark.
Participants accrued person-years from entry until 
their ﬁ rst tuberculosis episode, emigration, death, or 
end of follow-up (Dec 31, 2011). We ascertained 
tuberculosis through linkage to the National Tuberculosis 
Register and checked censoring by death or emigration 
in the population register. Prophylactic treatment for 
latent tuberculosis infection was seldom used in Norway 
before 2002 and was therefore not a concern. We linked 
data sources directly using the birth number, a unique 
11 digit personal identiﬁ er allocated to all Norway 
residents at birth or immigration and used across 
administrative databases.
The tuberculosis mass screening database contained 
information about date and results of chest radiography 
and TST and about BCG vaccination. BCG status was 
ascertained from health cards (about 87%), scar exam-
ination (about 7%), and self-reported vaccination history 
(about 6%). The National Tuberculosis Register provided 
notiﬁ cations of tuberculosis since 196223,24 and county-
level tuberculosis rates. Its completeness was estimated 
at 95% in 2008 on the basis of crosschecking carried out 
since 1975 with rifampicin prescriptions and laboratory 
results.23,25 Census data (1960 and 1970) provided 
information about potential confounders, which were 
birthdate, sex, and marital status, and proxy measures for 
socioeconomic position (head of household’s education 
Figure 1: Flowchart from the population cohort to the study sample
TST=tuberculin skin test.
85 137 unvaccinated
1716 excluded because last 
 screening before 1962 
1 025 621 TST negative
1 739 996 individuals with data 
 captured
1 334 686 eligible 
309 065 excluded
 306 318 TST positive
 2638 BCG status unknown
 18 suspected of previous tuberculosis
 91 with data coding error
405 310 ineligible
 328 856 aged older than 50 years  
  at screening
 29 769 aged younger than 12 years 
  at screening
  46 685 TST status and year of screening 
 unknown
83 421 included in study sample 297 905 included in study sample
940 484 vaccinated
469 195 excluded because last 
 screening before 1962 
173 384 excluded because year of 
                 vaccination missing 
                 (included in sensitivity 
                 analysis with use of multiple 
                 imputation)
  21 358 aged 12–13 years in 
                                1962 (included in 
                                         pragmatic sensitivity
                                    analysis) 
Vaccinated (n=297 905) Unvaccinated (n=83 421)
Sex
Female 163 634 (55%) 54 340 (65%)
Male 134 271 (45%) 29 081 (35%)
Age at entry (years)
12–15 145 366 (49%) 3171 (4%)
16–20 67 990 (23%) 6251 (7%)
21–30 29 989 (10%) 5943 (7%)
31–40 27 217 (9%) 21 315 (26%)
≥41 27 343 (9%) 46 741 (56%)
(Table 1 continues on next page)
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level and occupation, number of residents in the 
household, and urban or rural category of place of 
residence) at enrolment. 
Statistical analysis
We transformed quantitative variables into categories. We 
classiﬁ ed 5 year average annual tuberculosis rates at the 
county level during 1961–6526 (proxy for local epidemiology) 
into three levels (less than 20, 20–25, and 26 and more per 
100 000 person-years). We grouped head of household’s 
education level into lower secondary or less (up to tenth 
grade), higher secondary (11th to 13th grade), and 
postsecondary, vocational, or tertiary. We grouped head of 
household’s occupation by sectors related to tuberculosis 
infection risk in Norway27—namely, manufacturing, 
construction, mining and blasting, technical, scientiﬁ c, 
humanities and arts, administration and management, 
sales and services, agriculture, forestry and ﬁ shing, trade 
transportation and communication, military, and other. 
Finally, we grouped household size into four categories 
(zero to two, three to four, ﬁ ve to six, and seven and more 
residents).
We computed HRs and 95% CIs comparing overall 
and time-speciﬁ c (5 year and 10 year intervals) 
tuberculosis rates in BCG-vaccinated individuals with 
unvaccinated individuals by ﬁ tting Cox regression 
models to the data. We adjusted for age-speciﬁ c 
tuberculosis risk as a time-updated variable; we also took 
into account demographic and socioeconomic factors 
and time (in 10 year bands from 1960 to account for 
secular changes during the long follow-up). 7093 (2%) of 
381 326 individuals had data missing for at least one 
covariate; we excluded them from analyses. Starting 
with a model only including BCG status ﬁ tted on the age 
timescale, we added calendar time and then potential 
confounders in turn on the basis of descending order of 
magnitude of confounding at bivariable analysis. We 
checked their eﬀ ects on overall vaccine eﬀ ectiveness 
(VE) and any collinearity with vaccination status. We 
obtained time-speciﬁ c HRs by ﬁ tting an interaction 
between split follow-up time and BCG status. We 
assessed statistical evidence of log-linear change in HR 
(thus VE) between time intervals and departure from 
linearity. We obtained p values using Wald or likelihood 
ratio tests as appropriate. We assessed the proportional 
hazard assumption graphically using Nelson-Aalen 
cumulative hazard plots. We obtained BCG VE and 
95% CIs using the formula VE=(1 – HRv/u) × 100, where 
v=vaccinated and u=unvaccinated. We repeated analyses 
for pulmonary tuberculosis. We did statistical analyses 
using Stata 13.
We did two sensitivity analyses: ﬁ rst, of TST stringency 
(by excluding individuals who developed tuberculosis in 
the ﬁ rst 2 years after screening who would probably have 
already been infected but not yet been reactive to TST), 
and, second, of missing information of the year of 
vaccination (missing in 18% of BCG-vaccinated 
individuals across the database, of whom a proportion 
would have been vaccinated after 1962 and so be eligible 
for the study). We used two approaches for this second 
sensitivity analysis: ﬁ rst, we assumed that all were 
Vaccinated (n=297 905) Unvaccinated (n=83 421)
(Continued from previous page)
Birth cohort (year of birth)
1910–19 5026 (2%) 38 771 (46%)
1920–29 30 566 (10%) 26 813 (32%)
1930–39 25 371 (9%) 7272 (9%)
1940–49 67 809 (23%) 5930 (7%)
≥1950 169 133 (57%) 4635 (6%)
Marital status
Married 78 321 (26%) 63 932 (77%)
Single or other 216 162 (73%) 18 455 (22%)
Missing 3422 (1%) 1034 (1%)
Education level of head of household
Lower secondary or less 151 968 (51%) 52 554 (63%)
Higher secondary 120 522 (40%) 27 430 (33%)
Tertiary, vocational, or postsecondary 243 83 (8%) 2652 (3%)
Missing 1032 (<1%) 785 (1%)
Type of municipality
Rural 125 580 (42%) 36 765 (44%)
Urban 171 916 (58%) 46 489 (56%)
Missing 409 (<1%) 167 (<1%)
Number of residents in household
0–2 21 002 (7%) 19 504 (23%)
3–4 132 790 (45%) 41 137 (49%)
5–6 109 416 (37%) 18 292 (22%)
≥7 34 276 (12%) 4319 (5%)
Missing 421 (<1%) 169 (<1%)
Occupation of head of household 
Manufacture, construction, or mining and 
blasting
119 232 (40%) 34 571 (41%)
Technical, scientiﬁ c, or humanities and arts 24 814 (8%) 4653 (6%)
Administration and management, sales, or 
services
38 234 (13%) 11 475 (14%)
Agriculture, forestry, or ﬁ shing 54 497 (18%) 17 025 (20%)
Trade, transport, or communication 49 356 (17%) 13 178 (16%)
Military, other 10 136 (3%) 1438 (2%)
Missing 1636 (1%) 1081 (1%)
5 year average annual tuberculosis notiﬁ cation rate for 1961–65 per 100 000 person-years 
<20 127 961 (43%) 41 976 (50%)
20–25 78 637 (26%) 17 310 (21%)
≥26 91 300 (31%) 24 135 (29%)
Missing 7 (<1%) 0
Follow-up
Median (years) 44 (41–46) 41 (32–49)
Total (person-years) 1 242 5273 3 131 918
Number of ﬁ rst tuberculosis episodes (rate per 100 000 person-years) 
All tuberculosis 157 (1·3) 103 (3·3)
Pulmonary tuberculosis 121 (1·0) 78 (2·5)
Data are n (%) or median (IQR), unless otherwise indicated. 
Table 1: Baseline characteristics 
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vaccinated as soon as they reached the eligible age 
(pragmatic sensitivity analysis) and, second, we used 
predictive mean matching (PMM) multiple imputation 
by chained equations28 (appropriate for truncated 
quantitative data: in our case, the year of vaccination 
limited to 1948–75 during the mass screening). We 
generated ten imputed datasets using a PMM imputation 
model including all baseline covariates and the age-
adjusted cumulative tuberculosis hazard. We repeated 
the Cox multivariable analysis for each imputed dataset 
restricted to eligible individuals (ie, enrolled during 
1962–75) and obtained the imputed HRs by combining 
estimates across datasets using Rubin’s rules.29
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication. 
Results
1 334 686 (77%) of 1 739 996 individuals registered in the 
tuberculosis screening database were eligible, of whom 
1 025 621 (77%) were TST negative (ﬁ gure 1). 940 484 (92%) 
of these individuals were vaccinated and 85 137 (8%) were 
unvaccinated. The ﬁ nal study sample included 83 421 
(22%) TST-negative unvaccinated and 297 905 (78%) 
BCG-vaccinated individuals. Baseline charac teristics are 
presented in table 1. BCG vaccinated individuals were 
more likely to be male and younger at enrolment than 
were unvaccinated individuals. The head of household’s 
education level was higher in vaccinated (144 905 [48%] of 
297 905 higher secondary or better) than in unvaccinated 
(30 083 [36%] of 83 421) individuals, although the 
distribution of occupational groups was similar between 
groups. Finally, a higher proportion of BCG vaccinated 
individuals (143 692 [49%] of 297 905) lived in households 
with ﬁ ve or more residents than did unvaccinated 
individuals (22 611 [27%] of 83 421). The distribution of 
other baseline characteristics was otherwise broadly 
similar between groups. Median follow-up was 44 years 
(IQR 41–46) for vaccinated and 41 years (32–49) for 
unvaccinated individuals. Censoring by emigration was 
negligible (5627 [1%]), and age-adjusted overall survival 
was similar between groups (appendix).
Age-adjusted tuberculosis rates were similar across 
categories for most baseline characteristics (appendix), 
except for sex: tuberculosis rates of men were more than 
twice those of women (2·2 vs 5·6 per 100 000 person-
years; HR 2·46 [95% CI 1·67–3·62]). We noted no 
interaction between baseline variables and BCG VE, 
except for weak evidence for education-level (lower VE 
for lower education levels) and county-level (lower VE in 
counties with an incidence of more than 25 per 
100 000 person-years) tuberculosis rates (appendix). 
Stratiﬁ ed analyses were consistent with only weak 
confounding by individual baseline variables.
Overall, 260 ﬁ rst episodes of tuberculosis were 
reported, of which 103 cases per 3 131 917 person-years 
See Online for appendix
Number of 
tuberculosis cases/
person-years
Crude rate (per 
100 000 person-
years)
Crude HR* Crude VE* p value Adjusted HR† Adjusted VE (%)† p value
Overall
Unvaccinated 103/3 131 917 3·3 (2·7 to 4·0) ·· ·· ·· ·· ·· ··
Vaccinated 157/12 425 272 1·3 (1·1 to 1·5) 0·36 (0·27 to 0·48) 64% (52 to 73) <0·0001 0·51 (0·35 to 0·74) 49% (26 to 65) <0·0001
0–9 years (including tuberculosis events in ﬁ rst 2 years after screening)
Unvaccinated 29/812 004 3·6 (2·5 to 5·1) ·· ·· ·· ·· ·· ··
Vaccinated 46/2 920 797 1·6 (1·2 to 2·1) 0·45 (0·25 to 0·80) 55% (20 to 75) 0·006 0·49 (0·26 to 0·93) 51% (7 to 74) 0·03
0–9 years (excluding tuberculosis events in ﬁ rst 2 years after screening)
Unvaccinated 27/812 000 3·3 (2·3 to 4·8) ·· ·· ·· ·· ·· ··
Vaccinated 36/2 920 781 1·2 (0·9 to 1·7) 0·41 (0·23 to 0·76) 59% (24 to 77) 0·005 0·39 (0·20 to 0·76) 61% (24 to 80) 0·006
10–19 years
Unvaccinated 44/784 840 5·6 (4·2 to 7·5) ·· ·· ·· ·· ·· ··
Vaccinated 45/2 874 574 1·6 (1·2 to 2·1) 0·35 (0·21 to 0·58) 65% (42 to 79) <0·0001 0·42 (0·24 to 0·73) 58% (27 to 76) 0·002
20–29 years
Unvaccinated 15/704 774 2·1 (1·3 to 3·5) ·· ·· ·· ·· ·· ··
Vaccinated 29/2 794 374 1·0 (0·7 to 1·5) 0·72 (0·36 to 1·43) 28% (–43 to 64) 0·35 0·62 (0·29 to 1·32) 38% (–32 to 71) 0·22
30–40 years
Unvaccinated 15/830 300 1·8 (1·1 to 3·0) ·· ·· ·· ·· ·· ··
Vaccinated 37/3 835 528 1·0 (0·7 to 1·3) 0·72 (0·35 to 1·46) 28% ( to 46 to 65) 0·36 0·58 (0·27 to 1·24) 42% (–24 to 73) 0·16
Data in parentheses are 95% CIs. HR=hazard ratio. VE=vaccine eﬀ ectiveness. *Adjusted for present age (years; Cox model ﬁ tted on age timescale). †Fully adjusted for present age, time, and baseline characteristics 
(test for log-linear trend in HRs by timeband p=0·015). 
Table 2: BCG vaccine eﬀ ectiveness against all tuberculosis
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occurred in unvaccinated individuals (crude rate of 3·3 
[95% CI 2·7–4·0] per 100 000 person-years) and 157 cases 
per 12 425 272 person-years occurred in vaccinated 
individuals (1·3 [1·1–1·5] per 100 000 person-years), 
corresponding to an age-adjusted HR of 0·36 (95% CI 
0·27–0·48) and VE of 64% (95% CI 52–73; table 2). After 
adjustment for calendar time and baseline covariates, the 
HR was 0·51 (0·35–0·74), with an average adjusted VE of 
49% (26–65) during 40 years. Baseline covariates had 
little confounding eﬀ ect (appendix), with most 
confounding due to calendar time.
Adjusted BCG VE was 51% (95% CI 7–74) in the ﬁ rst 
10 years after vaccination (61% [95% CI 24–80] if 
excluding tuberculosis episodes in the ﬁ rst 2 years), 
remaining at 58% (27–76) 10–19 years after vaccination, 
and then subsequently dropping to 38% (–32 to 71) at 
20–29 years and 42% (–24 to 73) at 30–40 years. We noted 
weak evidence that change in HRs between time intervals 
was not log-linear (p=0·015). Detailed results are 
presented in table 2. A further breakdown of VE in 5 year 
bands for the ﬁ rst 20 years after vaccination is provided 
in the appendix. Estimates remained similar, except for 
the ﬁ rst 10 years, when VE is lower, at 21% (–102 to 69; 
42% [–76 to 81] if excluding tuberculosis episodes in the 
ﬁ rst 2 years) in the ﬁ rst 5 years after vaccination, than in 
5 years to less than 10 years after vaccination (61% 
[17–81]). Nelson-Aalen cumulative hazard plots did not 
show severe deviation from the proportionality assump-
tion (appendix).
The adjusted VE against pulmonary tuberculosis 
during 40 years was 55% (95% CI 32–70). It was 57% 
(8–80; 67% [95% CI 27–85] if excluding tuberculosis 
episodes in the ﬁ rst 2 years) for 0–9 years and 63% 
(32–80) for 10–19 years, falling to 50% (–19 to 79) 
20–29 years after vaccination and 40% (–46 to 76) 
30–40 years afterwards (ﬁ gure 2, appendix). We noted 
some statistical evidence that change in HRs between 
time intervals was not log-linear (p=0·012). Time-speciﬁ c 
VE estimated either assuming those with missing BCG 
date were vaccinated as soon as they reached the eligible 
age or with use of PMM imputation were consistent with 
the complete data analysis beyond the ﬁ rst 10 years after 
vaccination (appendix). Sensitivity estimates for the ﬁ rst 
10 years were lower and less precise than were the 
complete data.
Discussion
Findings from our study show that BCG vaccination was 
associated with an almost halving of the risk of tuberculosis 
during a 40 year period after vaccination. If examined by 
decades, we noted that BCG was associated with about a 
60% reduction in risk during the ﬁ rst two decades after 
vaccination. VE was about 40% between 20 years and 
40 years after vaccination, although the evidence was 
weaker. The vaccine seemed to reduce the risk of 
pulmonary tuberculosis, the infectious form of the disease, 
more than it did of all tuberculosis. These results are only 
the second, to our knowledge, to present evidence in 
support of BCG protection against tuberculosis during a 
period of 40 years or longer, the ﬁ rst being follow-up of 
participants in the Native American and Alaska Natives 
BCG trial,16 and our results are the ﬁ rst in a European 
population.
Advantages of our study included the large sample size, 
good documentation of TST and BCG vaccination status, 
and linkage to 50 years of good routine tuberculosis 
surveillance and various administrative databases. The 
study also had limitations: it had few cases in each time 
period due to low tuberculosis rates in Norway since the 
1960s30,31 (due to, in turn, an eﬀ ective nationwide 
tuberculosis control programme in the 1940s to 1970s and 
improvement in living conditions)27 and a lower 
stringency of TST than in trials (people were tested only 
once at each screening round, and the aP test could have 
been less sensitive than was the Mantoux test,32 whereas 
some trials used high tuberculin doses and two-stage 
testing5,7); this lower stringency of TST than in trials 
would cause non-diﬀ erential inclusion of some TST 
positives and, thus, an underestimation of VE. The low 
VE estimate in the ﬁ rst 5 years is consistent with this 
hypothesis. The higher VE obtained if excluding 
tuberculosis cases in the ﬁ rst 2 years than if not excluding 
them suggests that TST sensitisation was more often due 
to infection with M tuberculosis than to environmental 
mycobacteria.
Potential exists for selection bias and confounding. 
Those who declined vaccination might have had a higher 
tuberculosis risk than did the general population, leading 
to an overestimation of VE. The information available 
did not support this assumption: age-adjusted all-cause 
mortality and loss to follow-up through emigration were 
similar in unvaccinated and vaccinated individuals, as 
were most baseline sociodemographic characteristics. 
The unvaccinated group was, however, older than was 
the vaccinated group, so was likely to have been exposed 
to higher risk of tuberculosis earlier in their life; however, 
Figure 2: BCG vaccine eﬀ ectiveness against pulmonary tuberculosis by time 
since vaccination
Error bars are 95% CIs. Tuberculosis cases occuring in the ﬁ rst 2 years after 
screening are excluded.
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these individuals also remained TST negative at several 
successive screening rounds and were therefore more 
likely to be at a lower risk of tuberculosis. We therefore 
deem that the study underestimates BCG eﬀ ectiveness. 
Nonetheless, we acknowledge that, in our study, as in 
most observational studies, a potential for residual 
confounding exists, including from unmeasured con-
founders.
Our estimates of BCG eﬀ ectiveness in the ﬁ rst 5 years 
were lower than were previous estimates in similar 
populations. BCG eﬀ ectiveness was about 90% with use 
of data from the Norway routine school vaccination 
programme,21 although those investigators used a case-
population approach known to slightly overestimate VE. 
Trials in the UK, USA, and Canada yielded VEs of 
70–80%.5,15,33 The diﬀ erence might partly be attributable 
to lower stringency of TST and selection through 
repeated screening of unvaccinated individuals at lower 
risk of tuberculosis in this study, both discussed earlier; 
similarly low VE was reported in a previous trial34 without 
stringent tuberculin testing before randomisation. 
Another factor might be that revaccination might have 
been captured in the database as a ﬁ rst vaccination; 
revaccination was not uncommon in individuals who 
were TST negative despite previous vaccination.18,19 
Postvaccination TST induration is not associated with 
BCG eﬃ  cacy,35 and evidence suggests that revaccination 
has no to, at most, a slight boosting eﬀ ect on BCG-
derived immunity.36,37 In such revaccinated individuals, 
VE at the start of follow-up could have already decreased 
since their ﬁ rst vaccination, thus underestimating VE.
BCG eﬀ ect beyond 5 years was consistent with 
literature reports from similar settings. VE 5–10 years 
after vaccination was similar to estimates in cohorts from 
Norway21 and France,38 and consistent with the Native 
American and Alaska Natives16 and British Medical 
Research Council5 BCG trials. The overlap between our 
estimates and those from these two trials continued 
10–15 years after vaccination, although these two trials 
had higher point estimates and narrower CIs than our 
study had, consistent stringent TST, and complete case 
ascertainment. The other trials in the northern hem-
isphere above the tropics had too few tuberculosis 
episodes beyond 10 years to measure VE.15 The Native 
American and Alaska Natives trial16 measured BCG 
eﬃ  cacy 15–20 years after vaccination at 52% (95% CI 
28–68), the sole trial with enough data beyond 15 years. 
This ﬁ nding is similar to ours and to those of Gernez-
Rieux and Gervois38 who reported a VE of 51% during the 
same interval in a French cohort. Overall, the VE 
estimated in our study during the ﬁ rst 20 years after 
vaccination seems consistent with the scientiﬁ c literature.
In a systematic review,15 only investigators of the Native 
American and Alaska Natives trial were noted to have 
measured BCG eﬀ ectiveness beyond 20 years after 
vaccination. VE was 55% (95% CI 31–77) after 60 years of 
follow-up, similar to ours after 40 years, with estimates 
20–30 years and 30–40 years after vaccination of about 
62% (–5 to 88).16 A comparison of our VE with that of the 
Native American and Alaska Natives trial is given in the 
appendix. We had less power than did the Native 
American and Alaska Natives trial beyond 20 years 
because of the very high tuberculosis incidence in their 
trial population, but ﬁ ndings from both studies showed 
persistence of BCG protection against tuber culosis 
beyond 20 years after vaccination.
VE seemed to wane beyond the ﬁ rst 20 years after 
vaccination, although the low study power precluded 
statistical evidence. A similar trend was noted in the 
Native American and Alaska Natives trial and is 
consistent with a review15 of duration of BCG protection. 
Two hypotheses could explain a decrease in VE esti-
mates with time—namely, reduction in the unvacc-
inated individuals’ susceptibility or waning of the 
vaccinated individuals’ immunity. Cross-immunity 
from sensi tisation by environmental mycobacteria in 
un vac cinated individuals might progressively mask 
persistent BCG eﬀ ect, therefore giving the false 
impression of decreasing VE. The fall could also be 
caused by waning of BCG-derived immunological 
memory, one of the premises for development of BCG 
booster vaccines.14 These two hypotheses are not 
mutually exclusive and both might have played some 
part in our ﬁ ndings.
Our results are consistent with long-lived BCG-derived 
immunity, adding to the evidence that BCG vaccination 
of individuals not yet infected by M tuberculosis nor 
sensitised by environmental mycobacteria might confer 
some protection against tuberculosis for at least 
20 years.15 Besides the emerging evidence that BCG 
vaccination might also protect against M tuberculosis 
infection itself,10,11 a longer duration of protection than 
that previously assumed would imply that the vaccine is 
more cost eﬀ ective than was previously estimated. In the 
absence of any new and more eﬀ ective tuberculosis 
vaccine than the BCG vaccine, the ﬁ rst pillar of WHO’s 
new End Tuberculosis Strategy recognises the potential 
contribution of continued BCG vaccination of in-
dividuals at high risk of tuberculosis to their vision of a 
“world free of tuberculosis”,39,40 a contribution that is 
strengthened by BCG’s long protection. Furthermore, in 
view of how widely BCG has been used across the world 
and the possibility that it may interact with future 
tuberculosis vaccines, such long-lived eﬀ ect should be 
accounted for during development of new tuberculosis 
vaccines.
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eFigure1: Age-adjusted cumulative survival probability during follow-up by 
vaccination status 
The graph suggests that the age-adjusted survival is broadly similar between the BCG vaccinated and 
unvaccinated subjects, in spite of the age difference at start of follow-up. This supports the fact that analysis 
using a Cox model adjusted for age as a time updated variable (i.e. fitting the model on the age (in years) 
time scale) provided a reasonable control for confounding by age. 
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 eFigure 2: Nelson-Aalen Cumulative Hazard plot by vaccination status 
The solid blue and dashed red lines respectively represent cumulative TB hazards in unvaccinated and BCG 
vaccinated subjects for successive 10-year bands since vaccination, after adjustment for current age. The 
Nelson-Aalen plots of cumulative hazard by vaccination status for each time band suggest that overall, there 
is no gross violation of the proportionality assumption. 
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eFigure 3: BCG effectiveness against all tuberculosis - results from Norwegian 
cohort compared to 60-year follow-up of American Indians and Alaska Natives BCG 
Trial1 (Vertical bars represent 95% confidence intervals; TB cases occuring in first 2 years after screening 
are excluded) 
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eTable 1: Age-adjusted association of baseline characteristics to risk of all type of 
tuberculosis among unvaccinated study participants 
 TB rate per 
100,000pyr (# / 
pyrs) 
Hazard Ratio 
(95%CI) 
Sex 
Female 2.2 (47/2126580) - 
Male 5.6 (56/1005338) 2.46 (1.67;3.62) 
Marital status 
Married 3.1 (77/2451020) - 
Single/Other 3.8 (26/680898) 0.85 (0.54;1.36) 
Education level of head of household
1
 
Lower secondary or less 3.3 (65/1953514) - 
Higher secondary 3.1 (33/1073866) 0.92 (0.61;1.40) 
Tertiary / Vocational / Post-2ry  4.8 (5/104538) 1.41 (0.46;3.52) 
Type of Municipality at entry (Urban/Rural) 
Rural 2.9 (39/1363433) - 
Urban 3.6 (64/1768485) 1.26 (0.84;1.87) 
Number of residents in household at entry 
0-2 4.0 (27/674049) - 
3-4 2.9 (46/1565386) 0.73 (0.45;1.18) 
5-6 3.3 (24/723736) 0.82 (0.47;1.43) 
7+ 3.6 (6/168747) 0.87 (0.36;2.13) 
Occupation category of head of household at entry 
Manufacture, construction, mining  3.4 (45/1314856) - 
Technical, scientific, humanities 2.7 (5/185927) 0.79 (0.31;1.98) 
Administration, sales, services 2.9 (13/444628) 0.86 (0.46;1.59) 
Agriculture, forestry, fishing 3.2 (20/623615) 0.94 (0.56;1.60) 
Trade, transport, communication 3.3 (17/510265) 0.97 (0.56;1.70) 
Military, Other 5.7 (3/52627) 1.64 (0.51;5.28) 
Annual TB rates 1965   
<20per100000 3.4 (53/1550626) - 
20-25per100000 3.5 (23/649109) 1.03 (0.63;1.68) 
26+per100000 2.9 (27/932183) 0.83 (0.52;1.33) 
All Hazard Ratios adjusted for current age 
  
1
 In absence of detailed information on income for all members of the household and given the fact we used census data from 1960 and 
1970, the head of household was defined for practical purpose as (husband if married (or own if husband is unemployed)), father if <21 
or in school (or mother if father is unemployed or not available) or own otherwise). This is as close as we could to definitions in place in 
Norway in the 1960-70s (oldest person in household – Keilman – Household Statistics in Europe – consequences of different definitions 
http://www.ssb.no/a/histstat/aap/aap_befolkning_199203.pdf retrieved on 03Dec2013). 
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eTable 2: BCG Effectiveness per stratum and adjusted for age and potential 
baseline confounders 
 BCG vaccine No BCG vaccine Stratum-specific 
age adjusted VE 
(%) (95%CI)2 
p-value 
(test 
homoge
neity) 
Bivariable 
adjusted VE 
(%) (95%CI) 
Characteristics # TB Rate3 # TB Rate3    
Overall (‘Crude’) 157 1.3 103 3.3 64 (52 to 73)  64 (52 to 73) 
Sex        
Female  73 1.1 47 2.2 59 (38 to 73)   
Male 84 1.5 56 5.6 70 (56 to 80) 0.25 65 (54 to 74) 
Marital status        
Married 37 1.2 77 3.1 63 (44 to 75)   
Single/Other 120 1.3 26 3.8 62 (40 to 75) 0.91 62 (49 to 72) 
Education level of head of 
household at entry 
       
Lower secondary or less 93 1.5 65 3.3 52 (32 to 66)   
Higher secondary 55 1.1 33 3.1 72 (54 to 94) 0.02 61 (49 to 71) 
Tertiary / Vocational / Post-
2ry  
9 0.9 5 4.8 89 (65 to 99)   
Type of Municipality of 
Residence 
       
Rural 66 1.3 39 2.9 60 (38 to 74)   
Urban 91 1.3 64 3.6 51 (50 to 76)  0.63 63 (51 to 72) 
Number of residents in 
household at entry 
       
0-2 12 1.5 27 4.0 56 (09 to 78)   
3-4 57 1.0 46 2.9 64 (46 to 76) 0.94 63 (50 to 72) 
5-6 63 1.4 24 3.3 66 (41 to 81)   
7+ 25 1.7 6 3.6 59 (-8 to 85)   
Occupation category of 
head of household at entry 
       
Manufacture, construction, 
mining  
53 1.1 45 3.4 69 (51 to 80)   
Technical, scientific, 
humanities 
8 0.8 5 2.7 80 (23 to 95)   
Administration, sales, 
services 
14 0.9 13 2.9 69 (24 to 87) 0.74 64 (52 to 73) 
Agriculture, forestry, fishing 38 1.7 20 3.2 58 (19 to 78)   
Trade, transport, 
communication 
35 1.7 17 3.3 49 (3 to 73)   
Military, Other 9 2.1 3 5.7 54 (-56 to 87)   
County-level Annual TB 
rates 1965 
       
<20per100000 58 1.1 53 3.4 69 (53 to 80)   
20-25per100000 30 0.9 23 3.5 74 (53 to 86) 0.06 63 (51 to 72) 
26+per100000 69 1.8 27 2.9 39 (0 to 64)   
 
  
2
 VE = Vaccine effectiveness; 95%CI = 95% Confidence Interval 
3
 Rate of tuberculosis per 100,000 person-years 
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eTable 3: BCG vaccine effectiveness against all TB with 5-year bands break down for initial 20 years after vaccination 
 Time since 
vaccination 
# TB 
cases/pyears 
Rate (per 
100,000pyears) 
‘Crude’ HR 
(95%CI) 
Crude VE (95%CI) 
(%) 
p-
value 
Adjusted HR 
(95%CI) 
Adjusted VE 
(%)(95%CI) 
p-value 
0-4 years         
Unvaccinated 9/406289 2.2 (1.2;4.3)       
BCG vaccinated 19/1463866 1.3 (0.8;2.0) 0.65 (0.26;1.60) 35 (-60 to 74) 0.35 0.79 (0.31;2.02) 21 (-102 to 69) 0.62 
0-4 years (excluding TB events occurring in first 2 years) 
Unvaccinated 7/406285 1.7 (0.8;3.6)       
BCG vaccinated 9/1463850 0.6 (0.3;1.2) 0.52 (0.18;1.49) 48 (-49 to 82) 0.22 0.58 (0.19;1.76) 42 (-76 to 81) 0.34 
5-9 years         
Unvaccinated 20/405715 4.9 (3.2;7.6)       
BCG vaccinated 27/1456931 1.9 (1.3;2.7) 0.33 (0.17;0.66) 67 (34 to 83) 0.002 0.39 (0.19;0.83) 61 (17 to 81) 0.01 
10-14 years         
Unvaccinated 19/398866 4.8 (3.0;7.6)       
BCG vaccinated 24/1444728 1.7 (1.1;2.5) 0.36 (0.18;0.72) 64 (28 to 82) 0.004 0.43 (0.21;0.89) 57 (11 to 79) 0.02 
15-19 years         
Unvaccinated 25/385974 6.5 (4.4;9.6)       
BCG vaccinated 21/1429846 1.5 (1.0;2.3) 0.33 (0.17;0.64) 67 (36 to 83) 0.001 0.43 (0.21;0.89) 57 (11 to 79) 0.02 
20-29 years         
Unvaccinated 15/704774 2.1 (1.3;3.5)       
BCG vaccinated 29/2794374 1.0 (0.7;1.5) 0.72 (0.36;1.43) 28 (-43 to 64) 0.35 0.62 (0.28;1.31) 38 (-31 to 71) 0.22 
30-~40 years         
Unvaccinated 15/830300 1.8 (1.1;3.0)       
BCG vaccinated 37/3835528 1.0 (0.7;1.3) 0.71 (0.35;1.46) 29 (-46 to 65) 0.35 0.58 (0.27;1.23) 42 (-23 to 73) 0.16 
Crude means adjusted only for current age (in years) (Cox model fitted on age timescale) 
Fully adjusted for current age, calendar time, and baseline characteristics  
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eTable 4: BCG Vaccine Effectiveness against Pulmonary TB 
Time since 
vaccination 
# PTB 
cases/pyears 
Rate (per 
100,000pyears) 
‘Crude’ HR* 
(95%CI) 
Crude VE* 
(95%CI) (%) 
p-
value 
Adjusted HR~ 
(95%CI) 
Adjusted VE~ 
(%)(95%CI) 
p-value 
Overall         
Unvaccinated 78/3131442 2.5 (2.0;3.1) -      
BCG vaccinated 121/12424654 1.0 (0.8;1.2) 0.36 (0.26;0.49) 64 (51 to 74) <0.001 0.45 (0.30;0.68) 55 (32 to 70) <0.001 
0-9 years         
Unvaccinated 20/811781 2.5 (1.6;3.8)       
BCG vaccinated 32/2920511 1.1 (0.8;1.5) 0.43 (0.22;0.85) 57 (15 to 78) 0.02 0.43 (0.20;0.92) 57 (8 to 80) 0.03 
0-9 years (excluding TB events occurring in first 2 years)  
Unvaccinated 19/811779 2.3 (1.5;3.7)       
BCG vaccinated 26/2920500 0.9 (0.6;1.3) 0.36 (0.18;0.74) 64 (26 to 82) 0.005 0.33 (0.15;0.73) 67 (27 to 85) 0.006 
10-19 years         
Unvaccinated 38/784707 4.8 (3.5;6.7)       
BCG vaccinated 36/2874390 1.3 (0.9;1.7) 0.31 (0.18;0.54) 69 (46 to 82) <0.001 0.37 (0.20;0.68) 63 (32 to 80) 0.002 
20-29 years         
Unvaccinated 11/704697 1.6 (0.9;2.8)       
BCG vaccinated 22/2794270 0.8 (0.5;1.2) 0.67 (0.30;1.50) 33 (-50 to 70) 0.33 0.50 (0.21;1.19) 50 (-19 to 79) 0.12 
30+ years         
Unvaccinated 9/830257 1.1 (0.6;2.1)       
BCG vaccinated 31/3835483 0.8 (0.6;1.1) 0.79 (0.34;1.87) 21 (-87 to 66) 0.60 0.60 (0.24;1.46) 40 (-46 to 76) 0.26 
*‘Crude’ HRs are in fact adjusted for current age (in years) (Cox model fitted on age timescale) 
~Fully adjusted for current age, calendar time, and baseline characteristics. Test for log-linear trend in HRs by timeband p=0.012  
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eTable 5: Distribution of baseline characteristics in BCG vaccinated subjects with 
date of BCG available and missing and aged 13 years or less in 1962  
 BCG date recorded 
(N=297,905) 
BCG date missing 
(N=24957) 
Sex   
Female (%) 163634 (54.9%) 11535 (46.2%) 
Male (%) 134271 (45.1%) 13422 (53.8%) 
Marital status   
Married 78321 (26.7%) 2414 (9.7%) 
Single/Other 216162 (73.3%) 22266 (89.2%) 
Missing 3422 (1.1%) 277 (1.1%) 
Education level of head of household   
Lower secondary or less 151968 (51.0%) 12459 (49.9%) 
Higher secondary 120522 (40.4%) 10864 (43.5%) 
Tertiary / Vocational / Post-secondary 24383 (8.2%) 1486 (6.0%) 
Missing 1032 (0.4%) 148 (0.6%) 
Type of Municipality at entry (Urban/Rural)   
Urban 171916 (57.7%) 15791 (63.3%) 
Rural 125580 (42.2%) 9109 (36.5%) 
Missing 409 (0.1) 57 (0.2%) 
Number of residents in household at entry   
0-2 21002 (7.0%) 2073 (8.3%) 
3-4 132790 (44.6%) 11165 (44.7%) 
5-6 109416 (36.7%) 8785 (35.2%) 
7+ 34276 (11.6%) 2876 (11.5%) 
Missing 421 (0.1%) 58 (0.2%) 
Occupation category of head of household at 
entry 
  
Manufacture, construction, mining  119232 (40.0%) 9724 (39.0%) 
Technical, scientific, humanities 24814 (8.3%) 1989 (8.0%) 
Administration, sales, services 38234 (12.8%) 3889 (15.6%) 
Agriculture, forestry, fishing 54497 (18.3%) 3449 (13.8%) 
Trade, transport, communication 49356 (16.6%) 4417 (17.7%) 
Military, Other 10136 (3.4%) 1300 (5.2%) 
Missing 1636 (0.6%) 189 (0.8%) 
Annual TB rates 1965     
<20per100000 127961 (43.0%) 10705 (42.9%) 
20-25per100000 78637 (26.4%) 4152 (16.6%) 
26+per100000 91300 (30.6%) 10097 (40.4%) 
 
The date of vaccination was missing in 173,384/940,584 (18.4%) subjects, some of whom would 
have been vaccinated after 1962 hence eligible for the study. As mentioned in the methods section, 
individuals aged 13 years or more after 1962 were more likely to have been vaccinated as soon as 
they became eligible (i.e. when they turned 13-14 years). 24,957/173,384 (14%) people with 
missing BCG date were 13 years old or less in 1962, and therefore included in a sensitivity analysis 
making the pragmatic assumption that they received BCG when aged 13 years. The distribution of 
baseline characteristics in these subjects, including socio-demographic and other TB risk factors is 
presented in the supplementary table 4 above.  
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eTable 6: Sensitivity analysis of BCG effectiveness against all TB 
Time since vaccination Adjusted HR (95%CI) p-value VE (%) (95%CI) 
Complete data analysis results 
0 to 9 years 0.49 (0.26;0.93) 0.03 51 (7 to 74) 
0 to 9 years excl TB in first 2 years 0.39 (0.20;0.76) 0.006 61 (24 to 80) 
10 to 19 years 0.42 (0.24;0.73) 0.002 58 (27 to 76) 
20 to 29 years 0.62 (0.29;1.32) 0.22 38 (-32 to 71) 
30 to ~40 years 0.58 (0.27;1.24) 0.16 42 (-24 to 73) 
    
Pragmatic Assumption*: BCG vaccinated subjects with missing value for year of vaccination 
were vaccinated when they reached 13 years old if did so after 1962 
0 to 9 years 0.48 (0.25;0.91) 0.025 52 (9 to 75) 
0 to 9 years excl TB in first 2 years 0.38 (0.19;0.75) 0.005 62 (25 to 81) 
10 to 19 years 0.44 (0.25;0.76) 0.003 56 (24 to 75) 
20 to 29 years 0.62 (0.29;1.33) 0.22 38 (-33 to 71) 
30 to ~40 years 0.56 (0.26;1.20) 0.13 44 (-20 to 74) 
    
Multiple Imputation using Predictive Mean Matching 
0 to 9 years 0.68 (0.37;1.25) 0.22 32 (-25 to 63) 
0 to 9 years excl TB in first 2 years 0.50 (0.26;0.98) 0.04 50 (2 to 74) 
10 to 19 years 0.42 (0.25;0.73) 0.002 58 (27 to 75) 
20 to 29 years 0.59 (0.28;1.26) 0.17 41 (-26 to 72) 
30 to ~40 years 0.55 (0.26;1.17) 0.12 45 (-17 to 74) 
    
*Under the pragmatic assumption, 24957 BCG vaccinated subjects with year of vaccination missing are included in analysis, as detailed 
in eTable 5.  
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eTable 7: Sensitivity Analysis of BCG effectiveness against Pulmonary Tuberculosis 
Time since vaccination Adjusted HR (95%CI) p-value VE (%) (95%CI) 
Complete data analysis 
0 to 9 years 0.43 (0.20;0.92) 0.03 57 (8 to 80) 
0 to 9 years excl TB in first 2 years 0.33 (0.15;0.73) 0.006 67 (27 to 85) 
10 to 19 years 0.37 (0.20;0.68) 0.002 63 (32 to 80) 
20 to 29 years 0.50 (0.21;1.19) 0.12 50 (-19 to 79) 
30 to ~40 years 0.60 (0.24;1.46) 0.26 40 (-46 to 76) 
    
Pragmatic Assumption*: BCG vaccinated subjects with missing value for year of 
vaccination were vaccinated when they reached 13 years old if did so after 1962 
0 to 9 years 0.42 (0.32;0.90) 0.026 58 (10 to 68) 
0 to 9 years excl TB in first 2 years 0.32 (0.15;0.71) 0.005 68 (29 to 85) 
10 to 19 years 0.38 (0.21;0.71) 0.002 62 (29 to 79) 
20 to 29 years 0.51 (0.21;1.20) 0.12 49 (-20 to 79) 
30 to ~40 years 0.57 (0.23;1.41) 0.22 43 (-41 to 77) 
    
Multiple Imputation using Predictive Mean Matching 
0 to 9 years 0.62 (0.30;1.30) 0.20 38 (-30 to 70) 
0 to 9 years excl TB in first 2 years 0.46 (0.21;0.99) 0.05 54 (1 to 79) 
10 to 19 years 0.37 (0.20;0.66) 0.001 63 (34 to 80) 
20 to 29 years 0.49 (0.21;1.15) 0.10 51 (-15 to 79) 
30 to ~40 years 0.57 (0.23;1.40) 0.22 43 (-40 to 77) 
    
*Under the pragmatic assumption, 24957 BCG vaccinated subjects with year of vaccination missing are included in analysis, as detailed 
in eTable 5.  
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10. General Discussion and Conclusions 
10.1 Introduction 
Whilst the burden of tuberculosis in England is lower than in most low-income developing 
countries, it remains relatively higher than in developed nations with comparable 
economic standing (1, 2). Until the recent 2 years, TB notification rates had not 
significantly declined for nearly three decades (3), with TB rates in the country’s largest 
city, London, amongst the highest in Western European and North American major cities, 
and earning London the unenviable label of “TB capital of Western Europe” for over a 
decade. By comparison, before the 1980s, England had experienced nearly 80 years of 
sustained decline in TB rates, with steady progress towards the disease’s elimination as a 
public health problem (4). The pace of decline slowed in the early 1980s, with TB rates 
plateauing soon after. The stagnation in national rates has been attributed to the high TB 
incidence among migrants from high TB burden parts of the world, and the resurgence of 
the disease in segments of the UK-born population (5).  
In the first part of my thesis, I examined the long-term trends in TB notifications in 
England over 30 years, and I explored the association between tuberculosis and 
deprivation in the UK-born population at the ecological and individual levels. I also 
measured the association of TB to some intermediate social determinants of health 
inequalities (SDH) as possible pathways through which poverty may partly affect the TB 
risk in a subsection of this population. I dedicated the second part of my thesis to BCG 
vaccination, one of the longstanding prevention tools, that has been less examined than 
case finding and treatment recently. Like several other low TB burden countries, England 
reviewed their BCG vaccination policy in the early 2000s to take into account changes to 
the disease epidemiology in the country. In light of the low incidence in the general 
population, and the limited impact of the HIV pandemic on the local TB epidemiology, 
the programme of routine universal vaccination of schoolchildren was replaced by 
targeted vaccination of infants at high risk (6). I presented a national survey of how the 
2005 change in policy was implemented at the local level, and I estimated the vaccine 
uptake after the policy change as well as explore how it related to some area-level factors. 
Lastly, I performed analyses measuring the long-term duration of BCG-derived protection 
against tuberculosis. Findings from the latter study, together with the growing body of 
additional evidence on BCG, are potentially relevant to vaccination policy as well as the 
ongoing research and development efforts to find new and more effective TB-vaccines.  
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In the following sections, I summarise the key findings from the different result chapters 
with comments on how they relate and flow from each other. I subsequently discuss some 
of the strengths and limitations of the works presented in this thesis. I then offer some 
reflections on the relevance of my findings to policy and potential implications, as well as 
proposing future line of enquiries that may build on these works. 
 
10.2 Key findings by research questions 
Tuberculosis notifications in England between 1983 and 2014 
The first result chapter of this thesis examined the trends in TB notifications in England 
and Wales over three decades, from 1983 to 2014, contrasting the pattern in foreign-born 
and UK-born populations by age and ethnicity. The aim was to help provide some insight 
into how the interplay between these factors may have affected the TB resurgence in 
England from the mid-1980s as well as recent trends, especially in the UK-born population.  
My analysis suggested that a relatively complex dynamic underscored recent trends in TB 
notifications. The failure of overall TB rates to continue to decline from the mid-1980s 
appeared to be mostly attributable to a steep increase of TB rates in the foreign-born 
population from Black ethnicity and the fact that TB rates in foreign-born subjects from 
the Indian Sub-Continent (ISC, mainly Indians, Pakistani and Bangladeshi) ceased to 
decline. However, there was also a non-negligible contribution from the UK-born 
population, in which the rapid decrease in TB notification rates observed for most of the 
20th century progressively slowed until rates stopped declining from the 1980s. I also found 
that whereas TB rates in the foreign-born population appear to have been declining since 
2006, TB rates in the UK-born population have remained mostly stagnant. My results also 
show that TB rates in older individuals have been declining consistently over the past three 
decades, whereas they have increased then stabilised in UK-born young adults. 
Furthermore, I found that the decline in TB rates observed in the foreign-born population 
since 2006 is mirrored in the TB rates in UK-born individuals from ethnic minority groups, 
whereas rates seem to have plateaued in the White ethnic group. Tuberculosis being a 
classic poverty-related disease, I therefore wanted to explore the role of socio-economic 
deprivation and poverty-related determinants of health in halting the progress towards 
the control of TB in a country where resources exist to effectively eliminate the disease as 
a public health problem. 
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An ecological analysis of the association between tuberculosis 
notification rates in England between 2008 and 2012 and small area-
level deprivation  
Following the findings in the first result chapter, that TB rates in the UK-born population 
have been mostly stagnant until recent years, especially in the White ethnic population, 
in the second result chapter, I investigated the association between TB notification rates 
in recent years (2008-2012) and area-level deprivation level, stratified by place of birth 
(UK-born versus foreign-born populations). The intention was to attempt to disentangle 
the potential role of deprivation from that of place of birth (and associated TB risk) in 
driving variations in TB risk across the country.  
I found that even after accounting for confounding by age, sex, urban/rural area 
classification and the area-level proportion of non-White residents, area-level deprivation 
remained positively associated with overall TB rates, with higher notifications in most 
deprived areas. The results also suggested a stronger association between the area-level 
deprivation and TB rates in the UK-born compared to the foreign-born population. After 
adjusting for confounding, TB notification rates in UK-born subjects living in the most 
deprived quintile areas of England were about two-and-a-half times higher than the least 
deprived quintile areas, whereas the magnitude of the equivalent association in the 
foreign-born population was just about an 80% increase in those from the most deprived 
quintile areas compared to those in the least deprived quintile areas. The analyses also 
revealed a strong association (nearly three times higher rates in the most deprived quintile 
areas compared to least deprived) between area-level deprivation and TB rates in children 
aged 0-14 years, a group mostly UK-born and in which the majority of TB cases are likely 
to result from recent infection. 
 
Social determinants of tuberculosis in UK-born adults: a case-control 
study 
The third result chapter built on the results from the analysis of TB trends in England 
(Manuscript 1) that suggested low, but stubbornly stagnant TB notification rates in the 
UK-born population, notably young adults from White ethnic background; and the 
ecological analyses reported in chapter 2 that showed a strong gradient in TB notification 
rates across small-area level deprivation in the UK-born population. These results 
supported the need to further assess the association between socio-economic status (SES) 
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and TB at the individual level, and investigate some underlying determinants. Here, I 
conducted secondary analyses of data collected as part of an England-wide population-
based case-control study on the duration of BCG effectiveness against tuberculosis. 
Information was collected on a range of social-determinants of health inequalities (SDH) 
in young adults UK-born TB cases from White ethnic background and randomly selected 
community-based controls. My main objective was to use a formal causal framework to 
disaggregate and measure the respective association between those individual-level social-
determinants of health and TB, in an attempt to help map out how SES overall may affect 
the risk of TB along some of these pathways. Using education level as a proxy-measure for 
socio-economic status, the study showed that the risk of TB in subjects with none or 
education below O-level was about four times higher compared to those with a degree or 
higher qualification. The results also suggested that besides small-area deprivation level 
in the place of residence, the intermediate social determinants of health associated with 
higher risk of TB included tobacco smoking, misuse of controlled drugs, and history of 
homelessness. The Population Attributable Fraction (PAF) estimates suggested that 
interventions to reduce tobacco smoking and drug use may respectively contribute to 
preventing up to 18% and 15% TB cases in young UK-born adults, thus supporting the case 
for integrated health and social services in high-risk young adult population groups. 
 
A National survey of the implementation of childhood BCG vaccination 
policy at the local level in England 
The fourth and fifth result chapters of my thesis focused on BCG, the sole preventive 
vaccine with proven effectiveness against TB in several settings including the UK. 
Considering the stagnation of TB rates over decades, the rationale for this part of my thesis 
was to examine the effectiveness and service delivery of one part of the TB control toolkit 
that has been relatively neglected in recent years. The fourth chapter specifically reports a 
survey of BCG vaccination policy in England following the major change in policy in 2005 
from routine universal vaccination of schoolchildren to targeted vaccination of high-risk 
infants. I also used routinely available data to estimate the BCG vaccination uptake in the 
target population in the 3-year period after the change (2006-2008) and the association 
between uptake and some area characteristics, including the vaccination policy and main 
delivery pathway, deprivation level, and percentage of minority ethnic births in the area.  
The BCG vaccination policy in England changed in 2005, when routine universal 
vaccination of schoolchildren was discontinued and replaced by targeted vaccination of 
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infants at higher risk of TB (6). The recommended approaches to implementing the new 
policy of targeted vaccination included universal vaccination of all infants in areas with 
higher TB rates, and selective vaccination of specific groups in areas with lower TB rates, 
with the area-level TB rates cut-off threshold set at 40 cases per 100,000. I contributed to 
a national survey on the state of the implementation of the new recommendations at local 
level by years 2010-2011. We found that the new policy had been implemented in most 
areas in the country in line with recommendations, with about 7 in 10 areas using selective 
vaccination of high-risk children and the rest using universal vaccination. The survey also 
highlighted the heterogeneity in health care delivery pathways between areas, as well as 
some complexities and challenges in the identification of, and services delivery to high-
risk groups. For example, areas using selective vaccination of high-risk groups employed 
a wider variety of channels (e.g. maternity records, baby’s hospital notes, child health 
record, birth notification records etc.) to identify ‘at-risk’ children as well as to administer 
the vaccine (such as postnatal ward, community clinics, chest clinics, paediatric clinics), 
compared to areas using universal vaccination of all infants, where there was no need to 
identify ‘at-risk’ infants, and vaccination is mostly offered through community clinics. The 
multiple pathways in selective vaccination areas has the potential to result in missed 
opportunities for vaccination due to lack of clear responsibilities, as well as a greater risk 
of failure of linkage to care. Other examples of challenges in implementing the policy 
included shortages in staff with suitable training to administer BCG intra-dermally, and 
unclear or lack of service-level agreement to organise vaccination for babies born in 
maternities with catchment areas enclosing different primary care areas with different 
healthcare pathways for BCG vaccination. 
 
Estimation of BCG vaccine uptake following a major change in policy 
There in currently no routine denominator data for the continuous monitoring of BCG 
vaccine uptake in England since the 2005 policy change to targeted vaccination of high-
risk infants. In the fifth result chapter, I used routinely available administrative data on 
the number of BCG doses administered and the number of live-births by areas to estimate 
infant-BCG vaccine uptake in the 3-year period (2006-2008) after the change in policy. I 
also explored the association between uptake levels and some area-level factors (current 
and past vaccination policy and main place of vaccine delivery, deprivation rank, and 
percentage of ethnic minority birth in the area). These analyses suggested that nearly a 
third of eligible infants may have missed BCG vaccination during the study period (average 
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uptake 68%), and that vaccine uptake was slightly higher in areas using universal 
vaccination (72%), compared to those using selective vaccination of high-risk groups 
(66%). The vaccine uptake not surprisingly also appeared to be better in areas primarily 
delivering the vaccine immediately after birth, in post-natal wards (73%), compared to 
those having to come to community clinics for vaccination some weeks later (64%). 
 
A population-based cohort study of the duration of BCG-derived 
protection against tuberculosis 
In the fifth and final result chapter of my thesis, I used readily available linked-register 
data from Norway, a European country with relatively low-TB incidence in the native 
population as in England, to conduct a population-based historical cohort study 
measuring the duration of BCG-derived protection against tuberculosis.  
Overall, the follow-up of nearly 300,000 BCG vaccinated and 83,000 tuberculin-negative 
unvaccinated individuals over more than 40 years suggested that BCG provide an average 
60% protection against tuberculosis in the first 20-year post-vaccination, possibly waning 
to about 40% vaccine effectiveness 20-40 years after vaccination. The protection levels 
found in my analysis were similar to observations from a North American BCG trial with 
long follow-up, and consistent with the hypothesis of a long-lived BCG-derived immunity 
against TB. 
The evidence generated may be relevant to the cost-effectiveness assessment of BCG 
vaccination strategies in such settings, thus policy planning, as well as to ongoing efforts 
to develop new and more effective TB vaccines, whose potential interaction with BCG may 
be important to consider in view of the widespread use of BCG across the world. 
 
10.3 Strengths and limitations of the research presented 
The respective methodological strengths and limitations specific to the studies included 
in his thesis have been discussed in more detail in the relevant sections of each manuscript. 
More generally, a feature common to most analyses presented here is their reliance, fully 
or in part, on routine surveillance data. These data had the advantage of being readily 
available and relatively inexpensive, thus allowing for a rapid exploration of the research 
questions that I set out to explore, and potentially contributing to the evidence at a lower 
cost, compared to purposefully designed prospective data collection. The fact that these 
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were nationwide data and of reasonably good quality adds confidence to the validity of the 
inference made, and the findings’ generalisability to the target populations. The analyses 
of long-term trends in TB notifications may have been more complete if detailed annual 
surveillance data with patients’ place of birth and ethnicity were readily available at the 
national level prior to 1999 when the central surveillance system was established. 
However, the comprehensive nature and rigorous methods of the 5-yearly periodic 
national TB surveys has provided us with useful snapshots of the TB situation over these 
years.  
The focus of my thesis was on TB in the UK-born population of England, in which rates 
have been stagnant for decades. In line with some of the strategies proposed by WHO to 
achieve the long-term goal of TB elimination in a near future, one of my main aims was to 
help understand how social determinants of health inequalities (SDH) may contribute to 
increased TB risk in the target population. The availability of detailed information on 
several SDH at the individual-level in the nationwide case-control study reported in the 
thesis provided an opportunity to explore this research question at a deeper level. There 
are some limitations, not least because the study was not primarily designed to explore 
this research question. More detailed information on the overall social-economic status 
(e.g. income, social class etc.) and some potentially relevant determinants of TB could have 
been measured, for example the nutritional status. Furthermore, the retrospective data 
collection added difficulties in establishing the temporal sequence between the risk factors 
examined and the risk of TB. However, the consistency of findings with existing knowledge 
and the biological plausibility contribute to their robustness.  
The survey of the implementation of the BCG vaccination policy at the local level, and the 
estimation of vaccine uptake, were both conducted just before a substantial re-
organisation of England’s health system architecture. At the time of the studies, 
vaccinations were organised through 152 Primary Care Trusts (PCTs), which is the 
administrative level at which analyses were done. However, since 2013, PCTs have been 
abolished, and routine vaccinations and other public health activities are delivered 
through Clinical Commissioning Groups (CCGs), with England divided into 211 CCGs as of 
2015. This has had implications in terms of local vaccination policies that may warrant an 
update to the survey. The Cover of Vaccine Rapidly Evaluated (COVER) service of Public 
Health England (PHE) has also been developing a system for continuous monitoring of 
BCG vaccine uptake, which eventually will inform the evaluation of the vaccination 
programme; however, the system is still being tested (PHE 2016). 
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10.4 Recommendation for research and potential future 
studies  
Besides stagnant TB rates in the UK-born population, the analyses of TB trends in England 
also showed an interesting steep decline in TB rates in the foreign-born population in 
recent years, which was beyond the scope of my thesis to investigate further. The 
explanation for these recent trends are unclear and may warrant further exploration to 
help policy and planning. Notably, it would be important to apportion the respective roles 
of local TB control measures from that of global TB trends (thus emphasising the impact 
on local TB epidemiology of the UK contribution to global TB control) and trends in 
population movements.  
The pathways through which poverty affect the risk of TB could also benefit from 
additional exploration, including prospective data collection for a better measurement of 
the role of various social determinants of health inequalities (SDH). In the context of a 
study prospectively collecting more detailed data, it may also be helpful to conduct a 
formal mediation analysis to quantify the respective contributions of intermediate SDH to 
the poverty-related TB risk, which could help policy makers focus the resources where 
they are likely to have the biggest impact.  
As mentioned in section 10.3, the survey implementation of BCG vaccination policy 
requires an update given the re-organisation of England’s health-care system since the 
survey reported in this thesis. The Cover of Vaccine Rapidly Evaluated (COVER) service of 
Public Health England (PHE) has been developing a system for continuous monitoring of 
BCG vaccine uptake. The first experimental data were published in 2016, limited to data 
from areas that offer universal neonatal BCG vaccination (10 out of more than 150 local 
authorities) (7). This is a welcome development, although the system is new and does not 
yet cover the whole country, and data quality is still variable. Until the system is more 
stable and established, and include areas with selective vaccination of children at higher 
risk, it might be useful to explore if any available routine data could be used to obtain a 
recent picture of the vaccine coverage in the country since the re-organisation of care. 
Finally, results from my study of duration of BCG-derived protection against TB can be 
included in the most recent systematic review on the duration of BCG protection (8), to 
update the meta-analyses and provide more robust evidence on which to base any new 
BCG or new TB vaccines policy. 
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10.5 Reflections on relevance of findings to policy and 
potential implications 
My findings from the examination of TB trends appear to challenge the assumption that 
TB rates in the UK-born population are mostly driven by an aging population and 
increasing population of UK-born subjects with family ties to high-TB burden parts of the 
world. The long-term trends show that TB rates have continued to decline in older UK-
born subjects at a similar pace over the past 30 years, and that rates in young-adult UK-
born from ethnic minorities have be decreasing steadily in the past decade, mirroring the 
trends in foreign-born populations. The later observation is likely explained by the fact 
that a substantial driver of the TB risk in UK-born subjects from ethnic minority is their 
family ties to high-TB burden parts of the world. On the other hand, TB rates in UK-born 
young adults from White ethnicity seem stagnant. I also show that the association between 
deprivation and TB is stronger in the UK-born population, and the case-control analysis 
suggest that the deprivation-related increased in TB risk may be explained in part at the 
individual-level by SDH like tobacco smoking and use of controlled-drugs, as well as 
homelessness and possibly history of stay in prison. In spite of their limitations, those 
findings are intuitively consistent with other more direct observations on recent social 
changes. There have been several reports of rising social inequalities and deprivation in 
England since the 1980s, including higher prevalence of homelessness among young adults 
(9), and decline in the quality of accommodation in metropolitan areas (10). There is also 
a large body of evidence linking poverty and deprivation to higher prevalence of a number 
of habits potentially deleterious to health, including tobacco smoking (e.g. (11)).  
The recent WHO’s post-2015 End-TB strategy appreciates the imperative need to address 
social inequalities as part of any efforts to eliminate TB as a public health problem (12). 
While the reduction of social injustice and related health inequalities is a long-term and 
much more complex goal to achieve, a better understanding of some of the pathways 
through which poverty affects the risk of tuberculosis can help inform and/or improve 
targeted interventions that are within the grasp of public health, such as tobacco smoking 
cessation, prevention of drug use etc. The findings presented in this thesis lend support to 
the idea that innovative approaches may be required in combatting TB, including for 
example integrated approaches that support individuals, not as patients screened and/or 
diagnosed with a specific disease, but as whole entities whose health and other social 
needs should be better understood and supported. Such integration of services may also 
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prove more cost-effective, as many of the health determinants prevalent in the vulnerable 
populations with high TB burden as also risk factors for several other diseases. 
Regarding the place of BCG vaccination in TB prevention among UK-born subjects in 
England, the revision of policy in 2005 was motivated by changes to the TB epidemiology, 
including relatively lower incidence rate in the general population, as well as a judgment 
on the benefit compared to the risk of BCG-related adverse events.  However, there has 
since been new evidence emerging of BCG vaccination that is relevant to policy. For 
example, whereas it was assumed that BCG does not protect against infection, a number 
of studies and a meta-analysis have suggested that BCG offer some protection against 
infection (13), which is important in view of the spread of multi-drug resistant strains. 
Another interesting development was the development of a new laboratory test for the 
diagnosis of latent TB infection (LTBI), the Interferon Gamma Release Assay (IGRA), 
which unlike the tuberculin skin test (TST), is specific to Mycobacterium tuberculosis and 
is unaffected by BCG vaccination (14). While the assay remains relatively costlier than the 
TST and is more labour-intensive, this development may warrant the reconsideration of 
the argument upon which BCG vaccination had to be balanced against a compromised 
ability to screen for LTBI as part of TB control efforts in low-incidence settings.  
In the same vein as these new facts of BCG, some findings from my thesis are consistent 
with a duration of BCG-derived protection against TB longer than previously assumed. 
This information is directly relevant to calculations of the cost-effectiveness of the vaccine, 
thus of vaccination strategies. A further development with relevance to BCG vaccination 
policy is the fact that whereas there was great hope that a new and more effective TB would 
quickly become available, there is greater now appreciation that several gaps remain in 
the understanding of the immune response to Mtb, and vaccine development efforts will 
likely be more laborious than initially thought. The most promising TB vaccine candidate, 
the MVA85A BCG-booster vaccine, underwent human phase 3 trial, unfortunately 
providing little to no more additional protection than BCG alone (15). Of the thirteen 
vaccine candidates currently at various stage of development, only two (M72 adjuvant 
fusion protein and Mycobacterium vaccae lysate) are undergoing human efficacy testing 
(16). BCG is therefore likely to remain for the near future the sole TB prevention vaccine, 
and the emerging evidence as new developments discussed should help reconsider the 
role and potential contribution of BCG to TB control efforts.  
The review of local vaccination policy also highlighted how heterogeneities and complex 
delivery pathways at the local level may lead to missed vaccination opportunities for high-
risk children, and this was reflected in the estimates of vaccine uptake. In recently 
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published data on BCG uptake in areas with universal neonate vaccination in 2015, Public 
Health England estimated that in 24 London local authorities with data available, BCG 
uptake varied from 2.4% to 94.7%, with uptake in the nine areas with highest TB rates 
varying from 32.3% to 91.6% (7). The vaccine uptake may have been affected by the global 
shortage in BCG supply in the past few years (17) and possibly unstable data from the new 
monitoring system. However, the low uptake in some areas and the large variation in the 
estimated local uptakes should be reason for concern and prompt a review of the approach 
to vaccine delivery and perhaps more harmonisation of care pathways across areas.   
 
10.6 Conclusion 
High-income countries like the UK are in a better position to achieve TB elimination in a 
near future compared to low-income countries where resources are more constrained. 
However, the research reported in this thesis highlighted the stagnant TB rates in the UK 
born White population of England, notably in young adults, an age group that has received 
less attention than TB in the foreign-born population. My investigations also suggested 
that deprivation and the related harms remain associated with TB in this population 
group, which is a concern in view of the upswing in poverty noted in recent years. Further 
studies are warranted to examine the underlying social determinants of TB in this 
population, while addressing the limitations of the results presented in my thesis.   
My research also put the spotlight on BCG vaccination, an often-neglected part of the TB 
control toolkit, which despite its shortcomings remains the sole effective TB vaccine 
available. I showed that the current vaccination programme faced several challenges to 
service delivery, which may have affected the vaccine uptake in the current target 
population. I also found that the vaccine efficacy lasts longer than previously estimated, 
albeit at moderate levels. In an era when Multi-Drug Resistance is spreading, this 
information, combined to the emerging evidence that BCG may also protect against Mtb 
infection, points to a further relevance of the vaccine for vulnerable groups from the 
general population in which the poverty-related risk of TB could last from infancy until 
adulthood.   
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Note 1: This questionnaire is to be used for both cases and controls, for adults and children.  
The questionnaire will be administered using computer aided interviewing, which allows 
questions to be altered depending on the age of the subject. For children under the age of 16, 
the questions will be asked of the parent, and the words ‘were/did /have/do you’ will be 
replaced with ‘was/did/has/does your child’ throughout. For children under the age of 16, 
questions relating to occupation will be asked of/about the parent.  
For questions to 16 to 22 year olds related to vaccine history will be asked of the parent – if 
necessary by use of a form for the information, which can be shown to the parent, or posted.  
 
Note 2: Some questions are only asked of particular groups.  Where this is the case, it is 
indicated in italics before the question or questions that it applies to.  
 
SECTION A  INTRODUCTION AND EARLY HISTORY 
 
A1 INTERVIEWER – RECORD RESPONDENT’S NAME 
 
A2  INTERVIEWER – ASK OR RECORD RESPONDENT’S SEX 
 Male 
 Female 
 
A3 What is your date of birth? 
 ENTER DATE IN NUMBERS , E.G. 02/01/1972.   
IF (Name) DOES NOT KNOW HIS/HER DATE OF BIRTH, PLEASE GET AN ESTIMATE. 
 
IF DATE GIVEN AT A3 
A4 Can I just check, what was your age last birthday?    
 
IF A4 = NOT KNOWN/REFUSED  
A5  What do you estimate your age to be? 
 
ASK ALL 
A6 Were you born in the United Kingdom? This includes England, Scotland, Wales or 
Northern Ireland? 
 Yes 
 No 
 
(IF NO, EXPLAIN THAT FOCUS OF STUDY IS ON UK HEALTH POLICY FOR BABIES AND 
CHILDREN, SO R NOT ELIGIBLE.  THANK AND END INTERVIEW.) 
 
ASK ALL 
A7 We are interested in the immunisations that people received when they were babies 
and children.  Immunisation policies have changed over time and may also vary according to 
where you live.  We would like to know where you were living at different times when you 
might have been offered certain immunisations. 
First, could you tell me the town or city where you were born?  (INTERVIEWER: RECORD 
NAME OF THE TOWN AND THE COUNTY. IF A LARGE CITY, ASK:)  In which borough or 
district were you live? 
 
(INTERVIEWER: RECORD NAME OF TOWN AND COUNTY.) 
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IF AGE<23 
A8 Were you born in a hospital? 
 Yes 
 No 
 Don’t know 
 
IF A8=YES 
A9 What was the name of the hospital where you were born?  (INTERVIEWER: RECORD 
NAME OF HOSPITAL IN FULL) 
 
ASK IF AGE <22 YEARS 
A10 Where did you live when you were a baby, from when you were born to when you were 
4 years old? That is before <DATE OF R’S 4TH BIRTHDAY>?  (IF MORE THAN ONE PLACE) 
Where did you live for the longest time?  (INTERVIEWER: RECORD NAME OF THE TOWN 
AND THE COUNTY. IF A LARGE CITY, ASK:)  In which borough or district did you live? 
 
A11 Did you move to a different area between the ages of 4 and 11? That is between <DATE 
OF R’S 4TH BIRTHDAY> and <DATE OF R’S 11TH BIRTHDAY>. 
Yes 
 No 
 
IF A11=YES, ASK 
A12 Where did you live between the ages of 4 and 11?   (IF MORE THAN ONE PLACE) 
Where did you live for the longest time?  (INTERVIEWER: RECORD NAME OF THE TOWN 
AND THE COUNTY. IF A LARGE CITY, ASK:)  In which borough or district did you live? 
 
ASK ALL 
 A8 Where did live between the ages of 11 and 14? That is between <DATE OF R’S 11TH 
BIRTHDAY> and <DATE OF R’S 14TH BIRTHDAY>.  (IF MORE THAN ONE PLACE) Where did 
you live for the longest time?  (INTERVIEWER: RECORD NAME OF THE TOWN AND THE 
COUNTY. IF A LARGE CITY, ASK:)  In which borough or district did you live? 
 
SECTION B IMMUNISATION HISTORY 
 
ASK IF UNDER 2 YEARS OLD  
B1 Has (CHILD’S NAME) had any immunisations yet?  
Yes  
No 
  
IF B1= YES OR AGE>2 AND <16  
B2 (INTERVIEWER: SHOW EXAMPLE RED BOOK) When children are given 
immunisations, these are usually marked in a red Child Health Record Book (or Red Book) 
which is kept by the parent or guardian at home. Do you have (CHILD’S NAME)’s red book to 
hand?  
INTERVIEWER: IF YES, ASK PARENT TO GET BOOKLET AND ENCOURAGE THEM TO 
CONSULT IT TO FIND OR CHECK RESPONSES. CODE WHETHER BOOK AVAILABLE AND 
USED.  
Red book available and consulted 
 Red book not available/not used 
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IF AGE>=16 AND <=22 YEARS  THEN 
B3 The next questions are about immunisations, including some that are usually given to 
babies and small children. If there are any immunisations that you are not sure of, may we 
have your permission to ask your parents?  INTERVIEWER CODE: 
 Parent(s) present, able to answer questions now in person 
Parents able to answer questions now on phone 
Parents live with respondent – can leave form and come back/call back for information 
Parents live elsewhere – respondent gives permission to contact them 
Respondent doesn’t give permission for parental contact 
 
ASK ALL 
B4 SHOW CARD A  
As far as you are aware, have you had any of the immunisations on this card?  
(If you need to, please refer to the red (Child Health Record) book to check.)  
Yes  
No  
 
IF B4 = YES  
B5 SHOW CARD A  
Which ones have you had?  
INTERVIEWER: CODE ALL THAT APPLY.  IF HAD SEPARATE JABS FOR MEASLES, MUMPS 
AND/OR RUBELLA (INSTEAD OF ALL THREE COMBINED (MMR) DO NOT USE CODE 45, 
BUT CODE THESE AS SEPARATE.  
Diphtheria/ Tetanus/ Whooping Cough  
Polio  
Hib (Haemophilus Influenzae type b)  
5-in-1 injection: Diptheria/ Tetanus/ Whooping Cough/ Polio/ Hib (Haemophilus 
Influenzae type b)  
Measles, Mumps, Rubella combined (MMR)  
Meningococcal C  
Pneumococcal vaccine (Pneomococcal conjugate vaccine, PCV)  
CODE IF APPLICABLE: Measles as a separate immunisation 
CODE IF APPLICABLE: Mumps as a separate immunisation 
CODE IF APPLICABLE: Rubella as a separate immunisation 
CODE IF APPLICABLE: Don’t know 
 
IF B5=DON’T KNOW 
B6 As far as you aware, do you think you probably had (READ OUT) … 
 all the usual infant vaccinations  
 some of the usual infant vaccinations, or 
 none of the usual infant vaccinations. 
CODE IF APPLICABLE: Don’t know 
 
ASK ALL: 
B7 (As far as you know), did you have the BCG vaccination when you were a baby, that is, 
before your first birthday?   
(INTERVIEW CHECK RED BOOK, IF AVAILABLE (PAGE 11B – BCG VACCINATION.   
PROMPT IF NECESSARY):  The BCG vaccination is given in the upper arm.  Sometimes it 
causes a spot or sore that lasts for a few weeks, and sometimes it leaves a permanent scar. 
 Yes 
No 
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Don’t know 
 
IF B7=YES 
B8 Where were you given the BCG vaccination?  Were you (READ OUT) … 
 in hospital,  
 in a hospital outpatient clinic (for example, a chest clinic)  
 at your GP’s surgery 
 at another clinic or health centre (not your GP) , or 
somewhere else? 
 (DO NOT READ OUT) Don’t know/can’t recall 
 
IF B8=SOMEWHERE ELSE 
B9  Where were you given the BCG vaccination? (INTERVIEWER: WRITE IN) 
 
IF B2=RED BOOK AVAILABLE AND CONSULTED 
B10 We are interested in the vaccination policies in different areas.  Can I check the red 
book to see whether any reason was given when the BCG was given to <NAME>? 
(INTERVIEWER: CODE ‘REASON FOR BCG’ FROM PAGE 11B OF RED BOOK. CODE ALL 
THAT APPLY. DO NOT ASK FAMILY.  NOT ALL COPIES OF THE RED BOOK HAVE THIS 
SECTION.) 
 Reason not recorded in book 
All babies in the area were vaccinated (called “universal neonatal programme”) 
 Parent/grandparent born in a country with a high TB rate 
 TB in a relative or close contact 
 Travel to a country with a high TB rate 
 Born or lived in a country with a high TB rate 
 Other (specify at next question) 
  
IF B10=OTHER 
B11 INTERVIEWER WRITE IN REASON WHY BCG GIVEN 
 
IF B7=NO OR DON’T KNOW & AGED OVER 11 YEARS 
B12 Some people who did not have the BCG as a baby were given it later on at school. As 
far as you remember, were you given the BCG at school when you were aged between 11 and 
13?  (INTERVIEWER PROMPT IF NECESSARY)  The BCG vaccination is given in the upper 
arm.  Sometimes it causes a spot or sore that lasts for a few weeks, and sometimes it leaves a 
permanent scar. 
 Yes 
No 
Don’t know 
 
IF B7=NO OR DON’T KNOW & AGED <=11 YEARS OR B12 = NO 
B13  Do you remember having the BCG vaccination at any other age, or somewhere other 
than school?   
  Yes  
  No 
  Don’t know 
 
IF B13=YES 
B14 How old were you when you had the BCG vaccination?  
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B15 Where were you given the BCG vaccination?  Were you (READ OUT) … 
 in hospital,  
 in a hospital outpatient clinic (for example, a chest clinic)  
 at your GP’s surgery 
 at another clinic or health centre (not your GP) , or 
somewhere else? 
 (DO NOT READ OUT) Don’t know/can’t recall 
 
IF B15=SOMEWHERE ELSE 
B16  Where were you given the BCG vaccination? (INTERVIEWER: WRITE IN) 
 
IF AGE >=23 YEARS 
B17 Before the BCG immunisation is given to school children a test is usually done which 
involves an injection with one needle, or with 6 pins in a circle, into the inside of the lower 
arm (interviewer to show on place on their own arm).  Do you remember having a test like this 
when you were at school? 
 Yes 
No 
Don’t know 
 
IF B17=YES 
B18     Did you receive the BCG immunisation as a second injection a few weeks after this test? 
    
Yes  
No 
 
IF B18=NO 
B19 Was this because (READ OUT) …. 
 you were told you did not  need a BCG vaccine as a result of the test 
you refused to have the second injection, or  
you missed the second injection?  
 (DO NOT READ OUT) Don’t know/can’t recall 
   
ASK ALL: 
B20 If you had the BCG vaccination it may have left a small scar on the upper left arm. 
Would you mind If we looked  at your upper arm to see if there is a BCG scar? INTERVIEWER 
RECORD:  
 Respondent agreed 
 Respondent refused 
 
IF B20=RESPONDENT AGREED 
B21  INTERVIEWER RECORD RESULT OF INSPECTION 
BCG scar identified 
No BCG scar visible 
Not sure – a scar is present, but not in the normal place 
Not sure – a scar is present, but looks more like a cut 
Not sure – a scar is present, but is raised rather than indented 
Not sure – some other reason 
Not examined 
 
B22 Would you be willing for us to take a photograph of your arm? 
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INTERVIEWER RECORD:  
 Respondent agreed 
 Respondent refused 
 
IF B22=RESPONDENT AGREED 
B23 INTERVIEWER RECORD TIME AND DATE OF PHOTOGRAPH OR ‘NOT TAKEN’. 
THANK RESPONDENT. 
 
SECTION C GENERAL HEALTH 
 
ASK ALL 
C1 Did a doctor or nurse ever tell you that you had asthma? 
 Yes 
  No 
 
IF C1 = YES  
C2 How old were you when you were first told by a doctor or nurse that you had 
asthma?  (ENTER AGE IN YEARS) 
 
ASK ALL 
C3 Did a doctor ever tell you that you had pneumonia?  
 Yes 
 No 
 
IF C3= YES  
C4 How old were you when you when you were first told by a doctor that you had 
pneumonia?  (ENTER AGE IN YEARS) 
 
ASK ALL 
C5 Are you currently being treated for diabetes? 
 Yes 
 No 
 
IF C5= YES  
C6  How old were when you were told that you had diabetes? (ENTER AGE IN YEARS) 
 
C7     How is your diabetes currently being managed?  (INTERVIEWER: CODE ALL THAT 
APPLY.) 
 Injections 
 Tablets 
 Diet 
 
SECTION D TB HISTORY 
 
ASK ALL 
D1 Have you ever been treated for TB (Tuberculosis)? 
 Yes 
  No 
D2  How old were when you were treated for TB? (ENTER AGE IN YEARS) 
 
IF D1= YES  
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D3 Have you been treated for TB (Tuberculosis) in the last five years? 
 Yes 
  No 
 
IF D3= YES  
D4 What year was this?  (INTERVIEWER RECORD YEAR) 
 
D5 Which type of health service did you go to first when you became ill with TB? Was it 
(READ OUT) … 
 a GP 
 an NHS Walk-in centre 
 a Hospital A&E department 
 via NHS Direct (the NHS phone helpline), or 
somewhere else? 
 (DO NOT READ OUT) Don’t know/can’t recall 
 
IF D5=SOMEWHERE ELSE 
D6 Which type of health service did you go to first when you became ill with TB? 
(INTERVIEWER: WRITE IN) 
 
D7 SHOWCARD B 
Who was the first person to suggest that your illness might be TB? (INTERVIEWER: CODE 
ONE ONLY) 
 Family member (for example, parent, husband or wife, brother or sister)  
 Friend 
 Other non-medical person (for example a colleague, acquaintance) 
 GP 
 Doctor or nurse at an NHS Walk-in centre 
 Doctor or nurse at a hospital A&E department 
 Advisor on NHS Direct (the NHS phone helpline) 
 Someone else 
 
IF D7=SOMEONE ELSE 
D8 Who was the first person to suggest that your illness might be TB? (INTERVIEWER: 
WRITE IN) 
 
D9 There are several different types of treatment you may have for TB.  Some people take 
one type of tablet only, and other people take two or more tablets every day. When you started 
your treatment for TB, did you just take one type of tablet or were you prescribed two or more 
different tablets to take every day? 
  One type of tablet throughout the treatment  
  Two or more different tablets every day  
 
D10 Before you had TB did you know anyone else who had TB? 
 Yes 
 No 
 
IF D10=YES 
D11 Was that person someone who lived in the same household as you, or someone who 
lived elsewhere? 
 Someone in household 
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 Someone who lived elsewhere 
 
 
 
SECTION E RISKS (SELF-COMPLETION MODULE) 
 
ASK IF AGED >23 
To be completed by respondents.  Interviewers will not see answers.   
This module will include opening questions explaining how to complete and locking 
answers at the end so that they are not accessible to the interviewer. Respondents will 
be given a set of showcards. 
 
E1 Which one of these best describes you? 
 I smoke daily 
 I smoke, but not every day 
 I used to smoke but do not smoke at all now 
 I have never smoked 
 
IF E1=I SMOKE DAILY, OR I SMOKE BUT NOT EVERY DAY 
E2 On average, how many cigarettes do you currently smoke in a day?  
 Less than one per day 
 1 to 4 per day 
 5 to 9 per day  
 10 to 19 per day 
 20 to 39 per day 
 40 or more per day 
 
E3 How long have you smoked cigarettes? PLEASE TYPE IN THE NUMBER OF YEARS. 
IF LESS THAN ONE YEAR, CODE 0.  
 
IF E1= I USED TO SMOKE 
E4 When did you last smoke a cigarette? PLEASE TYPE IN YEAR (for example, 1998). 
 
E5 On average, when you used to smoke how many cigarettes did you smoke in a day?  
 Less than one per day 
 1 to 4 per day 
 5 to 9 per day  
 10 to 19 per day 
 20 to 39 per day 
 40 or more per day 
 
 E6 How long in total did you smoke cigarettes? PLEASE TYPE IN THE NUMBER OF 
YEARS. IF LESS THAN ONE YEAR, CODE 0.  
 
ASK ALL: 
E7 PLEASE LOOK AT SHOWCARD S1. 
[showcard options: In own home, in other people's homes, while travelling by car, other places 
indoors, other places out of doors] 
Are you regularly exposed to other people's tobacco smoke indoors in any of these places? 
 Yes 
 No 
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E8 Do you currently drink alcohol, including drinks you brew or make at home? 
 Yes, I currently drink alcohol  
 No, I used to drink alcohol but I don’t drink now 
 No, I have never drunk alcohol  
 
IF E8=YES, I CURRENTLY DRINK ALCOHOL 
E9 On average, how often do you have a drink containing alcohol? 
 Four or more times a week  
 Once or twice a week  
 Two to four times a month  
 Monthly  
 Less often 
 
E10 PLEASE LOOK AT SHOWCARD S2.  THIS SHOWS DIFFERENT TYPES OF DRINK, 
EQUIVALENT TO A SINGLE STANDARD DRINK 
[Showcard lists equivalents to a standard drink: half a pint of beer, a single measure of spirits or 
a small glass of wine] . 
How many standard drinks do you have on a typical day when you drink alcohol? 
 One or two drinks 
 Three or four drinks 
 Five or six drinks 
 Seven to nine drinks 
 Ten or more drinks  
 
IF E8=NO, I USED TO DRINK ALCOHOL BUT I DON’T DRINK NOW 
E11 When did you last have an alcoholic drink? PLEASE TYPE IN YEAR (for example, 
1998). 
 
E12 On average, how often did you have a drink containing alcohol? 
 Four or more times a week  
 Once or twice a week  
 Two to four times a month  
 Monthly  
 Less often 
 
E13 PLEASE LOOK AT SHOWCARD S2.  THIS SHOWS DIFFERENT TYPES OF DRINK, 
EQUIVALENT TO A SINGLE STANDARD DRINK 
[Showcard lists equivalents to a standard drink: half a pint of beer, a single measure of spirits or 
a small glass of wine] . 
How many standard drinks did you have on a typical day when you LAST DRANK alcohol? 
 One or two drinks 
 Three or four drinks 
 Five or six drinks 
 Seven to nine drinks 
 Ten or more drinks  
 
ASK ALL 
E14 PLEASE LOOK AT SHOW CARD S3. 
[Showcard lists common non-Class A drugs: cannabis, qat, glue, gas, solvents] . 
Have you ever taken any of the following drugs without a prescription?  
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 Yes 
 No 
 
IF E14=YES 
E15 When was the last time you took any of these drugs?  PLEASE TYPE IN YEAR (for 
example, 1998). 
 
ASK ALL 
E16 PLEASE LOOK AT SHOW CARD S4. 
[Showcard lists common Class A drugs: ecstasy, cocaine, crack, heroin, LSD, magic mushrooms 
speed or other amphetamines,] . 
Have you ever taken any of the following drugs without a prescription?  
 Yes 
 No 
 
IF E16=YES 
E17 When was the last time you took any of these drugs?  PLEASE TYPE IN YEAR (for 
example, 1998). 
 
E18 Have you ever smoked or inhaled any of these drugs? 
 Yes 
 No 
 
E19 Have you ever injected any of these drugs? 
 Yes 
 No 
 
ASK ALL 
E20 PLEASE LOOK AT SHOW CARD S5. 
[Showcard lists different types of homelessness: e.g. sleeping rough, living in a temporary hostel] 
Have you ever lived in one of these situations for a week or more?  
 Yes 
 No 
 
IF E20=YES 
E21 When was the last time you lived in one of these situations for a week or more?  
PLEASE TYPE IN YEAR (for example, 1998). 
 
E22 In total for how long did you live in one or more of these situations?  PLEASE TYPE 
IN THE NUMBER OF WEEKS: 
 1 month = 4 weeks 
 6 months = 26 weeks 
 1 year = 52 weeks 
 2 years = 104 weeks 
 
ASK ALL 
E23 In the last ten years, have you been detained in prison in the UK? This includes time 
spent on remand or after conviction.  
 Yes 
 No 
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E24 In the last ten years, have you been detained in prison outside the UK? This includes 
time spent on remand or after conviction.  
 Yes 
 No 
 
End of self-completion section.  Instructions on how to save and lock answers. 
 
SECTION F ETHNIC BACKGROUND AND FOREIGN TRAVEL 
  
ASK ALL 
F1 SHOWCARD C 
Which of these best describes your ethnic background? 
 White British 
 White Irish 
 Any other white background  
 Mixed White and Black Caribbean 
 Mixed White and Black African 
 Mixed White and Asian 
 Any other mixed background 
 Indian 
 Pakistani 
 Bangladeshi 
 Any other Asian/Asian British background 
Black Caribbean 
 Black Africa  
 Any other Black/Black British background 
 Chinese 
 Any other ethnic group 
 
IF F1=ANY OTHER WHITE BACKGROUND OR ANY OTHER MIXED BACKGROUND OR ANY 
OTHER ASIAN/ASIAN BRITISH BACKGROUND OR ANY OTHER BLACK/BLACK BRITISH 
BACKGROUND OR ANY OTHER ETHNIC GROUP 
F2 Please can you describe your ethnic group.  INTERVIEWER: RECORD VERBATIM. 
 
ASK ALL 
F3 SHOWCARD D 
Were your parents or your grandparents born in any of these regions? (IF YES) Where 
was that?  
INTERVIEWER IF ASKED – ‘PARENTS’ REFERS TO THE PERSON WHO BROUGHT UP 
R – NOT NECESSARILY THE BIOLOGICAL PARENT. 
CODE ALL THAT APPLY. 
 Africa 
 Asia 
 The Caribbean  
 Central or Eastern America 
 Eastern Europe 
 (INTERVIEWER CODE)  None of these 
 
F4 Are there any countries outside the outside the UK that you travel to regularly?  (By 
regularly I mean every few years or more often)?  
 Yes 
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 No 
 
IF F4=YES 
F5 Which country?  INTERVIEWER: PROBE: Any others?  
 
ASK ALL 
F6 (Apart from those countries), have you ever stayed in any country outside the UK for 
3 months or more?  
 
IF F6=YES 
F7 Which country?  INTERVIEWER: PROBE: Any others?  
 
SECTION G CLASSIFICATORY QUESTIONS 
 
G1 SHOW CARD E 
Which of these descriptions applies to what you were doing last week? 
CODE FIRST TO APPLY  
 Going to school or college full-time (including on vacation) 
  In paid employment or self-employment (or away temporarily) 
  On a Government scheme for employment training 
  Doing unpaid work for a business that you own, or that a relative owns 
  Waiting to take up paid work already obtained 
 Looking for paid work or a Government training scheme 
Intending to look for work but prevented by temporary sickness or injury 
(INTERVIEWER: CHECK 28 DAYS OR LESS) 
 Permanently unable to work because of long-term sickness or disability  
 Retired from paid work 
  Looking after the home or family 
  Doing something else  
 
IF G1= LOOKING FOR PAID WORK OR G1=WAITING TO TAKE UP PAID WORK ALREADY 
OBTAINED 
G2  How long have you been looking for paid work or a place on a government training 
scheme?  
 Not yet started  
 Less than 1 month  
 1 month but less than 3 months  
 3 months but less than 6 months  
 6 months but less than 12 months  
 12 months or more  
 
IF G1 = GOING TO SCHOOL OR COLLEGE FULL TIME, OR DOING UNPAID WORK, OR ON A 
GOVERNMENT SCHEME, OR NTENDING TO WORK BUT TEMPORARILY SICK OR INJURED, 
ORPERMANENTLY UNABLE TO WORK, OR RETIRED FROM PAID WORK, OR LOOKING 
AFTER HOME OR FAMILY, OR DOING SOMETHING ELSE 
G3 Have you ever had a paid job, apart from casual or holiday work? 
               Yes  
  No 
 
IF G3=YES 
G4 How long ago did you last have a paid job?  
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 Within past 12 months  
 1 year, less than 5 years  
 5 years, less than 10 years    
 10 years or more  
 Can’t say  
 
IF G1=IN PAID EMPLOYMENT OR SELF-EMPLOYMENT OR G3=YES 
G5 What did the firm or organisation you work(ed) for mainly make or do (at the place 
where you last worked)? 
DESCRIBE FULLY - PROBE MANUFACTURING OR PROCESSING OR DISTRIBUTING 
ETC.AND MAIN GOODS PRODUCED, MATERIALS USED, WHOLESALE OR RETAIL ETC.  
 
G6 What was your (main) job (last week)? 
ENTER JOB TITLE  
 
G7 What did you mainly do in your job? 
 
G8 Were you working as an employee or were you self-employed? 
 Employee 
 Self-employed 
 
IF G8=EMPLOYEE 
G9 In your job, did you have formal responsibility for supervising the work of other 
employees? 
DO NOT INCLUDE PEOPLE WHO ONLY SUPERVISE CHILDREN, E.G. TEACHERS, 
NANNIES, CHILDMINDERS, OR ANIMALS, SECURITY OR BUILDINGS, E.G.CARETAKERS, 
SECURITY GUARDS 
 Yes   
 No 
 
G10 How many people worked for your employer at the place where you worked? 
Were there (READ OUT)… 
 1 to 24 
 25 to 499 
 or 500 or more employees? 
 
IF G8=SELF-EMPLOYED 
G11 Were you working on your own or did you have employees? ASK OR RECORD 
 On own/with partner(s) but no employees 
 With employees 
 
IF G11=WITH EMPLOYEES 
G12 How many people did you employ at the place where you worked? 
Were there (READ OUT)… 
1 to 24 
25 to 499, or 
500 or more employees 
 
IF G8=EMPLOYEE OR G3=YES 
G13 In your (main) job were you working…(READ OUT) 
full time 
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or part-time? 
 
ASK ALL 
G14 At what age did you finish continuous full-time education at school or college? 
(RECORD AGE IN YEARS) 
 
ASK ALL AGED 23+ 
G15 SHOW CARD F 
Which of these qualifications do you have? CODE THE FIRST THAT APPLIES 
 Degree level qualification 
 Teaching qualification, HNC/HND, BEC/TEC Higher, BTEC Higher, NVQ level 4 
A Levels, SCE Higher, ONC/OND/BEC/TEC, City & Guilds Advanced Final Level, 
NVQ Level 3 
O Levels Grades A-C, GCSE Grades A-C, City & Guilds Craft/Ordinary Level, NVQ 
Level 2 
GCE Grades D or E, GCSE Grades D-G, NVQ Level 1 
 Other Qualifications. 
 None of these  
 
ASK ALL 
G16 We would like to know a bit about the secondary schools you attended as a child.  
What was the name of the first secondary school you attended at the age of 11?  
INTERVIEWER RECORD SCHOOL NAME AND TOWN.   
 
G17 How old were you when you started at that school? 
 
G18 How old were you when you left that school? 
 
IF G18<14 OR CURRENT AGE (WHICHEVER IS LOWEST) 
G19 What was the name of the next secondary school you attended?  
INTERVIEWER RECORD SCHOOL NAME AND TOWN.   
 
G20 How old were you when you left that school? 
 
[INTERVIEWER: REPEAT FOR NEXT SCHOOL UNTIL AGE OF 14 OR CURRENT AGE 
REACHED] 
 
ASK ALL 
G21 SHOWCARD G 
 Which of these describes the way your household occupies this accommodation? 
 Own it (includes homes being bought with a mortgage) 
 Pay part rent and part mortgage (shared ownership) 
 Rented from a private landlord 
 Rented from local authority or housing association 
 Other 
 
G22  Do you have any close family members, for example brothers, sisters, or cousins who 
live nearby and who are about the same age as you (up to two years younger or older)? 
(INTERVIEWER: INCLUDE PEOPLE WHO LIVE IN THE SAME HOUSEHOLD.) 
 Yes 
 No 
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 Don’t know 
 
IF G22=YES 
G23 How many close family members of about your age live nearby?  
 
H Nominated controls for infant BCG vaccination study  
 
Note 1: These questions will be asked of the sample of cases (that is people identified through 
HPA records). 
Note 2: Questions vary according to type of sample. 
 
IF R PART OF THE INFANT IMMUNISATION SAMPLE AND CONTROL REQUIRES ETHNIC 
MATCHING 
H1 A final set of questions now.  As part of the study we would like speak to the parents 
of other children with a similar immunisation history.  When your child was born in [NAME 
OF DISTRICT], children in that area whose parents or grandparents were born in [PART OF 
WORLD – SEE QUESTION F3]  received additional immunisations.   
 
In order to see how effective these were, we are looking for parents of other children who were 
born in [DISTRICT] between (2 years before case) and (2 years after case), and whose parents 
were born in ……………….  
 
Would you know any people like this?  
 Yes 
 No 
 Don’t know 
 
IF R PART OF THE INFANT IMMUNISATION SAMPLE AND CONTROL DOES NOT REQUIRE 
ETHNIC MATCHING 
H2 A final set of questions now.  As part of the study we would like speak to the parents 
of other children with a similar immunisation history. We are looking for parents of other 
children who were born in [NAME OF DISTRICT] between (2 years before case) and (2 years 
after case).  
 
Would you know any people like this?  
 Yes 
 No 
 Don’t know 
 
IF R PART OF THE SCHOOL IMMUNISATION SAMPLE, check that (s)he was not born in any 
of the infant immunisation sample areas. 
H3 A final set of questions now.  As part of the study we would like speak to other people 
who went to secondary school in the same area as you.  
 
We are looking for people who were born between (2 years before case) and (2 years after 
case). 
 
Would you know any people like this?  
 Yes 
 No 
 Don’t know 
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IF H1= YES OR H2=YES or H3=YES  
H4 GIVE RESPONDENT COPY OF LETTER AND INFORMATION SHEET.  
Would you be willing to help us make contact with people like this?  We are looking for one to 
five people.  We would send them this letter and information sheet to ask if they would like to 
take part.  It says that they have been suggested as someone who could help with this study of 
past immunisations in the area where you were born/went to school.  Your responses today 
would remain confidential and would not be shared with anyone.  We would not say that we 
chose you from health records, or anything about your health.   
 
Would you be willing for us to contact anyone you know using this letter? 
 Yes 
 No 
 Unsure 
 
IF H4= YES  
H5 Would be willing to give us details of anyone we could contact straight away?  
 Yes 
 No 
 Unsure 
 
IF H5= NO OR UNSURE  
H6 Would you be willing to consider giving us details of anyone once you have had a 
chance to speak to them and ask their permission?  Can we contact you again in a week or so? 
INTERVIEWER: NOTE THAT YOU WILLCONTACT RESP AGAIN IN A WEEK FOR DETAILS 
(E.G. IF NEED TIME TO FIND THEM, OR UNCOMFORTABLE GIVING DETAILS WITHOUT 
PERMISSION) 
 Yes 
 No 
 
IF H6=YES, REPEAT FOR UP TO FIVE CONTACTS 
H7 INTERVIEWER RECORD PERSON’S NAME, OR LEAVE BLANK IF RETURNING FOR 
THIS INFORMATION LATER. 
 
H8 INTERVIEWER RECORD PERSON’S PHONE NUMBER, OR LEAVE BLANK IF 
RETURNING FOR THIS INFORMATION LATER. 
 
H9 INTERVIEWER RECORD PERSON’S ADDRESS, OR LEAVE BLANK IF RETURNING 
FOR THIS INFORMATION LATER. 
 
H10 INTERVIEWER RECORD PERSON’S E-MAIL ADDRESS, OR LEAVE BLANK IF 
RETURNING FOR THIS INFORMATION LATER. 
 
H11 INTERVIEWER RECORD ANY OTHER USEFUL INFORMATION ABOUT 
CONTACTING THIS PERSON, OR LEAVE BLANK IF RETURNING FOR THIS 
INFORMATION LATER. 
 
ASK ALL 
H12 With your permission, we would like to consult the records held by the NHS Child or 
School Health Service to confirm whether or not if you had the BCG vaccine.  
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Please read this form, it explains more about what is involved. 
INTERVIEWER: GIVE THE RESPONDENT THE CONSENT FORM AND ALLOW THEM TIME 
TO READ THE INFORMATION.  
 Consent given 
Consent not given 
 
IF H12= CONSENT GIVEN  
H13 Before I can pass your details on, I have to obtain written consent from you. 
ENTER THE RESPONDENT'S SERIAL NUMBER ON THE TOP OF THE CONSENT FORMS.  
ASK RESPONDENT TO SIGN AND DATE BOTH FORMS. 
GIVE THE SECOD COPY OF THE FORM TO THE RESPONDENT. 
CODE WHETHER SIGNED CONSENT OBTAINED. 
 Consent signed 
 No signed consent 
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Tilradning fra Avdeling for prosjektst@tte
Saken gjelder s¢knad om prosjektgodkjenning fra REK for prosjektet "Kohortstudie om varighetene
av BCG-vaksinens beskyttelse". Prosjektet utf¢res i regi av Nasjonalt folkehelseinstitutt i samarbeid
med forskere fra Health Protection Agency i London og London School of Hygiene and Tropical
Medicine.
Det s¢kes om forhandsgodkjenning av prosjektet og dispensasjon fra taushetsplikt for kobling av
data sarnlet inn i helsetjenesten med data fra sentrale helseregistre og om tillatelse til ny og endret
bruk av data sarnlet inn i helsetjenesten etter helseforskningsloven § 35.
Formal
Prosjektet er en statistisk kohortstudie som skal undersf/Ske hvor lenge BCG-vaksinasjon beskytter
mot tuberkuloseinfeksjon. Funnene i studien viI ha stor betydning i forbindelse med planlegging,
vurdering og gjennomff/Sring av vaksinasjonsprogrammet i Norge og for liknende
vaksinasjonsprogrammer internasjonalt. Studien viI gi nyttig informasjon om varighet av beskyttelse
og om eventuell endring av beskyttelseseffekt over tid.
Utvalg
Utvalget viI besta av 715000 individer fra den norske populasjonen. Studiecohorten viI hovedsakelig
bli rekruttert ved a bruke screeningdata fra f¢dselscohortene som var med i massescrenningen som
foregikk i perioden 1948 til 1975. Noe vil i tillegg bli rekruttert fra skolescreeningprogrammet som
ble gjennomff/Srt for 9. klassinger i perioden fra 1975 til 1997.
Metode/design
Prosjektet er en historisk kvantitativ populasjonsbasert studie og viI kun benytte data som allerede er
sarnlet inn i forbindelse med rutinemessig screeing/overvlling av forekomst, i regi av helsetjenesten
og i sentrale helseregistre. Ved a koble data fra Tuberkuloseregisteret og Vaksinasjonsregisteret
(SYSVAK) med screeningdata og sosio¢konomiske data om utdanning og inntekt fra SSB viI man
kunne studere vaksineeffekten i opp til 35 ar etter vaksinasjonstidspunktet.
Personvern og informasjonssikkerhet
Dataene som inngar i prosjektet viI bli behandlet i overensstemmelse med Sikkerhetsmal og strategi
for nasjonalt folkehelseinstitutt, FHI R 501, samt underliggende sikkerhetsdokumentasjon.
Forskningsdata viI bli oppbevart pa et dedikert omrade i FHIs servere under streng tilgangskontroll.
Forskere vil kun bearbeide avidentifiserte data og prosjektet viI ikke ta kontakt med
studiepopulasjonen.
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Vurdering
Formiilet med studien er a unders(Z)ke effekten av BCG-vaksinen og beskyttelsens varighet. Funnene i
studien viI kunne bidra med nyttig informasjon til helsemyndighetene bade i Norge og i andre land
hvor tuberkulose er langt mer utbredt enn i Norge. Studier som dette bidrar med opplysninger som
kan gj(Z)re helsemyndighetene bedre rustet til a foreta kost-nytte vurderinger av vaskinasjonsstrategien
og dette viI vrere en fordel for samfunnet, helsemyndighetene og for befolkningen. Abenytte data
som allerede er samlet inn i forbindelse med screeningprogrammer til dette formalet er etter vart
skj(Z)nn lite inngripende med tanke pa de registrertes personvern sammenliknet med samfunnet og
befolkningens nytte av a vurdere den faktiske effekten av vaksiner som tilbys i
vaksinasjonsprograrnmet.
Basert pa foreliggende utkast til REK-s(Z)knad og forskningsprotokoll finner Avdeling for
prosjektst(Z)tte a kunne gi tilradning til at prosjektet gjennomf(Z)res.
Eventuelle endringer i prosjektet skal meldes til avdeling for prosjektst(Z)tte.
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